PosterSessionOnline

EUROPEAN HEMATOLOGY ASSOCIATION

EHA2025 Hybrid Congress

June, 12-15 Milan

N. Poster

Poster title

Applicant name

Status


PF-340	ENHANCING IMMUNOTHERAPY IN B-ALL: THE ROLE OF MTORC1-AKT-FOXO1 SIGNALING IN CD20 UPREGULATION MEDIATED BY MTORC1 INHIBITORS	Agnieszka Dabkowska	Received

PF-342	HIGH-RISK CLINICAL FEATURES AND POOR OUTCOMES IN PEDIATRIC PAX5R B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: FLT3 TARGETING AS A POTENTIAL NOVEL TREATMENT STRATEGY	Nicolò Peccatori	Received

PF-344	DESIGNER PEPTIDES FOR THE TREATMENT OF DUX4-R+ ACUTE LYMPHOBLASTIC LEUKEMIA	Mara Salomè	Received

PF-345	IDENTIFICATION OF NOVEL THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF INFANT PATIENTS WITH KMT2A-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA BY DRUG REPURPOSING	Simona Procopio	Received

PF-346	AN INTEGRATIVE, MULTIOMIC ANALYSIS OF PEDIATRIC B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA	Olga Krali	Received

PF-349	DEVELOPMENT OF PRECLINICAL MODELS FOR THE EVALUATION OF CONVENTIONAL AND IN VIVO CAR-T THERAPIES	Hongyan Sun	Received

PF-350	NON-GENETIC FACTORS CONTRIBUTING TO TREATMENT RESPONSE IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Sanni Moisio	Received

PF-352	BCP-ALL INDUCED IMMUNE REPRESSION CAUSES FAILURE OF BLINATUMOMAB-DEPENDENT KILLING AT INITIAL DIAGNOSIS	Babette D. J. Hoen	Received

PF-353	RESOLVING COMPLEX REARRANGEMENTS AND IMPROVING VARIANT ANALYSIS IN PEDIATRIC B-ALL USING OPTICAL GENOME MAPPING	Anna Beko	Received

PF-354	FERROPTOSIS: AN IRON-EXPLOITING STRATEGY TO TARGET ACUTE LYMPHOBLASTIC LEUKEMIA (FIEST-ALL)	Martina Maria Capelletti	Received

PF-355	RNA SEQUENCING IMPROVES MOLECULAR CHARACTERIZATION OF A SINGLE-CENTRE PAEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA COHORT	Mercè Richarte-Franqués	Received

PF-356	CD123 EXPRESSION AND OUTCOMES IN CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Eftichia Stiakaki	Received

PF-357	FREQUENCY OF VARIANT ALK-FUSIONS AND PROGNOSTIC IMPACT OF CLINICAL AND MOLECULAR FEATURES IN CHINESE PEDIATRIC ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)	Yonghong Zhang	Received

PF-359	TARGETING FLT3 IN B-ALL: FROM GENOMIC INSIGHTS TO THERAPEUTIC APPLICATIONS	Anna Ferrari	Received

PF-360	INVESTIGATING PREDNISONE-INDUCED SIGNALING PATHWAY CHANGES IN PEDIATRIC T-ALL	Daniela Kužílková	Received

PF-362	COMBINING MENIN INHIBITION (ZIFTOMENIB) WITH VENETOCLAX ENHANCES ANTI-LEUKEMIC ACTIVITY IN PRECLINICAL MODELS OF HUMAN KMT2AR ACUTE LYMPHOBLASTIC LEUKEMIA	Marianna Giorgi	Received

PF-364	ASSESSING THE EFFICACY OF NK CELLS IN COMBINATION WITH BH3-MIMETICS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Colin Fortner	Received

PF-365	ACTIVIN A INFLUENCES THE CROSS-TALK BETWEEN B-CELL TYPE ACUTE LYMPHOBLASTIC CELLS AND MESENCHYMAL STROMAL CELLS MEDIATED BY THE RELEASE OF EXTRACELLULAR VESICLES	Erica Dander	Received

PF-367	MINIMAL RESIDUAL DISEASE ASSESSMENT BY DIGITAL DROPLET PCR USING PATIENT-SPECIFIC FUSION GENES IN PHILADELPHIA-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA	Deborah Cardinali	Received

PF-368	COHESINS: CROSSROAD BETWEEN CORNELIA DE LANGE SYNDROME AND CANCER PREDISPOSITION	Stefano Rebellato	Received

PF-370	DECIPHERING B-ALL AND MSC INTERACTION: PATHWAYS TO CHEMORESISTANCE AND CELL CONTACT DYNAMICS	Emily Cutler	Received

PF-371	TARGETING M2-LIKE TUMOR-ASSOCIATED MACROPHAGES BY MEANS OF NEW TLR4 AGONISTS	Alice Martina Giussani	Received

PF-373	BICISTRONIC CD19/CD22 CAR T-CELL THERAPY EXHIBITS CLINICAL ACTIVITIES IN RELAPSED OR REFRACTORY CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Hua Zhang	Received

PF-375	HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION COMBINED WITH UMBILICAL CORD BLOOD VS. HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS: A MULTICENTER REAL-WORLD STUDY	Yifan Shen	Received

PF-376	IKZF1PLUS GENOTYPE ACCELERATES T315I MUTAGENESIS IN ADULT BCR::ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA	Jin WANG	Received

PF-379	THE OUTCOMES FROM A REAL-WORLD STUDY OF INATICABTAGENE AUTOLEUCEL IN CHINESE PATIENTS WITH B-ALL	Ying Wang	Received

PF-381	PERFORMANCE OF BLINATUMOMAB FOR MRD TREATMENT AND BRIDGE TO ALLO-SCT IN PH-NEGATIVE B-ALL PATIENTS TREATED WITH PEDIATRIC INSPIRED LAL1913 PROGRAM (SUBANALYSIS OF THE CAMPUS-ALL LAL1913 STUDY).	Anna Candoni	Received

PF-383	EXPRESSION OF THE THYMIC STROMAL LYMPHOPOIETIN RECEPTOR (TSLPR) IS CLOSELY ASSOCIATED WITH CYTOKINE RECEPTOR-LIKE FACTOR 2 (CRLF2) REARRANGED PHILADELPHIA (PH) LIKE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)	Julian Liebaert	Received

PF-385	COMPARISON OF LONG-TERM OUTCOMES BETWEEN FLUMATINIB AND DASATINIB MAINTENANCE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTICENTER RETROSPECTIVE STUDY	Yi Yu	Received

PF-386	A PROSPECTIVE STUDY OF FLUMATINIB WITH CHEMOTHERAPY FOR NEWLY DIAGNOSED BCR::ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS: RJ-ALL2020.2A TRIAL	Weiyang Liu	Received

PF-387	OSTEONECROSIS AS A SIDE EFFECT OF A PEDIATRIC-BASED TREATMENT REGIMEN IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS	Felix Klingler	Received

PF-389	IMMUNE RECONSTITUTION STABILITY AFTER CAR-T HAD AN IMPACT ON OUTCOMES OF B-ALL PATIENTS	Zhihuan Yang	Received

PF-390	A PHASE 2 STUDY OF OLVEREMBATINIB FOR THE TREATMENT OF MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT	Wenzhi Cai	Received

PF-391	EXCELLENT LONG-TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY PH+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FAILING TO ACHIEVE COMPLETE MOLECULAR REMISSION	Yanzhi Song	Received

PF-392	COMPARISON OF DIFFERENT DOSES OF RABBIT ANTI-THYMOCYTE GLOBULIN (ATG-T) AND ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) IN TBI-BASED MYELOABLATIVE CONDITIONING FOR HAPLOIDENTICAL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS	Yue Lu	Received

PF-394	FLOW CYTOMETRY MINIMAL RESIDUAL DISEASE STATUS COMBINED WITH CYTOGENETICS RISK CLASSIFICATION PREDICTS SURVIVAL AND RELAPSE RISK IN ADOLESCENTS AND ADULTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Jiayan Gu	Received

PF-395	IMPROVING LYMPHOPENIA AND REDUCING THE RISK OF INFECTION THROUGH THE INFUSION OF CD7 GENE KNOCK-OUT LYMPHOCYTES FOR R/R T-ALL AFTER CD7 CAR T CELL THERAPY	Jing Pan	Received

PF-396	EXPLORATORY STUDY ON THE RELATIONSHIP BETWEEN THE EFFICACY OF BLINATUMOMAB TREATMENT AND T CELL FUNCTION IN PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA USING THE FULL-SPECTRUM FLOW CYTOMETRY ANALYSIS	Ruidong Zhang	Received

PF-397	USP7 MUTATIONS PREDICT ADVERSE LONG-TERM OUTCOMES IN PEDIATRIC T CELL ACUTE LYMPHOBLASTIC LEUKAEMIA AND LYMPHOMA	fengfeng niu	Received

PF-398	FULL PEDIATRIC INDUCTION INCLUDING HIGH DOSES OF ASPARAGINASES RESULTS IN EXCELLENT OUTCOME IN ADULT ALL PATIENTS AGED UP TO 60 YEARS, ESPECIALLY AMONG T-ALL PATIENTS	Paola Minetto	Received

PF-399	INVASIVE FUNGAL DISEASE IN CHILDREN ALL RECEIVING CHEMOTHERAPY-AN ANALYISIS OF MUTI-CENTER CLINICAL TRIAL CCCG-ALL-2015	Xuedong Wu	Received

PF-401	REAL WORLD ANALYSIS OF OUTCOMES USING A MODIFIED DFCI PROTOCOL FOR ADULTS WITH BCR-ABL NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA – IMPACT OF MRD	Joseph Brandwein	Received

PF-403	KTE-X19 IN RELAPSED OR REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN THE CHINESE POPULATION: A PHASE II MULTICENTER STUDY	Meng Lv	Received

PF-404	VARS: A VENETOCLAX/AZACITIDINE SCRNA-SEQ RESISTANCE SIGNATURE ASSOCIATED WITH TREATMENT RESPONSE IN ACUTE MYELOID LEUKEMIA	Anne Merbach	Received

PF-405	COMPREHENSIVE MULTI-OMICS PROFILING REVEALS THE DISTINCT EOMAST-LIKE CELLULAR SUBSET IN T(8;21) ACUTE MYELOID LEUKEMIA WITH CLINICAL SIGNIFICANCE	Yu Liu	Received

PF-406	SINGLE-CELL MULTIOMICS DATA-DRIVEN MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENT USING MULTIDIMENSIONAL FLOW CYTOMETRY (MFC) IN ACUTE MYELOID LEUKEMIA (AML)	Carmen Gonzalez	Received

PF-407	TRACKING THE STEMNESS MECHANISMS IN REFRACTORY MECOM REARRANGED ACUTE MYELOID LEUKEMIAS AT SINGLE CELL RESOLUTION	Ilse Kaaja	Received

PF-408	UNCOVERING CD180 AS A NOVEL MARKER AND THERAPEUTIC TARGET OF CHEMORESISTANCE AND RELAPSE IN KMT2A-REARRANGED PAEDIATRIC AML.	Madonna Eltoukhy	Received

PF-409	INHIBITION OF CSF1R-CSF1 AXIS WITH AXATILIMAB EFFECTIVELY TARGETS LEUKEMIA STEM CELLS AND MONOCYTES IN BH3 MIMETICS-RESISTANT AML	Bing Carter	Received

PF-411	PROTEIN S-ACYLATION DYNAMICS PROVIDE METABOLIC FLEXIBILITY TO ACUTE MYELOID LEUKEMIA CELLS	Nick van Gastel	Received

PF-412	REM-422, A SMALL MOLECULE MYB MRNA DEGRADER, DEMONSTRATES ANTI-LEUKEMIC ACTIVITY AS A MONOTHERAPY AND IN COMBINATION WITH STANDARDS OF CARE IN PRECLINICAL MODELS OF AML	Charles Kung	Received

PF-418	LOW-TOXICITY ANTIBODY DRUG-CONJUGATE THERAPY FOR AML PATIENTS TARGETING THE GLYCOSAMINOGLYCAN ONCOFETAL CHONDROITIN SULFATE	Priya Khadgawat	Received

PF-419	HARNESSING ENGINEERED INVARIANT NATURAL KILLER T CELLS (INKT CELLS) AGAINST CD117: A NOVEL STRATEGY FOR TREATING ACUTE MYELOID LEUKEMIA	chaiyaporn boonchalermvichian	Received

PF-420	GLYCOLYSIS-DRIVEN IMMUNE EVASION IN ACUTE MYELOID LEUKEMIA IMPAIRS MACROPHAGE-MEDIATED CLEARANCE	Isabel Weinhauser	Received

PF-421	COMPUTATIONAL MEASURABLE RESIDUAL DISEASE ASSESSMENT IMPROVES RELAPSE PREDICTION IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE VALIDATION IN THE HOVON-SAKK-132 TRIAL	Tim Mocking	Received

PF-423	KMT2E EXPRESSION DEFINES A SUBSET OF LEUKEMIC STEM CELLS WITH OXPHOS DEPENDENCE AND THERAPEUTIC SENSITIVITY TO RETINOIC ACID AND PARP1 INHIBITION	Luise A de A Simoes	Received

PF-424	OVERCOMING VENETOCLAX RESISTANCE BY SELECTIVE PARP1 INHIBITION IN ACUTE MYELOID LEUKEMIA	Justinas Daraskevicius	Received

PF-426	REFINING AML PATIENTS´ KARYOTYPES USING OPTICAL GENOME MAPPING. UNRAVELING CRYPTIC ALTERATIONS AND DECIPHERING COMPLEX KARYOTYPES.	Neus Torres Hernández	Received

PF-429	LEVELS OF 91 CIRCULATING INFLAMMATORY PROTEINS AND RISK OF ACUTE MYELOID LEUKEMIA : A MENDELIAN RANDOMIZATION STUDY	Tao Wu	Received

PF-432	MOLECULAR PROFILING OF PEDIATRIC AML: A NEXT-GENERATION SEQUENCING APPROACH IN A SINGLE-CENTER COHORT	Alba Crespo-Carrasco	Received

PF-433	INTRACELLULAR SIGNALING SIGNATURES IN THE MONOCYTIC COMPARTMENT DISTINGUISH ACUTE MYELOID LEUKEMIA FROM HEALTHY PERIPHERAL BLOOD AND BONE MARROW	Oriol Castells	Received

PF-435	PROTEIN ARGININE METHYLTRANSFERASE (PRMT2) IS INVOLVED IN JNK SIGNALING AND CYTOSKELETON REORGANIZATION BY COOPERATING WITH VAV1 AND WASP/WIPF1 IN ACUTE MYELOBLASTIC LEUKEMIA	Denis Masnikov	Received

PF-436	TP53-MUTATED AML: A MULTI-OMICS APPROACH TO UNDERSTAND HETEROGENEITY AND THERAPEUTIC VULNERABILITIES	Ana RIO-MACHIN	Received

PF-439	SINGLE CELL SEQUENCING DECIPHERING THE HETEROGENEOUS LANDSCAPE OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM WITH NOVEL MYB-ZFAT FUSION GENE	Ruijuan Li	Received

PF-440	IDH1/2-MUTATED AML: MOLECULAR PROFILE AND PROGNOSTIC IMPACT OF IDH1/2-MRD IN IDH1/2-MUTATED AML FROM THE FRENCH HAUTS-DE-FRANCE AML OBSERVATORY	Mélinda Dantec	Received

PF-441	WOGONIN INDUCES APOPTOTIC CELL DEATH THROUGH PI3K/AKT AND MAPK/ ERK PATHWAYS AND SYNERGIZES WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA	Xia Jiang	Received

PF-442	VENETOCLAX SYNERGIZES WITH HK2 INHIBITOR 2 - DG IN ACUTE MYELOID LEUKEMIA VIA THE ENDOPLASMIC RETICULUM STRESS PATHWAY.	Menghua Sun	Received

PF-443	PLINABULIN AND SELUMETINIB INDUCE AAMS REPROGRAMMING INTO M1-LIKE MACROPHAGES AND REDUCE AML CELL VIABILITY	Lucio Henrique Sousa Pinheiro	Received

PF-444	FLT3 MUTATION DRIVES THE IMMUNOPHENOTYPIC SIGNATURE OF LEUKEMIC DIFFERENTIATION ARREST AND ALTERS NK CELL PROFILE IN ACUTE MYELOID LEUKEMIA	Allana Carvalho	Received

PF-445	IN DEPTH CHARACTERIZATION OF COMPLEX KARYOTYPE ACUTE MYELOID LEUKEMIA (CKAML) WITH 5Q DELETIONS USING LONG READ SEQUENCING TECHNOLOGIES	Anna Dolnik	Received

PF-446	THE SYK INHIBITRO BAY 61-3606 DIHYDROCHLORIDE INDUCES APOPTOSIS OF ACUTE MYELOID LEUKEMIA CELLS BY MODULATING PI3K/AKT?NF/?B PATHWAY	Yanhan Zhou	Received

PF-447	DECIPHERING CLONAL HETEROGENEITY IN AML NPM1 THROUGH SINGLE-CELL MULTI-OMIC	Wencke Walter	Received

PF-448	ISOVALERYLSPIRAMYCIN I SUPPRESSES THE PROLIFERATION OF MYELOID MALIGNANCIES VIA NLRP3 INFLAMMASOME-MEDIATED PYROPTOSIS AND ROS-DRIVEN DNA DAMAGE RESPONSE.	wenbin yang	Received

PF-449	IDENTIFICATION OF LEUKEMIC STEM CELLS IN AML PATIENTS BY USING NEXT-GENERATION FLOW (NGF): A PERSONALIZED BIOMARKER OF PROGNOSIS AND PROGRESSION	Anna Sicuranza	Received

PF-450	NGS-DRIVEN DIGITAL PCR: A HIGHLY SENSITIVE AND EFFECTIVE TOOL FOR MONITORING MEASURABLE RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA.	Mirko Farina	Received

PF-451	CD52 PROMOTER METHYLATION PREDICTS RESPONSE TO AKT-TARGETING DRUGS IN ACUTE MYELOID LEUKEMIA	Carlos Quero-Dotor	Received

PF-454	OVERCOMING CHEMOTHERAPY RESISTANCE THROUGH TARGETED INHIBITION OF DNA-PK-DEPENDENT DNA REPAIR.	shuyu Qin	Received

PF-455	SELINEXOR MODULATES T CELL FUNCTION AND ALLEVIATES GVHD WHILE INHIBITING AML CELL PROLIFERATION	Xiwen Tong	Received

PF-456	DRUG SCREENING IN A ZEBRAFISH MODEL OF MLL-AF9-DRIVEN ACUTE MYELOID LEUKEMIA	Maryam Saberi	Received

PF-457	EPIDEMIOLOGY, CLINICAL FEATURES, AND MOLECULAR BASIS OF TTMV::RARA-DRIVEN ACUTE PROMYELOCYTIC LEUKEMIA	Xiaosu Zhou	Received

PF-459	DEVELOPMENT OF A DUAL TARGETING CD123-CD33 CAR-T CELL THERAPY AS A BRIDGE TO ALLO-HSCT IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA PATIENTS	Vladimir Mulens-Arias	Received

PF-461	COMPENSATORY KDM4 UPREGULATION IN IDH2-MUTANT AMLS REPRESENTS A THERAPEUTIC VULNERABILITY IN ENASIDENIB-SENSITIVE PATIENTS	Dominique Sternadt	Received

PF-462	SYNERGISTIC EFFICACY OF HDACI CHIDAMIDE WITH GL-V9 BY SUPPRESSING MYBL2 EXPRESSION IN ACUTE MYELOID LEUKEMIA	Zheng Ge	Received

PF-463	LIPOSOMAL MITOXANTRONE DEMONSTRATES SUPERIORITY TO TRADITIONAL MITOXANTRONE IN THE TREATMENT OF AML: DUAL MECHANISMS OF INDUCING APOPTOSIS AND BOOSTING IMMUNE RESPONSE	Suning Chen	Received

PF-465	LONG-TERM SURVIVAL FOR MYELOID NEOPLASMS AND NATIONAL HEALTH EXPENDITURE: A EUROCARE-6 RETROSPECTIVE, POPULATION-BASED STUDY	Daniel Zaldumbide	Received

PF-466	MONITORING OF (LEUKEMIA-SPECIFIC) IMMUNE CELLS IN STAGES, TREATMENT GROUPS AND IN THE COURSE OF DISEASE AND THERAPY CONTRIBUTES TO QUANTIFY ANTILEUKEMIC POTENTIAL AND SURVIVAL IN PATIENTS WITH AML.	Helga Schmetzer	Received

PF-468	VALIDATION OF A 4-GENE PROGNOSTIC INDEX IN A REAL-WORLD BRAZILIAN COHORT AND EVALUATION OF PHARMACOLOGICAL INHIBITION TO ENHANCE CHEMOTHERAPY RESPONSE IN ACUTE MYELOID LEUKEMIA	Maria Luiza Salustiano-Bandeira	Received

PF-471	THE SYNERGY OF DZNEP WITH CX-4945 AND THE CLINICAL RELEVANCE OF FOSL1 IN ACUTE MYELOID LEUKEMIA	Zheng Ge	Received

PF-472	COMPREHENSIVE CHARACTERIZATION OF THE BONE MARROW MICROENVIRONMENT IDENTIFIES A DISTINCT IMMUNE SIGNATURE ASSOCIATED WITH TUMOR BURDEN IN ACUTE MYELOID LEUKEMIA	Nicole Fincato	Received

PF-473	ZIFTOMENIB IN RELAPSED/REFRACTORY NPM1-MUTANT ACUTE MYELOID LEUKEMIA: PHASE 1B/2 CLINICAL ACTIVITY AND SAFETY RESULTS FROM THE PIVOTAL KOMET-001 STUDY	Amir Fathi	Received

PF-476	UPDATED RESULTS FROM THE ONGOING PHASE 1/2A STUDY OF MP0533, A TETRA-SPECIFIC DESIGNED ANKYRIN REPEAT PROTEIN (DARPIN; CD33 X CD123 X CD70 X CD3), IN PATIENTS WITH RELAPSED/REFRACTORY AML OR MDS/AML	Pierre Bories	Received

PF-478	TRANSCRIPTOMICALLY-REFINED ACUTE MYELOID LEUKEMIA, MYELODYSPLASIA-RELATED (AML-MR) REFINES SURVIVAL ASSOCIATIONS AND PRESENTS WITH DISTINCT BIOLOGICAL FEATURES	Lorenz Oelschlaeger	Received

PF-479	CPX-351 IN PATIENTS WITH NEWLY DIAGNOSED POST MYELOPROLIFERATIVE NEOPLASMS ACUTE MYELOID LEUKEMIA . FINAL RESULTS OF THE CPX-TA SMP PHASE II TRIAL.	Sylvain Garciaz	Received

PF-480	FINAL RESULTS OF VEN A QUI TRIAL: A PHASE I-II TRIAL COMPARING VENETOCLAX WITH LOW DOSE CYTARABINE OR AZACITIDINE COMBINED WITH QUIZATINIB IN NON-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA	Juan Miguel Bergua Burgues	Received

PF-481	REAL-LIFE OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA SECONDARY TO MYELOPROLIFERATIVE NEOPLASIA: RESULTS OF MULTICENTRIC ENEA-STUDY.	Giulia Ciotti	Received

PF-482	CONDITIONING INTENSITY, CONCURRENT NPM1 MUTATIONS, AND MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH FLT3-ITD AML UNDERGOING ALLOGENEIC TRANSPLANTATION: A POST-HOC ANALYSIS FROM BMT CTN 1506	Mark Levis	Received

PF-483	CLONAL ORIGIN AND EVOLUTION PATTERN UNDERLIE THE HETEROGENEITY OF FLT3-ITD–POSITIVE ACUTE MYELOID LEUKEMIA	Anli Lai	Received

PF-484	STANDARD CHEMOTHERAPY AS FIRST LINE TREATMENT FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS (BPDCN) IN THE ERA OF CD123 TRAGETED THERAPIES: FINAL RESULTS OF A FRENCH PROSPECTIVE TRIAL	Eric Deconinck	Received

PF-487	VALIDATION OF GENETIC RISK CLASSIFICATION ELN 2024 IN REAL-WORLD AML PATIENTS TREATED WITH HMA AND HMA/VEN BASED REGIMENS	Juan Miguel Bergua Burgues	Received

PF-488	MRD IN ACUTE MYELOID LEUKEMIA: A BABYLONIAN MISCOMMUNICATION?	Gwendolyn Van Gorkom	Received

PF-490	PROGNOSTIC IMPACT OF GERIATRIC ASSESSMENT IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH AZACITIDINE-VENETOCLAX	Marie Adeline Migeon	Received

PF-493	PHASE 1/1B TRIAL OF TALAZOPARIB AND GEMTUZUMAB OZOGAMICIN IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD33+ ACUTE MYELOID LEUKEMIA	Ross McCauley	Received

PF-494	CLINICAL IMPLICATIONS AND MOLECULAR PROFILING REVEAL AN APL-LIKE SUBGROUP OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA	Mingkai Shu	Received

PF-495	OUTCOMES OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA AFTER MENIN INHIBITION	Kuo-Kai Chin	Received

PF-496	EXPLORING OPTIMIZATION STRATEGIES BASED ON CD123 CAR-NK CLINICAL TRIAL RESULTS IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA	Anqi Zhang	Received

PF-497	PROGNOSTIC VALUE OF MEASURABLE RESIDUAL MUTATED IDH2 IN INTENSIVELY TREATED AML PATIENTS DEPENDS ON THE MEASURED TIME POINT	Lena Cimbalnik	Received

PF-500	REAL-WORLD UTILIZATION, SAFETY, AND CLINICAL OUTCOMES WITH GEMTUZUMAB OZOGAMICIN (GO) IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA	Elizabeth Herrity	Received

PF-501	IMPACT OF VENETOCLAX PEAK CONCENTRATIONS ON TREATMENT EFFICACY IN ACUTE MYELOID LEUKEMIA (AML)	Mengyun Zhang	Received

PF-502	THE EFFICACY AND SAFETY OF LUVOMETINIB (FCN-159) IN PEDIATRIC PATIENTS WITH REFRACTORY/RELAPSED LANGERHANS CELL HISTIOCYTOSIS: A MULTI-CENTER, OPEN-LABEL, SINGLE-ARM PHASE II STUDY	Rui Zhang	Received

PF-503	DO APL PATIENTS TREATED WITH ATO+ATRA ACHIEVE A NORMAL LIFE EXPECTANCY? INSIGHTS FROM THE LONG TERM FOLLOW-UP OF THE GIMEMA APL0406 STUDY	Alfonso Piciocchi	Received

PF-506	PRELIMINARY SAFETY, PHARMACOKINETIC, AND CLINICAL ACTIVITY RESULTS WITH FHD-286, A BRG1/BRM INHIBITOR, PLUS DECITABINE IN A PHASE 1 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY MYELOID MALIGNANCIES	Courtney DiNardo	Received

PF-507	PROGNOSTIC SIGNIFICANCE OF CLONAL MONITORING ASSESSED BY VAF IN UNFIT NEWLY DIAGNOSED AML: INSIGHTS FROM THE PETHEMA VEN-A-QUI TRIAL	Alba Mora	Received

PF-509	KMT2A REARRANGEMENTS IN PEDIATRIC INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA: FUSION PARTNER IMPACT AND PROGNOSTIC INSIGHTS. A COMPREHENSIVE SURVIVAL ANALYSIS	Hend Ali	Received

PF-511	EFFICACY AND SAFETY OF OLUTASIDENIB MONOTHERAPY IN PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA: A POST HOC ANALYSIS OF A PHASE 2 STUDY	Antonio Curti	Received

PF-513	RNA-SEQ FOR IDENTIFICATION OF TARGETABLE ALTERATIONS IN AML	Georgina El Hajjar	Received

PF-514	PROGNOSTIC IMPACT OF BCOR/BCORL1 MUTATIONS IN ND-AML PATIENTS TREATED WITH VEN-HMA	Guillaume BERTON	Received

PF-515	VARIANT T(8;21) TRANSLOCATIONS IN AML: DISTINCT CLINICAL OUTCOMES AND MUTATION PROFILES COMPARED TO CLASSIC T(8;21)	Bingbing Han	Received

PF-516	EFFECT OF MUTATION TYPE AND CO-MUTATIONS ON RESPONSE TO OLUTASIDENIB IN PATIENTS WITH RELAPSED/REFRACTORY MUTATED IDH1 AML	Stéphane De Botton	Received

PF-517	CLINICAL AND MOLECULAR CHARACTERISTICS OF AML WITH NUP98::HOXA9 FUSION: A COMPREHENSIVE ANALYSIS OF 116 CASES	Cui Wang	Received

PF-518	MEASURABLE RESIDUAL DISEASE TEST RESULTS OVER-RIDE IMPACT OF FLT3-ITD ON RELAPSE RISK IN ACUTE MYELOID LEUKAEMIA	Nan Yan	Received

PF-519	OUTCOME FOR PEDIATRIC PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA IN RUSSIA AND BELARUS TREATED ON THE APL 2003/2008 PROTO?OLS	Olga Aleinikova	Received

PF-521	MUTATIONAL LANDSCAPE AND PROGNOSTIC IMPLICATIONS IN KMT2A-R ACUTE MYELOID LEUKEMIA	Jiajia Pan	Received

PF-523	INNOVATIVE PERSONALIZED TARGET-SELECTED CAR-T CELLS: A PHASE I CLINICAL TRIAL FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA	Hai Yi	Received

PF-524	VENETOCLAX IN COMBINATION WITH CYTARABINE AND ACTINOMYCIN D (ACTIVE) FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA	Andrius Žucenka	Received

PF-526	LOCAL PAIRWISE METHYLATION DISCORDANCE AS A PREDICTIVE BIOMARKER IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING DECITABINE TREATMENT	Dong Hyun Kim	Received

PF-527	THE EFFECT OF SOCIOECONOMIC DEPRIVATION ON RECEIPT OF INTENSIVE CHEMOTHERAPY AND ENROLMENT IN CLINICAL TRIALS AMONG PATIENTS WITH ACUTE MYELOID LEUKAEMIA IN ENGLAND	Koki Shimizu	Received

PF-528	BIOLOGICAL ACTIVITY AND SAFETY OF GILTERITINIB IN SEQUENTIAL COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH R/R FLT3-ITD AML: INTERIM RESULTS FROM A MULTI-CENTER OPEN-LABEL PHASE 1/2 TRIAL	Jaymini Patel	Received

PF-529	AML WITH PRDMS REARRANGEMENT: UNIFYING PRDM16 AND MECOM REARRANGEMENTS AS A SINGLE ENTITY BASED ON CLINICAL SIMILARITIES	Bingbing Han	Received

PF-530	OLUTASIDENIB AS MAINTENANCE THERAPY AFTER TREATMENT RESPONSE IN MUTATED IDH1 ACUTE MYELOID LEUKEMIA	Andrew Wei	Received

PF-531	THE EFFICIENCY AND SAFETY OF LOW-DOSE VENETOCLAX AS A PROPHYLAXIS FOR DIFFERENTIATION SYNDROME IN THE INDUCTION REGIMEN OF ACUTE PROMYELOCYTIC LEUKEMIA	Yin Liu	Received

PF-533	REAL-WORLD EVIDENCE FOR PERIPHERAL BLOOD NPM1 MEASURABLE RESIDUAL DISEASE SURVEILLANCE IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA POST FIRST MORPHOLOGICAL REMISSION (CR1).	Siddarth Nayar	Received

PF-534	MRD EVALUATION AFTER THE 1ST INDUCTION COURSE IS AN OPTIMAL TIME POINT FOR DECISION MAKING REGARDING ALLO-HCST IMPLEMENTATION FOR DE NOVO NON-MRC AML PATIENTS	Elena Parovichnikova	Received

PF-535	VENETOCLAX BOOSTING IN ACUTE MYELOID LEUKEMIA (AML): PRELIMINARY PHARMACOKINETIC RESULTS FROM THE HOVON 171 TRIAL	Niels Westra	Received

PF-536	MUTATED RAS IN CHILDHOOD ACUTE MYELOID LEUKEMIA:MUTATED KRAS IS AN INDEPENDENT MARKER OF ADVERSE RISK	Wenyi Wang	Received

PF-540	NUTRITIONAL MONITORING VIA BIOELECTRICAL IMPEDANCE ANALYSIS IN PATIENTS INTENSIVELY TREATED FOR ACUTE MYELOID LEUKEMIA.	Corrado Zuanelli Brambilla	Received

PF-541	CD36: A SURFACE ANTIGEN MOLECULE SIGNIFICANTLY ASSOCIATED WITH POOR PROGNOSIS IN AML	Qing Ma	Received

PF-542	CLINICAL CHARACTERISTICS AND OVERALL SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) EQUAL OR OVER 60 YEARS IN CHILE. A STUDY FROM GRELAM-CHILE WITHIN AML-PETHEMA EPIDEMIOLOGIC REGISTRY.	Daniel Zaldumbide	Received

PF-543	ANALYSIS THE CONCENTRATIONS OF VENETOCLAX AND THE IMPACT OF TRIAZOLE ANTIFUNGALS IN PAIRED SAMPLES OF CSF AND PLASMA AT FIXED TIME POINT IN ACUTE LEUKEMIA PATIENTS	Zhenjiang Li	Received

PF-545	MANAGEMENT AND OUTCOME OF AML PATIENTS WITH HYPERLEUKOCYTOSIS: A SINGLE-CENTER EXPERIENCE	Michael Luebbert	Received

PF-547	CHARACTERISTICS OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA NOT RECEIVING TREATMENT	Aref Al-Kali	Received

PF-549	REAL-WORLD PATIENT MANAGEMENT PRACTICES IN RESPONDERS TO VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA	Ofir Wolach	Received

PF-550	AZACYTIDINE AND VENETOCLAX IN THE TREATMENT OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA: A SINGLE-CENTRE EXPERIENCE INCORPORATING THE UPDATED RISK CLASSIFICATION FOR LOW-INTENSITY REGIMENS	Maksim Granatkin	Received

PF-551	UNVEILING GERMLINE VARIANTS IN ACUTE MYELOID LEUKEMIA: INSIGHTS FROM A SINGLE-INSTITUTION ANALYSIS	Anna Krzeczowska	Received

PF-552	IMPACT OF COMPLETE HEMATOLOGIC RESPONSE ON SURVIVAL IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH NON-INTENSIVE REGIMENS	Giacomo Aquilino	Received

PF-553	CLINICAL CHARACTERISTICS AND OUTCOMES OF KIT-MUTATED ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COHORT STUDY OF 67 PATIENTS	Qingli Ji	Received

PF-555	SELINEXOR-BASED CHEMOTHERAPY-FREE OR LOW-DOSE CHEMOTHERAPY REGIMENS FOR ACUTE MYELOID LEUKEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROMES: EFFICACY AND SAFETY	Xiwen Tong	Received

PF-556	A META-ANALYSIS ON GILTERITINIB USING REAL-WORLD AND RANDOMIZED TRIAL DATA IN PATIENTS WITH FLT3-MUTATED REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA.	matteo molica	Received

PF-557	REL OVEREXPRESSION DRIVES RESISTANCE TO BTK INHIBITORS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH 2P GAIN	Léa Dehgane	Received

PF-558	BTK-A428D IS A CROSS-RESISTANT MUTATION TO BOTH BTK INHIBITORS AND DEGRADERS	Haitao Wang	Received

PF-559	EBF1 EXPRESSION DEFINES A SUBGROUP OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH DIFFERENTIAL BIOLOGICAL FEATURES	Víctor Jiménez-Martínez	Received

PF-560	BIOLOGICAL FEATURES OF B-CLL AND RESIDUAL IMMUNITY AT TREATMENT INITIATION DETERMINE IMMUNITY ON BTKI THERAPY.	Helen Parry	Received

PF-561	THE SECOND GENERATION BTK INHIBITOR ZANUBRUTINIB (ZANU) DEMONSTRATES ROBUST EFFICACY IN BOTH TP53 WILDTYPE AND MUTATED B CANCER CELLS IN PRECLINICAL STUDIES	Haitao Wang	Received

PF-563	A NOVEL EX VIVO 3D LYMPH NODE ENVIRONMENT MORE ACCURATELY REPRODUCE IN VIVO RESPONSES TO IBRUTINIB AND VENETOCLAX IN CHRONIC LYMHOCYTIC LEUKEMIA	Daniela Belloni	Received

PF-564	EVIDENCE FOR A PRE-SWITCHED POPULATION AND UNMUTATED IMMUNOGLOBULIN RECEPTORS IN IGG-EXPRESSING CLL STEREOTYPED SUBSET #4	Anastasia Iatrou	Received

PF-566	T CELLS FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS SHOW SIGNS OF ACCELERATED SENESCENCE	Elena Camerini	Received

PF-567	MICRORNA-203A IS ENRICHED IN STROMAL-CELL DERIVED EXTRACELLULAR VESICLES OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AND ASSOCIATED WITH TUMOR BURDEN	David Van Morckhoven	Received

PF-568	DISSECTING MECHANISMS OF MECHANORESPONCE IN CHRONIC LYMPHOCYTIC LEUKEMIA	Marta Sampietro	Received

PF-569	DEVELOPMENT OF A CHARTER FOR IMPROVING CARE FOR PEOPLE LIVING WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): SHARED DECISION-MAKING AS A KEY PRINCIPLE TO DRIVE PERSON-CENTERED CARE	Yasmine Hassan	Received

PF-570	PHASE 1/2 STUDIES OF DZD8586 IN CLL/SLL PATIENTS AFTER COVALENT OR NON-COVALENT BTK INHIBITORS AND BTK DEGRADERS	Jianyong Li	Received

PF-572	MEASURABLE RESIDUAL DISEASE KINETICS WITH FIXED-DURATION ACALABRUTINIB-VENETOCLAX COMBINATIONS IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: DATA FROM THE PHASE 3 AMPLIFY TRIAL	Paolo Ghia	Received

PF-573	PRELIMINARY RESULTS FROM A PHASE 1B STUDY OF NON-COVALENT PAN-MUTANT BTK INHIBITOR DOCIRBRUTINIB (AS-1763) IN PATIENTS WITH PREVIOUSLY TREATED B-CELL MALIGNANCIES	Akinori Arimura	Received

PF-575	PRELIMINARY RESULTS OF THE ONGOING MULTICENTER, PHASE 2 STUDY OF RETREATMENT WITH VENETOCLAX PLUS OBINUTUZUMAB (REVENG) IN PATIENTS WITH RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Matthew Davids	Received

PF-576	INTERPLAY OF COMPLEX KARYOTYPE, IGHV MUTATIONAL STATUS AND TP53/ATM ALTERATIONS AND THEIR IMPACT ON PROGNOSIS IN CLL PATIENTS	Alessandro Baldi	Received

PF-578	PROGNOSTIC IMPACT OF MEASURABLE RESIDUAL DISEASE IN HAIRY CELL LEUKEMIA: A 30 YEARS SINGLE CENTER EXPERIENCE	Beatrice Esposito Vangone	Received

PF-579	DEPLETION OF NORMAL B-CELLS IS ASSOCIATED WITH INCREASED MORTALITY IN EARLY-STAGE CLL	Andy Rawstron	Received

PF-581	THE LANCET GASTROENTEROLOGY & HEPATOLOGY, 7 (2022) 254-261. DOI:10.1016/S2468-1253(21)00297-1 LUCAS GUILLO MD 16.00 ACALABRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA: REAL-WORLD EFFICACY AND SAFETY FROM THE FRENCH NATIONAL ACALABRUTINIB OBSERVATIONAL STUDY (N	Anne Quinquenel	Received

PF-582	REAL WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH CLL PREVIOUSLY EXPOSED TO BOTH BTKI AND BCL2I THERAPY, INCLUDING THOSE WITH DOUBLE REFRACTORY DISEASE	Matthew Davids	Received

PF-583	INFECTIONS, SECOND PRIMARY MALIGNANCIES AND AUTOIMMUNE DISEASES IN MONOCLONAL B-CELL LYMPHOCYTOSIS AND EARLY-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA	Arianna Bevilacqua	Received

PF-584	IBROMICS: RESULTS OF A REAL-WORLD STUDY OF PARAMETERS DETERMINING RESPONSE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN FIRST LINE WITH SINGLE AGENT IBRUTINIB	José Antonio García Vela	Received

PF-587	CROSS-STUDY COMPARISON OF IBRUTINIB IN COMBINATION WITH VENETOCLAX (I+V) VS ACALABRUTINIB IN COMBINATION WITH VENETOCLAX (A+V) IN SUBJECTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Erin OBrien	Received

PF-591	ASCIMINIB EXHIBITS A FAVORABLE CARDIOVASCULAR SAFETY PROFILE - A COMPREHENSIVE IN-VITRO MODEL	Ayala Gover Proaktor	Received

PF-592	HIGH MIR-202-5P EXPRESSION AT INITIAL DIAGNOSIS AS A PREDICTIVE BIOMARKER FOR TYROSINE KINASE INHIBITOR RESISTANCE IN CHRONIC MYELOID LEUKEMIA-- A RESULT FROM A NESTED CASE-CONTROL STUDY	Zi-Yuan Nie	Received

PF-593	EXPLORATORY ANALYSIS OF PREVALENT ADDITIONAL GENOMIC ALTERATIONS (AGAS) AT BASELINE (BL) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM ASC4FIRST	Timothy Hughes	Received

PF-594	THE STRATEGY OF ASCIMINIB MANAGEMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IN TRANSPLANT PRACTICE	Yulia Vlasova	Received

PF-595	INTERIM ANALYSIS (IA) RESULTS FROM ASC2ESCALATE SUPPORT ASCIMINIB (ASC) AS A TREATMENT (TX) OPTION IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) AFTER 1 TYROSINE KINASE INHIBITOR (TKI)	Ehab Atallah	Received

PF-596	NEW PEDIATRIC FORMULATION OF ASCIMINIB IN CHILDREN WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: SECOND INTERIM ANALYSIS OF PHARMACOKINETICS, SAFETY AND GROWTH DATA FROM THE ASC4KIDS STUDY	Markus Metzler	Received

PF-597	ASCIMINIB AFTER ONE PRIOR TYROSINE KINASE INHIBITOR IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA – A PHYSICIAN PANEL-BASED CHART REVIEW STUDY IN THE UNITED STATES	David Wei	Received

PF-598	DNMT3A, GATA2 AND SETBP1 VARIANT STATUS IN BONE MARROW MONONUCLEAR CELLS IS PREDICTIVE OF TREATMENT-FREE REMISSION IN CML PATIENTS FROM THE DESTINY TRIAL	Shaun Patterson	Received

PF-599	THE EUTOS LONG-TERM SURVIVAL SCORE PREDICTS FAILURE-FREE SURVIVAL IN CHRONIC MYELOID LEUKEMIA PATIENTS IN THE ERA OF SECOND-GENERATION TYROSINE KINASE INHIBITORS: ANALYSIS FROM THE JALSG-JSH CML STUDY	Fumisato Takagi	Received

PF-600	NEW CHINESE SCORE FOR PREDICTING OUTCOMES TO FIRST-LINE CML THERAPY IS NOT SUPERIOR TO ELTS WHEN TESTED INA EUROPEAN POPULATION WITH AN OLDER MEDIAN AGE: A STUDY FROM THE ITALIAN CML CAMPUS NETWORK	Tiziana Rosso	Received

PF-602	INTEGRATED GENOMIC AND TRANSCRIPTOMIC ANALYSES REVEALS THE CLINICAL HETEROGENEITY OF NEWLY-DIAGNOSED ACCELERATED-PHASE CHRONIC MYELOID LEUKEMIA	Mei Bao	Received

PF-603	SUSTAINED IMPAIRMENT OF KIDNEY FUNCTION IN PATIENTS WITH PH+ CML TREATED WITH IMATINIB	Max V. John	Received

PF-604	TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DE NOVO ACCELERATED-PHASE AND/OR TYROSINE KINASE-INHIBITOR FAILURE: A RETROSPECTIVE MULTICENTER STUDY	Mengyao Yuan	Received

PF-605	HLA DIVERSITY IS ASSOCIATED WITH TREATMENT RESPONSE AND TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA	Charles Toulemonde	Received

PF-606	BCR::ABL1 KINETICS IN PERIPHERAL BLOOD DURING DOSE DE-ESCALATION PHASE ARE PREDICTIVE OF TFR SUCCESS: A SUB-STUDY OF THE DESTINY CLINICAL TRIAL	Shaun Patterson	Received

PF-607	RECAPITULATION OF PEDIATRIC MDS DISEASE PHENOTYPES USING HIPSCS: THE ROLE OF SETBP1 AND ASXL1 IN THE GATA2 DEFICIENCY	Joan Pera	Received

PF-608	MITOTIC DEFECTS IMPAIRED CD34+ PROLIFERATION IN GATA2 DEFICIENCY	Maria Magallon-Mosella	Received

PF-610	HMGB3 AS A CARGO PROTEIN FOR XPO1: IMPLICATIONS FOR MYELODYSPLASTIC SYNDROMES PROGNOSIS AND TREATMENT	Wenli Yang	Received

PF-611	DYSFUNCTIONAL CD4 T CELL SUBSETS CONTRIBUTE TO A DEFICIENT ANTITUMORAL IMMUNE RESPONSE IN LOW-RISK MYELODYSPLASTIC SYNDROMES	Ana Aldaz Sagredo	Received

PF-612	LINKING SENESCENCE TO MITOCHONDRIAL METABOLIC ALTERATIONS IN MESENCHYMAL STROMAL CELLS FROM MYELODYSPLASTIC SYNDROME PATIENTS	Cesarina Giallongo	Received

PF-613	MULTIPLE EFFECTS OF ARTESUNATE ON THE IMMUNE ENVIRONMENT OF A MYELODYSPLASTIC SYNDROME MODEL	João Vitor Facco	Received

PF-614	DECODING THE STRESS GRANULE PROTEOME REWIRING UPON SPLICING FACTOR MUTATIONS IN MYELOID MALIGNANCIES	Martina Vigorelli	Received

PF-615	ELEVATED EXPRESSION OF HEME METABOLISM HALLMARK GENES AS A FAVORABLE BIOMARKER IN SF3B1-MUTATED MYELODYSPLASTIC NEOPLASMS	Sophia Groh	Received

PF-620	MECHANISM OF VISTA UPREGULATING THE FUNCTION OF MDSCS TO MEDIATE THE SUPPRESSION OF CTL CELLS IN MDS PATIENTS	Lijuan Li	Received

PF-622	DISSECTING METABOLIC ABERRANCIES OF CD34+ PROGENITORS IN MYELODYSPLASTIC SYNDROMES.	Aikaterini Poulaki	Received

PF-625	VARIANT ALLELIC FREQUENCY (VAF) MATTERS: ARTIFICIAL INTELLIGENCE ALGORITHMS HIGHLIGHT VAF INFORMATIONAL VALUE IN ASCERTAINING THE DIAGNOSIS AND THE PROGNOSIS OF MYELOID NEOPLASMS.	Monia Marchetti	Received

PF-626	DECITABINE PLUS ALL-TRANS RETINOIC ACID VERSUS DECITABINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROMES WITH EXCESS BLASTS: A MULTICENTRE, RANDOMIZED CONTROLLED TRIAL	Xinping Zhou	Received

PF-627	ALLOGENEIC STEM CELL TRANSPLANTATION-RELATED OUTCOMES IN MYELODYSPLASTIC SYNDROMES: ANALYSIS OF A LARGE CONTEMPORARY COHORT	Alexandre Bazinet	Received

PF-629	A RANDOMIZED, MULTICENTER PHASE II TRIAL OF 3-DAY DECITABINE, 3-DAY AZACITIDINE, OR 5-DAY AZACITIDINE IN LOWER-RISK MYELODYSPLASTIC SYNDROME	Ian Bouligny	Received

PF-631	CONSIDERATION OF UNOBSERVED RISK FACTORS (FRAILTY) ON OVERALL SURVIVAL FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES WHO UNDERWENT HSCT	Udit Nangia	Received

PF-632	EVALUATING LUSPATERCEPT AS A SUPERIOR TREATMENT FOR ENHANCING CLINICAL AND HRQOL OUTCOMES IN TRANSFUSION-DEPENDENT PATIENTS WITH LOWER-RISK MDS: RESULTS FROM PHASE 3 COMMANDS STUDY	Esther Natalie Oliva	Received

PF-633	MANAGEMENT OF PATIENTS WITH HEMATOLOGICAL DISORDERS WITH GERMLINE PREDISPOSITIONS IN JAPAN	Mizuki Watanabe	Received

PF-635	HEMATOLOGIC IMPROVEMENT AND FATIGUE REDUCTION WITH ELRITERCEPT IN PARTICIPANTS WITH LOWER-RISK (LR) MYELODYSPLASTIC NEOPLASMS (MDS) WITH NON-TRANSFUSION DEPENDENT ANEMIA: RESULTS FROM AN ONGOING PHASE 2 TRIAL	Daniel Zaldumbide	Received

PF-636	ARTIFICIAL INTELLIGENCE-ENHANCED ANALYSIS OF HMA TREATMENT ON CLINICAL OUTCOMES IN A LARGE COHORT OF MDS PATIENTS: PRELIMINARY RESULTS FROM AN ANALYSIS FROM THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS) VALIDATE DATABASE	Tariq Kewan	Received

PF-637	APPLICABILITY OF CURRENT PROGNOSTICATION MODELS FOR MDS PATIENTS WITH DDX41 MUTATION	Nadia Toumeh	Received

PF-639	EFFICACY AND SAFETY OF LUSPATERCEPT AND ERYTHROPOIESIS-STIMULATING AGENT IN PATIENTS WITH MYELODYSPLASTIC NEOPLASMS WITH RING SIDEROBLASTS (MDS-RS): A MULTICENTER REAL-LIFE STUDY.	Thibault Comont	Received

PF-640	CLINICAL AND MOLECULAR CHARACTERIZATION OF ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES AND OUTCOMES WITH VENETOCLAX-BASED THERAPY	Alexandre Bazinet	Received

PF-643	CPX-351 FOR TRANSPLANT ELIGIBLE, HIGHER RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES: MOLECULAR RESPONSES AND LONG-TERM FOLLOW-UP	Veronica Guerra	Received

PF-644	IMPROVEMENTS IN HEMATOLOGICAL PARAMETERS AND QUALITY OF LIFE (QOL) WITH ELRITERCEPT: RESULTS FROM AN ONGOING PHASE 2 TRIAL IN PARTICIPANTS WITH LOWER-RISK (LR) MYELODYSPLASTIC NEOPLASMS (MDS)	Aristoteles Giagounidis	Received

PF-645	FLT3 MUTATIONS IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A MULTI-CENTER ANALYSIS	Juan Jose Rodriguez Sevilla	Received

PF-646	INCREASED DURATION OF TIME WITHOUT TRANSFUSION RELIANCE FOR PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH IMETELSTAT VERSUS PLACEBO IN THE IMERGE TRIAL	Esther Natalie Oliva	Received

PF-647	ERYTHROID STIMULATING AGENTS IN VEXAS SYNDROME: A MULTICENTER RETROSPECTIVE STUDY OF AN ITALIAN VEXAS COHORT	Elisa Diral	Received

PF-648	INFLUENCE ANALYSIS OF TP53 AND SETBP1 SINGLE NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME	Wang xianwei	Received

PF-650	PATIENT-DERIVED EXPANDED POTENTIAL STEM CELLS FROM PNH DEMONSTRATE GLYCOSYL-PHOSPHATIDYL INOSITOL ANCHORED PROTEIN AS A CRITICAL REGULATOR IN HEMATOPOIETIC DEVELOPMENT AND DIFFERENTIATION	Rong Fu	Received

PF-652	GENOTYPE-PHENOTYPE ANALYSIS IN GATA2 DEFICIENCY: INSIGHTS FROM 901 INDIVIDUALS	Lili Kotmayer	Received

PF-653	DIHYDROARTEMISININ MODULATES CD4+ T CELL DIFFERENTIATION THROUGH NOTCH SIGNALING IN APLASTIC ANEMIA	Jing Guan	Received

PF-655	HEROMBOPAG COULD RESTORE HEMATOPOIETIC AND IMMUNE HOMEOSTASIS OF APLASTIC ANEMIA PATIENTS BY REMODELING BONE MARROW MACROPHAGE POLARIZATION VIA ACTIVATING THE PI3K/AKT PATHWAY	Chenyuan Li	Received

PF-656	COMPREHENSIVE MULTIPROTEOMIC ANALYSIS REVEALS AN INFLAMMATORY PHENOTYPE WITH A TH1/17 AXIS IN IMMUNE APLASTIC ANEMIA	Audrey Le Floc´h	Received

PF-657	MULTIPOTENT MESENCHYMAL STROMAL CELLS FROM THE BONE MARROW OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA COMBINED WITH BONE MARROW FAILURE REVEAL PROFOUND CHANGES IN GENE EXPRESSION	Alena Dorofeeva	Received

PF-658	AUTOIMMUNE NEUTROPENIA AND CHRONIC IDIOPATHIC NEUTROPENIA OF CHILDHOOD ARE ASSOCIATED WITH A LOWER PERCENTAGE OF T REGULATORY CELLS	KONSTANTINA TOUTOUDAKI	Received

PF-661	EFFICACY AND SAFETY OF POZELIMAB PLUS CEMDISIRAN VERSUS RAVULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA WHO ARE NAÏVE TO COMPLEMENT INHIBITION	Christopher Patriquin	Received

PF-662	CLONAL HEMATOPOIESIS IN SEVERE APLASTIC ANEMIA AND ITS CLINICAL SIGNIFICANCE-ANALYSES OF MUTATIONS IN MYELOID MALIGNANCY-RELATED GENES AND HLA GENES, AS WELL AS LOSS OF HETEROZYGOSITY (LOH) OF HLA	Kuojui Sun	Received

PF-664	EFFICACY AND SAFETY OF AVATROMBOPAG IN RELAPSED OR REFRACTORY SEVERE APLASTIC ANAEMIA: RESULTS OF THE DIAAMOND-AVA-NEXT TRIAL	Zoe McQuilten	Received

PF-665	DEVELOPMENT OF DATA-DRIVEN MACHINE LEARNING ALGORITHMS TO HELP DIFFERENTIAL DIAGNOSIS BETWEEN INHERITED AND ACQUIRED BONE MARROW FAILURE SYNDROMES	Marta Bortolotti	Received

PF-666	SUSTAINED LONG-TERM CONTROL OF TERMINAL COMPLEMENT ACTIVITY WITH RAVULIZUMAB OR DANICOPAN ADD-ON TO RAVULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Christopher Patriquin	Received

PF-668	DIAMOND-BLACKFAN ANEMIA SYNDROME BASED ON SPLICE-SITE VARIANTS IN RPS7 IS CHARACTERIZED BY RELATIVELY MILD ANEMIA, CRANIOFACIAL ABNORMALITIES, AND A SUSPECTED HIGH CANCER RISK.	Evangelia Kiakou	Received

PF-669	ADDING HETROMBOPAG TO CYCLOSPORINE FOR FIRST-LINE TREATMENT OF PATIENTS WITH NON-SEVERE APLASTIC ANEMIA: A PHASE 2 MULTI-CENTER CLINICAL STUDY	Lele Zhang	Received

PF-670	REAL-WORLD OUTCOMES AND CLINICAL BURDEN OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Talha Munir	Received

PF-672	EARLY RESPONSE IN COMPLEMENT INHIBITOR NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN IN THE PHASE 3 PRINCE TRIAL	Austin Kulasekararaj	Received

PF-673	APPLICATION OF MACHINE LEARNING IN THE DIAGNOSTIC WORK-UP OF CHRONIC IDIOPATHIC NEUTROPENIA IN ADULTS	Grigorios Tsaknakis	Received

PF-674	CSFR3 MUTATION IN CONGENITAL NEUTROPENIA A LONG STORY: DATA FROM THE ITALIAN REGISTRY	Francesco Pegoraro	Received

PF-675	REAL-WORLD RETROSPECTIVE ANALYSIS OF PEGCETACOPLAN EFFECTIVENESS IN PATIENTS FROM CEE COUNTRIES WITH PNH AND NO OPTIMAL RESPONSE TO C5 INHIBITORS	Lukasz Szukalski	Received

PF-676	INTERIM ANALYSIS OF THE ONGOING COMPLETE STUDY ON THE REAL-WORLD EFFECTIVENESS OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)	Régis Peffault de Latour	Received

PF-678	VEXINATIONS: A MULTICENTER RETROSPECTIVE STUDY ON VACCINATIONS IN VEXAS SYNDROME	Gregorio Maria Bergonzi	Received

PF-679	DEVELOPMENT OF A PREDICTIVE MODEL FOR ADVERSE MATERNAL AND PERINATAL OUTCOMES IN PREGNANT WOMEN WITH APLASTIC ANAEMIA	Qiuyu Guo	Received

PF-680	PROTEOMIC LANDSCAPE OF CASTLEMAN DISEASE REVEALS THE IRF4-WFS1 AXIS DRIVES PROGRESSION VIA PLASMA CELL DIFFERENTIATION AND SURVIVAL	Peng Liu	Received

PF-681	LRP8-DEPENDENT CHOLESTEROL METABOLISM MODULATES MTORC1 SIGNALING AND APOPTOTIC PATHWAYS IN MULTIPLE MYELOMA	Yue Wang	Received

PF-682	AGE-ASSOCIATED MACROPHAGE POLARIZATION TO AN M2 PHENOTYPE DRIVES MYELOMA PROLIFERATION IN THE AGED BONE MARROW BY LOSS OF TUMOR-ASSOCIATED PHAGOCYTOSIS	Dominic Fowler-Shorten	Received

PF-683	IMMUNE BIOMARKERS OF INCREASED RISK OF INFECTION IN MULTIPLE MYELOMA (MM)	Aintzane Zabaleta	Received

PF-684	DISRUPTION OF NEAT1 DEPENDENT GENE EXPRESSION PROGRAM UNCOVERS NOVEL TARGETABLE VULNERABILITIES IN MULTIPLE MYELOMA.	Noemi Puccio	Received

PF-686	CD70/CD27 SIGNALING PROMOTES CLONAL PLASMA CELL EXPANSION IN MULTIPLE MYELOMA AND REPRESENTS A PROMISING THERAPEUTIC TARGET	Maxime Boy	Received

PF-687	SINGLE CELL RNA AND WHOLE GENOME SEQUENCING ANALYSIS REVEAL DISTINCT IMMUNE AND GENOMIC SIGNATURES IN WM PATIENTS RESISTANT TO IBRUTINIB THERAPY	Tina Bagratuni	Received

PF-688	RADIOMICS-BASED RESPONSE PREDICTION IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA	Guneet Janda	Received

PF-689	SELINEXOR POTENTIATES ANTIBODY-DEPENDENT CELLULAR-CYTOTOXICITY (ADCC) AND CAR-NK CELL ACTIVATION AGAINST MULTIPLE MYELOMA CELLS VIA DOWNREGULATION OF HLA-E	Matthew Blunt	Received

PF-690	PRECLINICAL ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMBINATION STRATEGIES WITH T CELL BISPECIFICS AND DARATUMUMAB TO SUPPORT OPTIMIZATION OF CLINICAL BENEFIT IN MYELOMA PATIENTS	Douglas Marvel	Received

PF-691	DIFFERENTIATING BETWEEN MM-LIKE AND MGUS-LIKE SMOLDERING MYELOMA	Anil Aktas Samur	Received

PF-693	IFN-RESPONSIVE STROMAL CELLS DRIVE NON-IMMUNE BONE MARROW NICHE ALTERATIONS IN MULTIPLE MYELOMA PROGRESSION AND VRD TREATMENT RESPONSE	Miguel Cócera	Received

PF-696	PROGNOSTIC SIGNIFICANCE AND MOLECULAR FUNCTION OF PSMD10 AS A REGULATOR OF PROTEOSTASIS IN MULTIPLE MYELOMA	ZUZANNA TRACZ-GASZEWSKA	Received

PF-697	MULTIOMIC IMMUNE BIOMARKERS OF MRD PERSISTENCE IN MULTIPLE MYELOMA	Maria Speciale	Received

PF-698	EXOSOME-DERIVED CIRCCOG5 ,AS A NEW PROGNOSTIC INDICATOR OF MBD, AGGRAVATED OSTEOLYTIC LESIONS BY CIRCCOG5 / MIR-625-3P / RANKL AXIS	Xing Cui	Received

PF-699	BONE MARROW BREAKOUT LESIONS ACT AS KEY SITES FOR TUMOR-IMMUNE CELL DIVERSIFICATION AND EXHAUSTION IN MULTIPLE MYELOMA	Llorenç Solé-Boldo	Received

PF-700	STUDY ON THE INHIBITION OF LACTATE METABOLISM IN MULTIPLE MYELOMA CELLS TO ENHANCE THE ANTI-TUMOR EFFECT OF BCMA CAR-T CELLS	Zhaoyun Liu	Received

PF-701	EFFICACY AND SAFETY OUTCOMES IN PATIENTS (PTS) WITH RENAL IMPAIRMENT IN THE PHASE 3 DREAMM-7 AND DREAMM-8 TRIALS	Marcelo Pitombeira De Lacerda	Received

PF-702	CARDIAC GLYCOSIDES INDUCE IMMUNOGENIC CELL DEATH IN MYELOMA CELLS AND ENHANCE THE EFFICACY OF THERAPEUTIC ANTIBODIES	Tomoyuki Nakamura	Received

PF-703	MALIGNANT PLASMA CELL-DERIVED CCL2 REPROGRAM MACROPHAGE PROMOTING DISEASE PROGRESSION IN MULTIPLE MYELOMA BONE MARROW MICROENVIRONMENT	HongYan Zhao	Received

PF-704	PROGNOSTIC VALUE AND MUTATIONAL PROFILE OF CIRCULATING CLONAL B CELLS IN WALDENSTRÖM MACROGLOBULINEMIA PATIENTS UNDERGOING IBRUTINIB THERAPY	Tina Bagratuni	Received

PF-705	INHIBITION OF CARBONIC ANHYDRASE IX AS A NEW THERAPEUTIC STRATEGY IN MULTIPLE MYELOMA	Giorgia Gazzaroli	Received

PF-707	HIGH-DIMENSIONAL SPATIAL PROFILING OF THE BONE MARROW MICROENVIRONMENT IN MULTIPLE MYELOMA	Shiva Nickaria	Received

PF-709	EXPLORATORY BIOMARKERS ASSOCIATED WITH TALQUETAMAB RESISTANCE AND RELAPSE IN THE MONUMENTAL-1 CHINA 400 COHORT BY DATA-DRIVEN UNSUPERVISED CLUSTERING ANALYSIS	Hongmei Xu	Received

PF-710	APPLICATION OF SPATIAL TRANSCRIPTOMICS FOR ANALYZING MULTIPLE MYELOMA	Sandra Haingartner	Received

PF-711	BRAIN MRI FINDINGS IN UNTREATED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)	Wilma Barcellini	Received

PF-712	THE NOVEL RECURRENT FUSION GENE DDX5-EEF1A1 SERVES AS A MOLECULAR BIOMARKER FOR PREDICTING DISEASE PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS.	Liu Hongchen	Received

PF-713	MASS SPECTROMETRY ENABLES PRECISE MONITORING OF BISPECIFIC ANTIBODY THERAPY IN MULTIPLE MYELOMA	M Teresa Cedena	Received

PF-716	PAEONIFLORIN AMELIORATES BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY BY RECTIFYING ABNORMAL INTERLEUKIN-6 SECRETION AND AUTOPHAGY LEVEL	Xing Cui	Received

PF-717	DEGRADATION OF IKZF1 VIA E3 UBIQUITIN LIGASE X BY DNA DEMETHYLATING AGENTS IS A POTENTIAL THERAPEUTIC TARGET FOR MULTIPLE MYELOMA	Yuta Yamamoto	Received

PF-718	SYSTEMIC DISSEMINATION AND RESPONSIVENESS TO CLINICALLY-USED THERAPEUTICS IS RECAPITULATED IN A CHICK EMBRYO XENOGRAFT MODEL OF MULTIPLE MYELOMA	Izabela Cymer	Received

PF-720	CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) VERSUS ELOTUZUMAB-KRD IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: INITIAL RESULTS FOR 3-YEAR PROGRESSION-FREE SURVIVAL (PFS)	Stefan Knop	Received

PF-722	LONG TERM EFFICACY AND SAFETY OF ETENTAMIG (ABBV-383), A B-CELL MATURATION ANTIGEN (BCMA) BISPECIFIC ANTIBODY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)	Muhamed Baljevic	Received

PF-723	MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) AND BORTEZOMIB (BORT) OR CARFILZOMIB (CFZ) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM THE CC-92480-MM-002 TRIAL	Irwindeep Sandhu	Received

PF-726	DREAMM-8: MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, POMALIDOMIDE, AND DEXAMETHASONE VS STANDARD-OF-CARE REGIMEN	Meletios A. Dimopoulos	Received

PF-727	ISA-VRD IMPROVES OUTCOMES IN HIGH-RISK (HR) NEWLY DIAGNOSED TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA (NDMM TI) USING THE IMS/IMWG CONSENSUS HR DEFINITION: RESULTS FROM THE BENEFIT PHASE 3 TRIAL (IFM 2020-05)	Aurelien Chedevergne	Received

PF-728	UPDATED RESULTS FROM PHASE 3 DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN PLUS POMALIDOMIDE AND DEXAMETHASONE VS POMALIDOMIDE PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	Meletios A. Dimopoulos	Received

PF-729	ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-VRD) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): OUTCOMES IN PATIENTS WITH 1Q21+ STATUS IN THE PHASE 3 IMROZ STUDY	Meletios A. Dimopoulos	Received

PF-730	CHALLENGING THE CONCEPT OF FUNCTIONAL HIGH-RISK MYELOMA THROUGH ADVANCED TRANSCRIPTIONAL AND GENETIC PROFILING.	Sina A Beer	Received

PF-732	PROSPECTIVE FUNCTIONAL BONE DISEASE EVALUATION OF NEWLY DIAGNOSED MULTIPLE MYELOMA WITH COMBINED USE OF (18)F-FDG-PET/CT AND WHOLE-BODY DIFFUSION WEIGHTED MAGNETIC RESONANCE	Marco Talarico	Received

PF-733	EXTENDED DOSING SCHEDULE OF BELANTAMAB MAFODOTIN IN COMBINATION WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: THE PHASE 1/2 BELADRD STUDY	Evangelos Terpos	Received

PF-735	CYTOPENIAS AND INFECTIONS FOLLOWING CILTACABTAGENE AUTOLEUCEL IN HEAVILY-PRETREATED RELAPSED OR REFRACTORY MULTIPLE MYELOMA	Danai Dima	Received

PF-736	OUTCOMES OF MYELOMA PATIENTS WITH DEL 17P WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION IN EBMT CENTRES BETWEEN 2016 AND 2022	Patrick Hayden	Received

PF-737	IBERDOMIDE, BORTEZOMIB, AND DEXAMETHASONE (IBERVD) IN TRANSPLANT-INELIGIBLE (TNE) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED RESULTS FROM THE CC-220-MM-001 TRIAL	Darrell White	Received

PF-739	DREAMM-7 STUDY OF BELANTAMAB MAFODOTIN + BORTEZOMIB + DEXAMETHASONE VS DARATUMUMAB + BORTEZOMIB + DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A HIGH-RISK CYTOGENETIC SUBGROUP ANALYSIS	Maria-Victoria Mateos	Received

PF-741	DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN + POMALIDOMIDE + DEXAMETHASONE VS POMALIDOMIDE + BORTEZOMIB + DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A HIGH-RISK CYTOGENETIC SUBGROUP ANALYSIS	Meletios A. Dimopoulos	Received

PF-743	IMPACT OF SELINEXOR DOSE REDUCTIONS ON SELINEXOR, BORTEZOMIB, DEXAMETHASONE (SVD) OUTCOMES IN PATIENTS (PTS) WITH LENALIDOMIDE (LEN)-REFRACTORY MULTIPLE MYELOMA (MM): BOSTON TRIAL SUBGROUP ANALYSIS	Sosana Delimpasi	Received

PF-744	TO TREAT OR NOT? A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED STUDIES ON SMOLDERING MULTIPLE MYELOMA	Ioannis Ntanasis-Stathopoulos	Received

PF-745	HIGHER USE OF HDT/ASCT IN FIRST-LINE LEADS TO SUPERIOR SURVIVAL IN MULTIPLE MYELOMA PATIENTS AGED 66-70: REAL-WORLD EVIDENCE FROM THE NETHERLANDS	Koen Klomberg	Received

PF-746	RISK FACTORS AND MODES OF PROGRESSION IN SOLITARY BONE PLASMACYTOMA WITH OR WITHOUT MINIMAL MARROW INVOLVEMENT	Kenneth Jin Chang Lim	Received

PF-748	RESUMPTION OF BONE-MODIFYING AGENTS IN RELAPSED MULTIPLE MYELOMA AND PATIENT OUTCOMES: A REAL-WORLD ANALYSIS	Malcolm Su	Received

PF-750	ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, DEXAMETHASONE (ISA-VRD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE (TI) NEWLY DIAGNOSED MYELOMA (NDMM) AND PLASMACYTOMAS: IMROZ SUBGROUP ANALYSIS	Elena Zamagni	Received

PF-752	ISATUXIMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO RELAPSED AFTER ONE LINE OF LENALIDOMIDE-CONTAINING THERAPY: A PHASE 2 STUDY BY THE GREEK MYELOMA STUDY GROUP	Evangelos Terpos	Received

PF-753	ETOPOSIDE+CYTARABINE+PEGFILGRASTIM VS CYCLOPHOSPHAMIDE+GRANULOCYTE COLONY-STIMULATING FACTOR FOR STEM-CELL MOBILIZATION IN PATIENTS WITH MULTIPLE MYELOMA: A PHASE III TRIAL	Peipei Ye	Received

PF-754	INTERIM ANALYSIS OF MRD-GUIDED MAINTENANCE THERAPY WITH BELANTAMAB MAFODOTIN AND LENALIDOMIDE AFTER AUTO-HCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA	Yosra Aljawai	Received

PF-756	WHOLE BODY MAGNETIC RESONANCE IMAGING FOR EARLY TREATMENT RESPONSE EVALUATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA	Ioannis Ntanasis-Stathopoulos	Received

PF-757	HIGH PREVALENCE AND INCIDENCE OF ATRIAL FIBRILLATION AMONG PATIENTS WITH MULTIPLE MYELOMA. A POPULATION-BASED STUDY ON 8 672 PATIENTS DIAGNOSED 2008-2021 FROM THE SWEDISH MYELOMA REGISTRY.	Karin Larsson	Received

PF-758	SEQUENTIAL BCMA CAR T-CELL THERAPY IN REFRACTORY MULTIPLE MYELOMA	Tim Richardson	Received

PF-759	BASELINE OCULAR CONDITIONS AND INCIDENCE OF OCULAR EVENTS IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) FROM THE DREAMM-7 AND DREAMM-8 TRIALS OF BELANTAMAB MAFODOTIN (BELAMAF)	Meletios A. Dimopoulos	Received

PF-760	REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ASIA – AN ASIAN MYELOMA NETWORK STUDY	Cinnie Soekojo	Received

PF-761	DENOSUMAB IN MULTIPLE MYELOMA: LONGITUDINAL IMPACT ON BONE MINERAL DENSITY DYNAMICS AND PROGRESSION-FREE SURVIVAL — A MULTICENTER PROSPECTIVE COHORT ANALYSIS	Li Bao	Received

PF-764	EFFICACY AND SAFETY OF ETENTAMIG, A BCMA X CD3 BISPECIFIC ANTIBODY, IN BLACK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A POOLED ANALYSIS OF PHASE 1 TRIALS	Eben Lichtman	Received

PF-769	CLINICAL CHARACTERISTICS AND OUTCOMES OF UNTREATED AL-AMYLOIDOSIS PATIENTS: AN ANALYSIS OF A POPULATION-BASED REGISTRY	Flores Weverling	Received

PF-773	INVESTIGATION INTO SECONDARY EXTRAMEDULLARY MYELOMA: A NOVEL FIVE-PREDICTOR SCORING SYSTEM HIGHLIGHTING DOUBLE-HIT CYTOGENETICS	Yi Tao	Received

PF-775	REAL-WORLD CLINICAL PRACTICE IN ITALIAN PATIENTS WITH MULTIPLE MYELOMA: PRELIMINARY ANALYSIS OF THE MY MYELOMA MULTICENTER REGISTRY	Giuseppe Bertuglia	Received

PF-777	DE-ESCALATED TECLISTAMAB DOSING IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: CZECH MYELOMA GROUP REAL-WORLD EVIDENCE STUDY	Martin Stork	Received

PF-778	IMWG/ECOG FRAILTY ASSESSMENT IN NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS	Chengcheng Fu	Received

PF-779	EARLY CLINICAL AND NON-GENETIC PREDICTORS OF FUNCTIONAL HIGH RISK NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS	Massimo Offidani	Received

PF-781	STEM CELL TRANSPLANTATION IN FIT ELDERLY MULTIPLE MYELOMA PATIENTS IS SAFE AND EFFECTIVE, A REAL-WORLD AGE GROUP COMPARISON	Koen Klomberg	Received

PF-782	IMPACT OF FREE LIGHT CHAINS BURDEN ON AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) OUTCOMES FOR AL AMYLOIDOSIS	Samer Srour	Received

PF-785	IDENTIFICATION OF BARD1 MUTATION AS A NOVEL INDICATOR FOR CONSTRUCTING A PROGNOSTIC NOMOGRAM IN MULTIPLE MYELOMA	Yun Lin	Received

PF-786	RISK-SCORING MODEL FOR THE PROGNOSTIC IMPACT OF ADDITIONAL COPIES OF CHROMOSOME 1Q IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA	Yi Li	Received

PF-787	REAL-WORLD EFFECTIVENESS OF BELANTAMAB MAFODOTIN, BCMA-CD3 BISPECIFIC ANTIBODIES AND TALQUETAMAB IN PATIENTS WITH TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA. FIRST RESULTS FROM THE DANISH ABCD-STUDY.	Astrid Hundebøll Torpe	Received

PF-791	THE TREATMENT OF PATIENTS PROGRESSING AFTER LENALIDOMIDE MAINTENANCE: AN ITALIAN REAL-LIFE STUDY OF 284 CASES	Gregorio Barilà	Received

PF-795	RELAPSE FROM MEASURABLE DISEASE NEGATIVITY AS INDICATION FOR TREATMENT IN MULTIPLE MYELOMA: THE PHASE 3 REMNANT STUDY	Frida Bugge Askeland	Received

PF-796	SINGLE AGENT ELRANATAMAB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/R MM) – MULTI-CENTRE REAL-WORLD OUTCOMES FROM 5 UNITED KINGDOM (UK) SITES	Oliver Tomkins	Received

PF-800	TRIAL IN PROGRESS: QUINTESSENTIAL A PHASE 2 STUDY OF ARLOCABTAGENE AUTOLEUCEL (ARLO-CEL) IN TRIPLE- AND QUAD-CLASS EXPOSED PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)	Daniel Zaldumbide	Received

PF-801	BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, INCB057643, IMPROVES BONE MARROW FUNCTION AND SHIFTS MEGAKARYOPOIESIS TO ERYTHROPOIESIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPNS)	Haley Maire	Received

PF-803	BCL-XL INHIBITION POTENTIATES INTERFERON-INDUCED APOPTOSIS IN MPN STEM CELLS	Steven Lane	Received

PF-808	THE DYNAMIC LANDSCAPE OF IMMUNE ENVIRONMENT FOR MM PATIENTS RECEIVING T CELL REDIRECTING THERAPIES	Jin Lu	Received

PF-809	A NOVEL JAK2 INHIBITOR OB756 INHIBITS MEGAKARYOPOIESIS DIFFERENTIATION AND PROPLATELET BIOGENESIS VIA PI3K-AKT SIGNALING PATHWAY IN PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS	Jian Huang	Received

PF-811	CLONAL DYNAMICS AND COMPLEXITY OF HEMATOPOIETIC STEM CELLS CO-MUTATED IN CALR AND TP53 DURING THE TRANSFORMATION OF CLASSICAL MYELOPROLIFERATIVE NEOPLASMS	Syrine BEL HAJ YAHIA	Received

PF-813	DIETARY IRON AFFECTS HAEMATOLOGY AND BONE HEALTH IN A MOUSE MODEL OF POLYCYTHAEMIA VERA	Cavan Bennett	Received

PF-815	TRANSCRIPTIONAL REPROGRAMMING OF SPLENIC ENDOTHELIAL CELLS IN MYELOFIBROSIS	Francesca Lazzaroni	Received

PF-817	THE INFLAMMASOME NEGATIVELY MODULATES HEME OXYGENASE 1 CONTRIBUTING TO BONE MARROW FIBROSIS IN MYELOPROLIFERATIVE NEOPLASMS	Jessica Ferrigno	Received

PF-818	HYDROXYUREA DRIVES CLONAL SELECTION OF TP53 MUTATED CELLS IN MYELOPROLIFERATIVE NEOPLASMS (MPN)	Nabih Maslah	Received

PF-819	JAK2 V617F VAF AND PRESENCE OF COPY NEUTRAL-LOH AT CHROMOSOME 9P (CHR9P) PREDICTS TRANSFORMATION TO MYELOFIBROSIS (MF) IN PATIENTS WITH POLYCYTHEMIA VERA (PV) ENROLLED IN REVEAL	Stephen Oh	Received

PF-821	THE CLONAL ORIGIN AND EVOLUTION OF HIGH-RISK MULTISYSTEM HISTIOCYTOSIS IN ADULTS	Kudzai Nyamondo	Received

PF-822	THROMBOCYTOPENIA IN MYELOFIBROSIS (MF) IS CHARACTERIZED BY INFLAMMATORY MEGAKARYOCYTES WITH REDUCED G6B EXPRESSION THROMBOCYTOPENIA IN MYELOFIBROSIS IS CHARACTERIZED BY INFLAMMATORY MEGAKARYOCYTES WITH REDUCED G6B EXPRESSION	Lilian Varricchio	Received

PF-823	THE SPATIAL DYSREGULATION OF MICROENVIRONMENT INVOLVING TENASCIN-C EXPRESSING CELLS CAN BE A CLINICALLY APPLICABLE MARKER FOR FIBROSIS PROGRESSION IN THE PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS.	Keiki Nagaharu	Received

PF-824	MECHANISMS OF FIBROCYTE INDUCTION IN LYMPHOID MALIGNANCIES: THE ROLE OF CCL22 AND TIMP-1 IN SECONDARY MYELOFIBROSIS	Noriaki Tachi	Received

PF-826	CD44 CONTRIBUTES TO EXTRAMEDULLARY HEMATOPOIESIS IN MYELOFIBROSIS PATIENTS BY REGULATING THE INTERPLAY BETWEEN MONOCYTE AND HEMATOPOIETIC STEM AND PROGENITOR CELLS	Camilla Tombari	Received

PF-827	NEW CRITERIA FOR EVALUATING OUTCOMES OF MYELOFIBROSIS THERAPY: THE EUROPEAN LEUKEMIANET DEMYOS (DESIRABILITY OF MYELOFIBROSIS OUTCOMES)	Monia Marchetti	Received

PF-828	SURVIVAL IMPACT AND KINETICS OF HEMOGLOBIN IMPROVEMENT WITH MOMELOTINIB IN PATIENTS WITH MYELOFIBROSIS AND MODERATE TO SEVERE ANEMIA: POST HOC ANALYSES OF SIMPLIFY-1 AND MOMENTUM	Francesca Palandri	Received

PF-829	SAFETY PROFILE OF LONG-TERM EXPOSURE TO RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS, ANALYSIS FROM A REAL-WORLD DATA NETWORK	Alberto Blanco Sánchez	Received

PF-830	IMPROVEMF UPDATE: PHASE 1/1B TRIAL OF IMETELSTAT (IME)+RUXOLITINIB (RUX) IN PATIENTS WITH INTERMEDIATE (INT)-1, INT-2, OR HIGH-RISK (HR) MYELOFIBROSIS (MF)	John Mascarenhas	Received

PF-833	FINAL RESULTS OF A PILOT STUDY OF ELOTUZUMAB IN PATIENTS WITH MYELOFIBROSIS	Prithviraj Bose	Received

PF-834	PROTECTIVE EFFECT OF ACETYLSALICYLIC ACID AND INTERFERON ALPHA ON LIVE BIRTH RATE IN MYELOPROLIFERATIVE NEOPLASMS: A META-ANALYSIS BASED ON THE SYSTEMATIC REVIEW OF 1,697 PREGNANCIES.	Monia Marchetti	Received

PF-835	SURVIVAL OUTCOMES IN ACCELERATED AND BLAST PHASE MPN: A REAL-WORLD ANALYSIS FROM THE UK MPN CLINICAL STUDY GROUP.	Alexandros Rampotas	Received

PF-836	DEFINING THE PROGNOSIS FOR ESSENTIAL THROMBOCYTHEMIA: A VALIDATION OF THE AAA+A RISK MODEL AND THE IDENTIFICATION OF A NEW PROGNOSTIC MARKER, THE LYMPHOCYTES-TO-MONOCYTES RATIO	Fabrizio Cavalca	Received

PF-837	GECACITINIB IN JAKI-NAÏVE AND JAKI-EXPOSED MYELOFIBROSIS PATIENTS: IMPROVED TRANSFUSION INDEPENDENCE	Yi Zhang	Received

PF-838	THROMBOSIS RISK AND HORMONE USE IN WOMEN WITH MPN : DATA FROM A CONTEMPORARY COHORT	Ikram-Nour Abda	Received

PF-839	GENE EXPLORATION AND CLINICAL CHARACTERISTICS IN TRIPLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA VIA WHOLE EXOME SEQUENCING	Siraphop Thammayot	Received

PF-840	IMPACT OF ELN CLINICAL SIGNS AND SYMPTOMS ON OUTCOMES IN POLYCYTHEMIA VERA PATIENTS TREATED WITH HYDROXYUREA OR RUXOLITINIB: A COOPERATIVE STUDY	Francesca Palandri	Received

PF-841	IMPACTMF, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED OR REFRACTORY TO JANUS KINASE INHIBITORS	John Mascarenhas	Received

PF-842	LYMPHOCYTE TO MONOCYTE RATIO MAY PREDICT TRANSFORMATION TO MYELOFIBROSIS FOR POLYCYTHEMIA VERA PATIENTS TREATED WITH RUXOLITINIB: EXPERIENCE FROM MAJIC-PV TRIAL	Andrea Duminuco	Received

PF-843	PROGNOSTIC IMPLICATIONS OF RED BLOOD CELL DISTRIBUTION WIDTH-TO-ALBUMIN RATIO IN PATIENTS WITH MYELOFIBROSIS: INSIGHTS FROM A 10-YEAR RETROSPECTIVE AND MULTICENTER COHORT	Jian Huang	Received

PF-844	A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL TO ADDRESS THE IMPACT OF TARGETED FLUDARABINE ON THE INCIDENCE OF VIRAL COMPLICATIONS AFTER aßTCR/CD19 DEPLETED ALLO-HCT	Moniek de Witte	Received

PF-847	STUDY DESIGN AND DEMOGRAPHICS OF IMPRSSION, A PHASE 2 OPEN-LABEL CLINICAL TRIAL EVALUATING TMPRSS6 ANTISENSE INHIBITOR SAPABLURSEN, IN POLYCYTHEMIA VERA	Daniel Zaldumbide	Received

PF-848	SEX INFLUENCES MPN PHENOTYPE AND CLINICAL OUTCOMES: A REAL WORLD STUDY OF 1167 SUBJECTS FROM THE QUEBEC REGISTRY	Geneviève Huynh-Trudeau	Received

PF-849	HEMATOLOGIC IMPROVEMENT EXPERIENCED BY PACRITINIB-TREATED PATIENTS WITH MYELOFIBROSIS IN REAL-WORLD CLINICAL SETTINGS	Michael Marrone	Received

PF-850	GECACITINIB-INDUCED SPLEEN VOLUME REDUCTION (SVR) AND ITS PROGNOSTIC VALUE FOR OVERALL SURVIVAL (OS) IN MYELOFIBROSIS	Yi Zhang	Received

PF-853	GECACITINIB THERAPY´S IMPACT ON SYMPTOM BURDEN IN THE ZGJAK016 STUDY	Yi Zhang	Received

PF-855	THE PROGNOSTIC IMPACT OF CYTOGENETIC AND MOLECULAR TESTING IN SECONDARY MYELOFIBROSIS	Holly Pertile	Received

PF-856	A PHASE 1B/2 STUDY OF DISC-0974, AN ANTI-HEMOJUVELIN ANTIBODY, IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA	Sima Bhatt	Received

PF-857	FACTORS INFLUENCING CHR AND MR ACHIEVEMENT AND MAINTENANCE IN POLYCYTHEMIA VERA PATIENTS WITH HYDROXYUREA RESISTANCE/INTOLERANCE TREATED WITH ROPEGINTERFERON ALFA-2B	Sung-Eun Lee	Received

PF-859	CLINICAL PATHWAYS AND PROGNOSTIC STRATEGIES IN MYELOFIBROSIS: A REAL-WORLD ANALYSIS OF GERMAN PRACTICE	Francisco Henriquez	Received

PF-860	ASSESSMENT OF RISK FACTORS AND ANTICOAGULATION STRATEGY IN MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED SPLANCHNIC VEIN THROMBOSIS (MPN-SVT): SINGLE-CENTRE, LONG-TERM, REAL-WORLD DATA.	Elena Torre	Received

PF-862	MYMPNVOICE APP: REMOTE LONGITUDINAL MONITORING OF PATIENT REPORTED OUTCOMES AND BIOMETRICS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS	Patrick Harrington	Received

PF-863	REAL-WORLD OUTCOMES OF PATIENT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB-VEDOTIN IN ASSOCIATION WITH BENDAMUSTINE: THE FRENCH LYSA EXPERIENCE	Gaétan BASILE	Received

PF-864	EVALUATION OF LONG-TERM OUTCOMES IN ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA TREATED WITH ABVD USING A PET-GUIDED STRATEGY	Jowon Laura Kim	Received

PF-865	TREATMENT EFFICACY FOR ADVANCED-STAGE CLASSIC HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS	Rong Tao	Received

PF-867	PROGNOSTIC VALUE OF PET/CT BEFORE AUTOLOGOUS STEM-CELL TRANSPLANTATION IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA	Justin Ferdinandus	Received

PF-868	FIVE-YEAR EXPERIENCE WITH PD-1 INHIBITOR COMBINATION REGIMENS IN REFRACTORY CLASSIC HODGKIN LYMPHOMA AFTER FAILURE OF IMMUNE CHECKPOINT INHIBITOR MONOTHERAPY	Julia Zhuravleva	Received

PF-870	CONSOLIDATION TREATMENT WITH BRENTUXIMAB VEDOTIN AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RELAPSED HODGKIN LYMPHOMA: ANALYSIS OF THE GHSG PHASE 2 BV-ALLO TRIAL	Christof Scheid	Received

PF-871	CHARACTERISTICS AND PREDICTORS OF EARLY DEATHS IN CLASSICAL HODGKIN LYMPHOMA	Cong Sun	Received

PF-873	REAL WORLD PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES FOR CHINESE PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA	Joey Zhen	Received

PF-874	ADULT LYMPHOMA-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: CLINICAL FEATURES, DIAGNOSTIC CHALLENGES, AND TREATMENT OUTCOMES—A 24-YEAR SINGLE-CENTER RETROSPECTIVE ANALYSIS	Humberto Nieves-Jiménez	Received

PF-876	EVOLUTION OF TREATMENT PARADIGMS AND SURVIVAL OUTCOMES IN HODGKIN´S LYMPHOMA: A 20-YEARS´ RETROSPECTIVE ANALYSIS OF 804 PATIENTS FROM A NATIONAL MEDICAL CENTER IN CHINA	Wenyan Yu	Received

PF-877	EVALUATION OF GONADAL FUNCTION IN FEMALE PATIENTS WITH HODGKIN LYMPHOMA (HL) AND PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) UNDERGOING CHEMOTHERAPY	ANGELIKI GEORGOPOULOU	Received

PF-878	EFFICACY AND SAFETY OF FIRST-LINE IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO WERE OLDER OR HAD TP53 MUTATIONS IN THE SYMPATICO STUDY	Gottfried von Keudell	Received

PF-879	TQB2825, A NOVEL 2:1 STRUCTURED CD20XCD3 BISPECIFIC ANTIBODY,IN THE RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA	Keshu Zhou	Received

PF-880	CAN MANTLE CELL LYMPHOMA BE CURED? INSIGHTS FROM 25 YEARS OF FOLLOW-UP IN THE NORDIC MCL2 AND MCL3 TRIALS	Mats Jerkeman	Received

PF-882	MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE-RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ECHO TRIAL	Michael L. Wang	Received

PF-884	IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL AMONG PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY	Floriske Stedema	Received

PF-885	EPCORITAMAB PLUS LENALIDOMIDE AND RITUXIMAB ACHIEVES HIGH RESPONSE RATES AND SURVIVAL BENEFITS COMPARED WITH USUAL CARE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A COMPARATIVE ANALYSIS	Lorenzo Falchi	Received

PF-889	CLINICAL CHARACTERISTICS AND OUTCOMES OF INCIDENTAL VS SYMPTOMATIC FOLLICULAR LYMPHOMA	Suheil Albert Atallah-Yunes	Received

PF-890	REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN HIGH-RISK, TREATMENT-NAIVE MANTLE CELL LYMPHOMA: A MULTINATIONAL ANALYSIS FROM THE UK, SWEDEN, AND FRANCE	Alex Smith	Received

PF-891	FREE LIGHT CHAIN (FLC) RATIO IS AN INDEPENDENT PROGNOSTIC RISK FACTOR FOR PROGRESSION TO SYMPTOMATIC WALDENSTROM´S MACROGLOBULINEMIA	Gianmarco Favrin	Received

PF-892	EZH2 MUTATION STATUS IS NOT PREDICTIVE IN R-CHOP AND R-B TREATED FOLLICULAR LYMPHOMA PATIENTS - A MULTICENTRIC COHORT STUDY AND META-ANALYSIS	Richárd Hanza	Received

PF-893	REAL WORLD EXPERIENCE FINDS NO DIFFERENCE IN TIME TO 2ND LINE TREATMENT BETWEEN OBINUTUZUMAB AND RITUXIMAB-CONTAINING REGIMENS AMONG PATIENTS WITH FOLLICULAR LYMPHOMA	Dor Shpitzer	Received

PF-894	RISK OF LYMPHOMA AND OTHER HAEMATOLOGIC MALIGNANCIES IN INCIDENTALLY DETECTED SPLENOMEGALY: PROSPECTIVE STUDY OF 47,066 CT/MR SCANNED GENERAL POPULATION INDIVIDUALS FROM DENMARK AND THE UNITED KINGDOM	Anne Rudbeck Juhl	Received

PF-895	IMPACT OF TP53 MUTATION STATUS ON OUTCOMES AFTER FIRST-LINE TREATMENT IN LYMPHOPLASMACYTIC LYMPHOMA.	Sherif Seif	Received

PF-897	CLINICAL CHARACTERISTICS AND MOLECULAR HETEROGENEITY IN FOLLICULAR LYMPHOMA WITH EXTRANODAL INVOLVEMENT	WeiLi Zhao	Received

PF-898	ORELABRUTINIB COMBINED WITH BENDAMUSTINE-RITUXIMAB OR OBINUTUZUMAB FOLLOWED BY ORELABRUTINIB MAINTENANCE IN UNTREATED MARGINAL ZONE LYMPHOMA (OPTIMIZE): A MULTICENTER, SINGLE-ARM, PHASE II STUDY	Wenjuan Yu	Received

PF-900	MATCHING-ADJUSTED INDIRECT COMPARISON OF LISOCABTAGENE MARALEUCEL VERSUS AXICABTAGENE CILOLEUCEL AND TISAGENLECLEUCEL FOR TREATMENT OF THIRD-LINE OR LATER R/R FL: UPDATE WITH 24 MONTHS OF FOLLOW-UP	Christa Parisi	Received

PF-902	FEATURES AND OUTCOMES OF ASYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA IN RELATION TO BONE MARROW INFILTRATION: AN ITALIAN UNIVERSITY HOSPITAL ANALYSIS	Nicolò Danesin	Received

PF-904	RARE LYMPHOID MALIGNANCIES; EPIDEMIOLOGICAL CHARACTERISTICS AT THE POPULATION LEVEL	Marc Maynadié	Received

PF-910	A PHASE 2 STUDY OF TAZEMETOSTAT (TAZ) IN CHINESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) HARBORING ENHANCER-OF-ZESTE-HOMOLOG-2 MUTATIONS (EZH2MUT)	Junning Cao	Received

PF-911	THE PROGNOSTIC ROLE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN WALDENSTRÖM MACROGLOBULINEMIA: AN INDEPENDENT PROGNOSTIC MARKER	David Kaldas	Received

PF-913	THE REAL-WORLD EFFICACY AND SAFETY OF OBINUTUZUMAB-BASED INDUCTION THERAPY FOR UNTREATED FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS	Fangfang LYU	Received

PF-916	POSITRON EMISSION TOMOGRAPHY-ADAPTED THERAPY IN LOW-RISK DIFFUSE LARGE B-CELL LYMPHOMA: 4-YEAR RESULTS OF A RANDOMIZED, PHASE III, NON-INFERIORITY TRIAL	Qing Shi	Received

PF-917	PET GUIDED OMISSION OF RADIOTHERAPY IN ELDERLY DLBCL PATIENTS WITH LESS FAVOURABLE PROGNOSIS IS SAFE: RESULTS OF 863 PATIENTS TREATED IN THE OPTIMAL>60 TRIAL OF THE DSHNHL/GLA	Viola Pöschel	Received

PF-918	RELMACABTAGENE AUTOLEUCEL (RELMA-CEL) AS SECOND-LINE THERAPY FOR R/R AGGRESSIVE B-NHL IN PATIENTS INELIGIBLE FOR HDCT/ASCT: PRIMARY ANALYSIS FROM A PHASE 2 STUDY	Yibei Zang	Received

PF-921	POLATUZUMAB VEDOTIN, RITUXIMAB, AND LENALIDOMIDE (POLA-R2) AS FIRST-LINE THERAPY FOR UNFIT AND FRAIL ELDERLY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: PRELIMINARY RESULTS FROM A PROSPECTIVE, PHASE II, MULTI-CENTER STUDY	Wei Wang	Received

PF-922	NOVEL ZCR (ZANUBRUTINIB, CHIDAMIDE, RITUXIMAB) ± CHOP REGIMEN DEMONSTRATES PROMISING EFFICACY IN FRONTLINE TREATMENT OF DOUBLE-EXPRESSOR DIFFUSE LARGE B-CELL LYMPHOMA(DE-DLBCL)	Zhi-Ming Li	Received

PF-923	ZANUBRUTINIB IN COMBINATION WITH R-CHOP FOR PREVIOUSLY UNTREATED MCD TYPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)	Wenjuan Yu	Received

PF-924	THREE-HOUR INFUSION OF METHOTREXATE AT 3 G/M2 SIGNIFICANTLY REDUCES CNS RECURRENCES AND IMPROVES SURVIVAL IN LARGE B-CELL LYMPHOMAS WITH INCREASED CNS RISK: ANALYSIS OF A SINGLE-CENTER COHORT OF 501 PATIENTS	Andrés Ferreri	Received

PF-926	IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL-LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY.	Luca Pagliaro	Received

PF-929	MOLECULAR FEATURES ENCODED IN THE DYNAMIC CTDNA MONITORING REVEAL ADDITIONALLY PROGNOSTIC VALUE, DIFFERENT CLINICAL COURSES AND CLONE EVOLUTION FOR DIFFERENT GENETIC SUBTYPES OF DIFFUSE LARGE B CELL LYMPHOMA	Jinhua Liang	Received

PF-930	FOLLICULAR LYMPHOMA: A REPORT FROM THE DANISH LYMPHOMA REGISTRY ON THE TREATMENT APPROACHES AND OUTCOMES IN NEWLY DIAGNOSED PATIENTS	Jelena Jelicic	Received

PF-931	THE PROGNOSTIC VALUE OF CIRCULATING CELL-FREE METHYLATED EBV-DNA IN EXTRANODAL NK/T CELL LYMPHOMA	Jinhua Liang	Received

PF-932	MOLECULAR SUBTYPE-GUIDED TARGETED THERAPY COMBINED WITH R-MINE (R-MINE+X) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY	Jinhua Liang	Received

PF-933	SUPERIOR OUTCOMES OF AUTOLOGOUS TRANSPLANTATION VERSUS CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN RELAPSED CNS LYMPHOMA TREATED IN COMPLETE REMISSION	Yuelu Guo	Received

PF-938	SAFETY AND EFFICACY OF DUAL-TARGET CD19/CD20 CAR-T THERAPY IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA	Liu Rui	Received

PF-941	LONG-TERM EFFICACY OF COMPLETE REMISSION PATIENTS WITH R/R DIFFUSE LARGE B-CELL LYMPHOMA AFTER CAR-T THERAPY: BTK INHIBITOR MAINTENANCE TREATMENT MAY PROLONG REMISSION DURATION	Liu Rui	Received

PF-943	EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN, ZANUBRUTINIB AND RITUXIMAB (POLA-ZR) IN UNTREATED ELDERLY AND FRAIL DLBCL PATIENTS: A PROSPECTIVE PHASE 2 CLINICAL TRIAL	Yuhong Ren	Received

PF-945	THE RESULT OF A SINGLE-ARM, PHASE IB, MULTI-CENTER STUDY OF RITUXIMAB, ACALABRUTINIB, AND DURVALUMAB (RAD) IN THE RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)	Kwang-Yu Chang	Received

PF-947	BOOM-BOOM RADIATION PRIOR TO LISOCABTAGENE MARALEUCEL IS FEASIBLE AND CONTRIBUTES TO HIGH COMPLETE RESPONSE RATES FOR AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA	Christopher D´Angelo	Received

PF-948	COMBINING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CD19/CD22 DUAL-TARGET CAR-T THERAPY: A PROMISING STRATEGY FOR REFRACTORY AND RELAPSED HIGH-RISK B-CELL LYMPHOMA	Xian Zhang	Received

PF-949	REAL-WORLD OUTCOMES OF MITOXANTRONE HYDROCHLORIDE LIPOSOME REGIMEN FOR PERIPHERAL T-CELL LYMPHOMA: A SHORT-TERM EFFICACY AND SAFETY ANALYSIS OF TREATMENT-NAÏVE POPULATION (MOMENT)	Ma Jun	Received

PF-950	POMALIDOMIDE, RITUXIMAB, ORELABRUTINIB, AND MINICHOP-LIKE (PRO-MINICHOP) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS FROM A PHASE II STUDY	Na-Na Ping	Received

PF-952	CONTROLLING NUTRITIONAL STATUS (CONUT) SCORE AS A PROGNOSTIC FACTOR FOR SURVIVAL IN CAR-T THERAPY FOR RELAPSED/REFRACTORY B-CELL LYMPHOMA	Yuelu Guo	Received

PF-953	A PHASE II STUDY OF DUAL EPIGENETIC MODULATION WITH OBINUTUZUMAB/LIPOSOMAL MITOXANTRONE IN CHEMORESISTANT DLBCL PATIENTS POST-SALVAGE THERAPY	Chang-Ju Qu	Received

PF-955	INTRAVENOUS MIDDLE-DOSE METHOTREXATE INCORPORATED INTO R-CHOP PREVENTED CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: A SINGLE-CENTER RETROSPECTIVE STUDY	Min Lang	Received

PF-958	TREATMENT OUTCOMES AND PROGNOSTIC FACTORS IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA: MULTICENTER REAL-WORLD DATA OF 166 PATIENTS	Selin Küçükyurt	Received

PF-960	VALIDATION OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) SCORE IN KOREAN AITL PATIENTS	bohyun moon	Received

PF-962	PHASE 2 STUDY OF DZD8586, A NON-COVALENT BBB PENETRANT LYN/BTK DUAL INHIBITOR, AS MONOTHERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: TAI-SHAN9 TRIAL	lugui qiu	Received

PF-963	COMBINATION OF MITOXANTRONE HYDROCHLORIDE LIPOSOME WITH GEMCITABINE, CISPLATIN AND DEXAMETHASONE (MGDP) IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA: A PROSPECTIVE, SINGLE-ARM, MULTICENTER, PHASE I/II STUDY	Chong Wei	Received

PF-964	CLINICOPATHOLOGIC FEATURES AND SURVIVAL OUTCOMES OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE BY LIVER TRANSPLANT DONOR GRAFT TYPE	Seong-Eun Kim	Received

PF-965	PROPENSITY SCORE-MATCHED ANALYSIS SUPPORTS THE SURVIVAL BENEFITS OF CAR-T THERAPY WITH TANDEM STEM CELL SUPPORT IN NHL: INSIGHTS FROM A REAL-WORLD STUDY IN CHINA	Haiwen Huang	Received

PF-966	PRIMARY EFFICACY AND SAFETY OF FIRST-LINE R-MTO REGIMEN (RITUXIMAB, METHOTREXATE, THIOTEPA, AND ORELABRUTINIB) FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PCNSL	Zengjun Li	Received

PF-967	A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES IN 104 NEWLY DIAGNOSED ENKTL PATIENTS	Haiwen Huang	Received

PF-969	REAL-WORLD ANALYSIS OF GLOFITAMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA	Zhiyong Zeng	Received

PF-971	SAFETY AND EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN CHINESE CD30-POSITIVE LYMPHOMA ADULTS: AN INTERIM ANALYSIS FROM BRAVE STUDY	WeiLi Zhao	Received

PF-972	LORLATINIB THERAPY IN RELAPSED/REFRACTORY ALK + LYMPHOMAS PREVIOUSLY TREATED WITH TYROSINE KINASE INHIBITORS	Carlo Gambacorti-Passerini	Received

PF-976	FREQUENCY AND PROGNOSIS OF T-CELL DISORDERS IN ADULT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	Kamolchanok Tanchotikul	Received

PF-977	SAFETY AND EFFICACY OF CAR-T THERAPY IN AUTOLOGOUS STEM CELL TRANSPLANTATION-FAILURE B-CELL NON-HODGKIN LYMPHOMA PATIENTS: A RETROSPECTIVE ANALYSIS	Liu Rui	Received

PF-978	CASPASE-3 AND CASPASE-7 AS PREDICTOR FACTORS OF RESPONSE AND RESISTANCE IN CEREBROSPINAL FLUID (CSF) IN PATIENTS WITH LYMPHOID MALIGNANCIES	Maher Salamoon	Received

PF-979	A NOVEL PROGNOSTIC MODEL INCORPORATING SERUM ß2-MICROGLOBULIN IN PRIMARY CNS LYMPHOMA	Yeokyeong Shin	Received

PF-981	CRP-ALBUMIN-LYMPHOCYTE (CALLY) INDEX: A PROMISSING PROGNOSTIC TOOL IN DIFFUSE LARGE B-CELL LYMPHOMA	Daniel Zaldumbide	Received

PF-983	COMPARISON OF WHOLE BRAIN RADIOTHERAPY (RT) VERSUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): A REAL WORLD PROPENSITY SCORE (PS) MATCHING ANALYSIS	Jiao Jie Cherie Tan	Received

PF-984	POLA-R-CHP PERFORMED WELL IN POLARIX TRIAL-INELIGIBLE AND LOW RISK (IPI 0-1) PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: A PROSPECTIVE OBSERVATIONAL STUDY	Yuhong Ren	Received

PF-986	REAL WORLD DATA ON USE OF RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED PATIENTS.	Lay Khandwala	Received

PF-987	SINGLE-CELL ATLAS OF PRIMARY CNS LYMPHOMA REVEALS AN IMMUNE-RICH TUMOUR MICROENVIRONMENT MODULATED BY ENDOTHELIAL CELLS AND CANCER-ASSOCIATED FIBROBLASTS	Keir Pickard	Received

PF-989	STROMAL CELL DIVERSITY IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA THROUGH SPATIAL TRANSCRIPTOME ANALYSIS AT SINGLE CELL RESOLUTION	Yuki Shimizu	Received

PF-991	CLINICAL IMPACT OF UNTARGETED BASELINE PLASMA METABOLOMICS IN NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA	Riccardo Dondolin	Received

PF-992	TARGETING MYH9-PRC1 AXIS EXERTS ANTI-TUMOR EFFECTS IN DIFFUSE LARGE B-CELL LYMPHOMA BY REGULATING PINK1/PARKIN-MEDIATED MITOPHAGY	Shunfeng Hu	Received

PF-994	CHARACTERIZING TUMOR MICROENVIRONMENT HETEROGENEITY IN EBV+NTNKL VS ENKTCL USING SPATIAL TRANSCRIPTOMICS AND MIF	Siyu Qian	Received

PF-996	WHOLE-GENOME SEQUENCING REVEALS THREE FOLLICULAR LYMPHOMA SUBTYPES WITH DISTINCT CELL-OF-ORIGIN AND PATIENT OUTCOMES	Weicheng Ren	Received

PF-997	INACTIVATION OF CYLD INDUCES THE EXPANSION OF SPLENIC MARGINAL ZONE PRECURSOR B CELLS	Athanasios Pseftogkas	Received

PF-1000	ARV-393, A PROTAC BCL6 DEGRADER, IS EFFICACIOUS IN PRECLINICAL MODELS OF DIFFUSE LARGE B CELL LYMPHOMA (DLBCL), NODAL T-FOLLICULAR HELPER CELL LYMPHOMA (NTFHL), AND TRANSFORMED FOLLICULAR LYMPHOMA (TFL)	Charlotte Pettigrew	Received

PF-1002	PROGNOSTIC VALUE OF CIRCULATING TUMOR DNA (CTDNA) DETECTION BY PHASED-SEQ AFTER AXICABTAGENE CILOLEUCEL (AXI-CEL) THERAPY IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)	Brodie Miles	Received

PF-1003	COMBINATION WITH MOSUNETUZUMAB AND LENALIDOMIDE ENHANCES THE NUMBER OF CD8+ T CELLS WITH HIGH T CELL-DEPENDENT CELLULAR CYTOTOXIC ACTIVITY AGAINST FOLLICULAR LYMPHOMA CELLS	Hayato Mizuta	Received

PF-1004	FGF SIGNALING BLOCKADE HAMPERS THE GROWTH OF C-MYC-DRIVEN AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA	Daniel Zaldumbide	Received

PF-1005	MAGNOLIN INHIBITS THE PROGRESSION OF DIFFUSE LARGE B-CELL LYMPHOMA BY ACTIVATING PPARG/PINK1-PARKIN AXIS AND PROMOTING MITOPHAGY	Shunfeng Hu	Received

PF-1007	LONG-TERM SURVIVAL FOR LYMPHOID NEOPLASMS AND NATIONAL HEALTH EXPENDITURE (EUROCARE-6): A RETROSPECTIVE, POPULATION-BASED STUDY	Claudia Vener	Received

PF-1008	CHIDAMIDE ENHANCES CD7 CAR T-CELL EFFICACY IN T-CELL LYMPHOMA THROUGH EPIGENETIC CD7 UPREGULATION AND MITOCHONDRIAL APOPTOSIS PATHWAY ENGAGEMENT	Hao Yao	Received

PF-1009	CIRCULATING TUMOUR DNA ANALYSIS IN FOLLICULAR LYMPHOMA TREATED WITH FIRST-LINE VENETOCLAX, LENALIDOMIDE AND OBINUTUZUMAB ON THE LEVERAGE TRIAL	Piers Blombery	Received

PF-1011	MOLECULAR AND CELLULAR RESPONSES TO EXTERNAL TRIGGERING IN PRIMARY SPLENIC SMALL B-CELL LYMPHOMAS: A TRANSCRIPTOMIC AND BIOENERGETIC PERSPECTIVE	Marina Gerousi	Received

PF-1012	ROLE OF NON-CODING RNAS AND DNA METHYLATION IN REGULATING INTRACELLULAR SIGNALING AND CYTOKINE PATHWAYS IN MYD88WT WALDENSTRÖM MACROGLOBULINEMIA: A MULTI-OMICS EPIGENETIC ANALYSIS	Karan Chohan	Received

PF-1013	TARGETING ARGININE METHYLTRANSFERASE PRMT5 AS A PROMISING THERAPEUTIC STRATEGY IN NKTCL	Siyu Qian	Received

PF-1014	MYD88 MUTATIONS ARE ASSOCIATED WITH DISEASE PROGRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA	Issa Ismail Issa	Received

PF-1016	THE RATIO OF BRAIN TO LIVER GLUCOSE ACTIVITY AND PROGNOSIS WITH CAR-T IN NON-HODGKIN LYMPHOMA	Sarah Dingli	Received

PF-1017	DEFERASIROX AS A NOVEL THERAPY TO OVERCOME MCL1-DRIVEN THERAPY ESCAPE IN MANTLE CELL LYMPHOMA	Saar Shapira	Received

PF-1019	ROR1 SMALL MOLECULE INHIBITOR OVERCOMES IBRUTINIB AND VENETOCLAX RESISTANCE IN MANTLE CELL LYMPHOMA (MCL)	Wen Zhong	Received

PF-1020	IMMUNOGENETIC LANDSCAPE OF WALDENSTRÖM MACROGLOBULINEMIA: CORRELATION WITH CLINICO-BIOLOGICAL FEATURES, PROGNOSIS AND COMPARISON WITH PHYSIOLOGICAL MEMORY-B CELLS AND PLASMA CELLS	Clotilde Bravetti	Received

PF-1021	GENOMIC PROFILING IDENTIFIES UNIQUE MOLECULAR SUBGROUPS IN SPLENIC SMALL B-CELL LYMPHOMAS	Antonia-Zoe Kouroutzidou	Received

PF-1022	INVESTIGATING THE PATHOGENIC MECHANISMS OF ANGIOPATHY IN SYSTEMIC CHRONIC ACTIVE EPSTEIN-BARR VIRUS DISEASE USING ENDOTHELIAL CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS	Miwako Nishio	Received

PF-1023	LCP2 MEDIATES SUV39H1-DRIVEN CELLULAR SENESCENCE-RELATED CHEMORESISTANCE IN NATURAL KILLER/T CELL LYMPHOMA	Yue Zhang	Received

PF-1024	TMSB4X 5´UTR ALTERATIONS ARE POSSIBLE DRIVER EVENTS HARBOURING PHASED VARIANTS WITH A POTENTIAL FOR DISEASE MONITORING ACROSS DLBCL GENETIC SUBGROUPS.	Luca Varga	Received

PF-1025	CHEMOCHINE RECECPTOR PROFILES AS PREDICTOR OF SURVIVAL AND EARLY PROGRESSION IN FOLLICULAR LYMPHOMA	Antonella Zupo	Received

PF-1026	DISTINCT IMMUNOGENETIC PROFILES IN SPLENIC SMALL B-CELL LYMPHOMAS: A REFLECTION OF DISTINCT ONTOGENY?	Anastasia Iatrou	Received

PF-1027	C-MYC ONCOPROTEIN IS STABILIZED BY FGFR ACTIVATION IN C-MYC-DRIVEN B-CELL NON-HODGKIN LYMPHOMA	Giulia Garattini	Received

PF-1030	RUXOLITINIB-INDUCED STAT3/BCL3 INHIBITION ACTIVATES NF-?B SIGNALING PATHWAY AND PROMOTES THE ACCUMULATION AND IMMUNOSUPPRESSIVE ACTIVITY OF G-MDSCS DURING ACUTE GRAFT-VERSUS-HOST DISEASE	Dai-Hong Liu	Received

PF-1031	MULTI-OMIC SEQUENCING IDENTIFIES NOVEL FACS MARKERS FOR PLATELET-BIASED HSC PURIFICATION	Bowen Zhang	Received

PF-1033	OVERCOMING TOXIC CONDITIONING IN HEMATOPOIETIC STEM CELL THERAPY LEVERAGING MOBILIZATION-RESISTANT CXCR4 VARIANTS	Gabriele Pedrazzani	Received

PF-1034	IMMUNE MODULATION IN LEUKEMIA PATIENTS AFTER HEMATOPOETIC STEM CELL TRANSPLANTATION WITH ACUTE OR CHRONIC GRAFT VS HOST DISEASE (A/CGVHD): 12-WEEK EXTRACORPOREAL PHOTOPHERESIS (ECP) REDUCES INFLAMMATORY AND ENHANCES INHIBITORY IMMUNE REACTIVE CELLS	Anying Huang	Received

PF-1035	DYNAMICS OF OVERALL AND ORGAN-SPECIFIC RESPONSES TO AXATILIMAB IN CHRONIC GRAFT-VERSUS-HOST DISEASE: ANALYSIS FROM THE AGAVE-201 STUDY	Mi Kwon	Received

PF-1036	EMAPALUMAB IN PATIENTS WITH PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: EFFICACY AND SAFETY OUTCOMES FROM A MULTINATIONAL, OPEN-LABEL, SINGLE-ARM STUDY	Stefan Duscha	Received

PF-1037	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ERCC6L2 DISEASE	Marja Hakkarainen	Received

PF-1038	IMPROVED OVERALL SURVIVAL FOLLOWING INTRODUCTION OF REDUCED TOXICITY CONDITIONING IN ALLO-HCT FOR MDS: A 25-YEAR RETROSPECTIVE SINGLE-CENTER ANALYSIS	Johanne Schovsbo	Received

PF-1039	ENTEROCOCCUS DEVASTATES THE GUT MICROBIOTA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION VIA THE PHOSPHOTRANSFERASE SYSTEM	Akihisa Hino	Received

PF-1041	CORRELATIONS OF CLINICIAN-REPORTED RESPONSES WITH OTHER RESPONSE MEASURES IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE: AN ANALYSIS FROM THE AGAVE-201 TRIAL	Valkal Bhatt	Received

PF-1044	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH NUP98-REARRANGED ACUTE MYELOID LEUKAEMIA:A SINGLE-CENTER LARGE-SAMPLE COHORT STUDY	hai he	Received

PF-1046	PHARMACOGENETIC PROFILING OF ALLOGENEIC STEM CELL TRANSPLANTATION PATIENTS	Lea Timmann	Received

PF-1047	COMPARISON OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM OFFSPRING OR MATCHED UNRELATED DONOR IN PATIENTS AGED 40-50 WITH RELAPSED OR REFRACTORY SEVERE APLASTIC ANEMIA: A RETROSPECTIVE ANALYSIS FROM THE CBMTR OVER THE LAST DECADE	Xin Zhao	Received

PF-1049	VALIDATION OF REDUCED BUSULFAN-BASED MODIFIED POST-TRANSPLANT CYCLOPHOSPHAMIDE REGIMEN IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA: A PROSPECTIVE COMPARATIVE STUDY	Donghua Zhang	Received

PF-1050	OUTCOME AFTER AUTOLOGOUS CORD BLOOD TRANSPLANTATION FOR PEDIATRIC ACQUIRED APLASTIC ANEMIA:A RETROSPECTIVE ANALYSIS OF MULTICENTER STUDY IN CHINA	Jiao Chen	Received

PF-1051	COMBINATION OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH UNRELATED UMBILICAL CORD BLOOD IN PATIENTS WITH APLASTIC ANEMIA: A RETROSPECTIVE STUDY OF 30 CASES	YU ZHANG	Received

PF-1053	HIGH DAY 90 NK CELL COUNTS IN EVENT-FREE PATIENTS PREDICT IMPROVED SURVIVAL AFTER IN VIVO T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION	Andrej Pešic	Received

PF-1054	CLINICAL OUTCOMES OF PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Zhixue Li	Received

PF-1055	PROGNOSTIC VALUE OF PET/CT IN ADULT T-CELL LYMPHOBLASTIC LYMPHOMA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Fangfang Yu	Received

PF-1056	THIOTEPA-BUSULFAN-FLUDARABINE CONDITIONING REGIMEN WITH ATG/PTCY-BASED GVHD PROPHYLAXIS AS PROMISING APPROACH FOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER, OPEN-LABEL, PROSPECTIVE STUDY	Xianbo Huang	Received

PF-1058	THE IMPACT OF BLAST PERCENTAGE ON POST-TRANSPLANT OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A RETROSPECTIVE ANALYSIS WITHIN THE IPSS-M FRAMEWORK	Zhong-Shi Lyu	Received

PF-1061	THE IMPACT OF EASIX SCORE ON MORTALITY AFTER IN VIVO T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION	Andrej Pešic	Received

PF-1064	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TREATMENT OF SHWACHMAN-DIAMOND SYNDROME: A REPORT OF 19 PEDIATRIC CASES FROM A SINGLE CENTER	Jiao Chen	Received

PF-1065	A NOVEL REDUCED TOXICITY CONDITIONING REGIMEN FOR OLDER MYELODYSPLASTIC NEOPLASMS PATIENTS UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A PROSPECTIVE COHORT STUDY	Wenjing Yu	Received

PF-1066	CRYOPRESERVATION OF OVARIAN TISSUE IN 46 PEDIATRIC GIRLS BEFORE UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Jiao Chen	Received

PF-1069	LENALIDOMIDE MAINTENANCE AFTER DELAYED OR SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION	Asad A. Haider	Received

PF-1070	PATIENTS WITH MDS/MPN,NOS SHOW A LESS AGGRESSIVE DISEASE COURSE COMPARED TO PATIENTS WITH CMML IN THE CONTEXT OF ALLOGENEIC HCT – AN ANALYSIS ACROSS 12 GERMAN CENTERS	Anna Hecht	Received

PF-1071	PRETRANSPLANT THROMBOTIC EVENTS AND THEIR IMPACT ON THE OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION	Haixia Fu	Received

PF-1072	EFFICACY AND SAFETY OF BELUMOSUDIL MONOTHERAPY AND COMBINATION WITH RUXOLITINIB IN REFRACTORY CHRONIC GRAFT-VERSUS-HOST-DISEASE: A SINGLE CENTRE, REAL-WORLD EXPERIENCE	Vinay Anand Guntiboina	Received

PF-1073	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN GERMLINE DDX41 MUTATED PATIENTS WITH MYELOID MALIGNANCIES	Michael Loschi	Received

PF-1075	THE IMPACT OF FEMALE-TO-MALE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ON SURVIVAL OUTCOMES VARIES BY RECIPIENT AGE.	Kosuke Takano	Received

PF-1078	PULMONARY ARTERIAL HYPERTENSION IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: EQUIVALENT SURVIVAL DEFICITS FOR PRETRANSPLANT AND POSTTRANSPLANT ONSET	Kexin Shen	Received

PF-1080	COMPARATIVE OUTCOMES OF HCT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN OLDER ADULTS: THE IMPACT OF DONOR TYPE	Yosra Aljawai	Received

PF-1081	OPTIMIZED CONDITIONING REGIMEN ENHANCES TCRaß+ CELL DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION ENGRAFTMENT IN PATIENTS WITH THALASSEMIA MAJOR	Jianyun Liao	Received

PF-1082	IMPACT OF DARATUMUMAB INDUCTION ON STEM CELL MOBILIZATION IN PATIENTS WITH MULTIPLE MYELOMA	Melinda Tan	Received

PF-1085	MYOSTEATOSIS BUT NOT SARCOPENIA IS OF PROGNOSTIC RELEVANCE IN THORACIC CT-SCANS PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)	Jule Ussmann	Received

PF-1087	THE EFFICACY AND SAFETY OF BELUMOSUDIL IN TREATING PEDIATRIC CHRONIC GRAFT-VERSUS-HOST DISEASE, A REAL-WORD STUDY	Min Zhou	Received

PF-1088	INCREASED CYCLOSPORINE LEVELS ARE ASSOCIATED WITH DECREASED TRANSPLANT-RELATED MORTALITY FOLLOWING ALLOGENEIC TRANSPLANT FOR MYELOFIBROSIS	John Marra	Received

PF-1090	TRIAL IN PROGRESS: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF AXATILIMAB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER =2 PRIOR LINES OF SYSTEMIC THERAPY	Tricia Fleming	Received

PF-1091	EVALUATING RUXOLITINIB TOXICITY IN PEDIATRIC PATIENTS WITH STEROID REFRACTORY GRAFT-VERSUS-HOST DISEASE: A SINGLE-CENTER EXPERIENCE	Mennatallah Elnaggar	Received

PF-1092	AUTOLOGOUS VS. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR T-CELL LYMPHOBLASTIC LYMPHOMA:ALLOGENEIC TRANSPLANTATION---A PREFERENTIAL SELECTION, BUT NO SIGNIFICANT ADVANTAGES	Haiwen Huang	Received

PF-1093	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) IN ADULTS WITH HEREDITARY MYELOID MALIGNANCIES, A SINGLE-CENTER STUDY	Amagoia Ruiz Martin	Received

PF-1094	OPTIMIZATION AND EFFICACY OF FULL-DOSE RECOMBINANT HUMAN THROMBOPOIETIN IN PLATELET ENGRAFTMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A REAL-WORLD RETROSPECTIVE STUDY	Shiyu Chen	Received

PF-1095	REDUCED INTENSITY T-REPLETE ALLOGENEIC TRANSPLANT CAN PROVIDE LONG TERM SURVIVAL IN PATIENTS WITH ANGIOIMMUNOBLASTIC T CELL LYMPHOMA ABOVE THE AGE OF 50 WHO PREVIOUSLY HAD AUTOLOGOUS STEM CELL TRANSPLANTATION	Ioannis Arvanitis	Received

PF-1096	IMMUNOLOGIC PREDICTIVE FACTORS FOR CMV REACTIVATION IN SR-CGVHD PATIENTS TREATED WITH RUXOLITINIB	Leonardo Maia Moço	Received

PF-1098	INFLUENCE OF BODY MASS INDEX (BMI) ON OUTCOMES AND TOXICITY ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR-T): A SINGLE-CENTRE DATA SET FROM THE ROYAL MARSDEN HOSPITAL	Ellouise Bishop	Received

PF-1099	THREE-MONTH WHOLE BLOOD CHIMERISM INDEPENDENTLY PREDICTS OVERALL SURVIVAL IN ALLOGENEIC STEM CELL TRANSPLANTS FOR HEMATOLOGICAL CANCERS: AN ANALYSIS ON BEHALF OF TWO UK CENTRES	Rebecca Goodhew	Received

PF-1102	DISTINCT TRANSCRIPTIONAL CHANGES IN DIFFERENT MURINE MULTIPOTENT PROGENITORS DURING EMERGENCY GRANULOPOIESIS	Srdjan Grusanovic	Received

PF-1104	A NOVEL "PLATELET PROTOCOL" TARGETS CYTOKINE STORM IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	Zhenyu Liu	Received

PF-1105	ADAPTIVE IMMUNITY GOVERNS THE CLEARANCE OF ONCOGENE-INDUCED SENESCENT HSPCS AND CONTROLS INFLAMMATION	Cristina Colleoni	Received

PF-1108	CONDITIONAL DELETION OF RIBOSOMAL PROTEIN SUBUNITS HIGHLIGHTS THEIR SPECIFIC REQUIREMENTS DURING FETAL HEMATOPOIESIS	Lionel Blanc	Received

PF-1110	DISRUPTED VCAM-1/VLA-4 INTERACTION CONTRIBUTES TO IMPAIRED ADHESION OF SPECIFIC HEMATOPOIETIC STEM AND PROGENITOR CELL SUBPOPULATIONS IN THE BONE MARROW, ULTIMATELY LEADING TO LEUKEMOGENESIS	Shlomit Yehudai-Reshef	Received

PF-1111	CHARACTERIZATION OF PD-L1 AS NOVEL THERAPEUTIC TARGET IN MASTOCYTOSIS	Elena Ratti	Received

PF-1114	SINGLE CELL ANALYSIS REVEALS A DISTINCT TRANSCRIPTOME SIGNATURE OF HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS UNDER CHEMOTHERAPY STRESS IN B-ALL	Xiaoli Chen	Received

PF-1115	MBD4 KNOCKOUT AS A TOOL FOR MODELLING MUTAGENESIS AND CLONAL OUTGROWTH	Sanne Massaar	Received

PF-1116	POT1 GERMLINE MUTATIONS IN LONG TELOMERE SYNDROME: IMPLICATIONS FOR CANCER RISK AND CLONAL HEMATOPOIESIS	Madeline Franke	Received

PF-1117	PIEZO1 DELAYS HUMAN ERYTHROCYTE DIFFERENTIATION THROUGH PHOSPHORYLATION AND DEGRADATION OF CALPASTATIN	Alexandre Willaume	Received

PF-1118	SINGLE-CELL MULTIOMICS OF PEDIATRIC BONE MARROW REVEALS AGE-DEPENDENT DIFFERENCES IN LINEAGE DIFFERENTIATION	Evelyn Hanemaaijer	Received

PF-1119	FUNCTIONAL VALIDATION OF THE ROLE OF GERMLINE VARIATION IN CLONAL HAEMATOPOIESIS	Michela Colombo	Received

PF-1120	SPONTANEOUSLY CIRCULATING HEMATOPOIETIC STEM/PROGENITOR CELLS AT SINGLE CELL RESOLUTION: LESSONS FROM A RARE BONE DISEASE	Valentina Capo	Received

PF-1121	HYPUSINATION-MEDIATED REGULATION OF MURINE ERYTHROPOIESIS IS ASSOCIATED WITH ALTERATIONS IN AUTOPHAGY	Pedro Gonzalez-Menendez	Received

PF-1126	SENESCENCE AND INFLAMMATION ARE UNINTENDED ADVERSE CONSEQUENCES OF CRISPR-CAS9/AAV6 MEDIATED GENE EDITING IN HEMATOPOIETIC STEM CELLS	Anastasia Conti	Received

PF-1127	SYSTEMIC INFLAMMATION MODULATES CAR T-CELL EXPANSION AND RESPONSE IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMAS	Cristiana Carniti	Received

PF-1128	HARNESSING CMV-VSTS FOR ALLOGENEIC CART84 THERAPY TO TARGET AML	Maria Val Casals	Received

PF-1129	EX VIVO EXPANDED HSCS IMPROVE GENE THERAPY OUTCOME IN AUTOSOMAL RECESSIVE OSTEOPETROSIS	Valeria Iannello	Received

PF-1131	MZB1-DIRECTED HLA-DEPENDENT CAR T CELLS FOR TARGETING B-CELL MALIGNANCIES	Elena Maroto Martín	Received

PF-1133	SINGLE-CELL PROFILING OF HAEMATOPOIETIC STEM CELL COLLECTION COMPOSITION AND ITS IMPACT ON POST-TREATMENT HAEMATOTOXICITY	li guangmei	Received

PF-1135	BASE EDITING OF HEMATOPOIETIC STEM CELLS AND T CELLS RESTORES PI3K SIGNALLING IN APDS1 AND APDS2 PATIENTS	Kate Orf	Received

PF-1137	HDR GENE CORRECTION AND SELECTION OF CD4+ T CELLS FOR THE TREATMENT OF HYPER IGM1: MOVING TOWARD AN ACADEMIC CLINICAL TRIAL	Daniele Canarutto	Received

PF-1143	BIOLOGICAL PROPERTIES AND CLONALITY OF ENGINEERED HEMATOPOIETIC STEM/PROGENITOR CELLS PERSISTING LONG-TERM AFTER GENE THERAPY	Serena Scala	Received

PF-1146	CXCR4-R334X MOUSE: A MODEL TO INVESTIGATE THE PATHOGENESIS OF WHIM SYNDROME AND ASSESS NOVEL GENE CORRECTION THERAPY	Alessandra Zecchillo	Received

PF-1147	SUCCESSFUL GENERATION OF IPSC-DERIVED TH1 CELLS WHICH ENHANCED CD8+ CAR-T CELL FUNCTION	Yoshiki Furukawa	Received

PF-1148	ANTI-CD19 CAR T-CELL THERAPY FOR HLA DESENSITIZATION IN A HIGHLY ALLOIMMUNIZED KIDNEY TRANSPLANT CANDIDATE	Jens Schrezenmeier	Received

PF-1149	PRECLINICAL MODELLING AND MECHANISTIC INSIGHTS INTO CAR-T CELL INDUCED NEUROTOXICITY	Rita El Khoury	Received

PF-1150	MULTI-OMIC ANALYSIS OF GUT MICROENVIRONMENT IN CHIMERIC ANTIGEN RECEPTOR T CELL-TREATED SYNERGETIC MICE FINDING PARVIBACTOR AS CRITICAL MICROBIOTA FOR ACTIVATING ENDOGENOUS CD8+ T CELLS	Kejia Hu	Received

PF-1151	BASE EDITING FOR SICKLE CELL DISEASE: ONGOING RESULTS FROM THE BEACON STUDY EVALUATING THE SAFETY AND EFFICACY OF BEAM-101, THE FIRST BASE-EDITED AUTOLOGOUS CD34+ HSPC ONE-TIME CELL THERAPY	Ashish Gupta	Received

PF-1152	RAPCABTAGENE AUTOLEUCEL (YTB323) IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE II TRIAL CLINICAL UPDATE	Mi Kwon	Received

PF-1153	INTRA-CSF DELIVERY OF DUAL CD19/CD22 CAR-T THERAPY FOR RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM B-CELL MALIGNANCIES: FIRST-IN-HUMAN CLINICAL TRIAL	Qingming Wang	Received

PF-1154	IMMUNE CELL SUBSETS AND CYTOKINE PROFILES ARE ASSOCIATED WITH IMMUNE-RELATED HYPERINFLAMMATORY STATES AFTER CAR T-CELL THERAPY	Melinda Tan	Received

PF-1155	RED BLOOD CELL (RBC) HEALTH AND FUNCTION POST BEAM-101 TREATMENT: MULTIPLE EXPLORATORY BIOMARKERS DEMONSTRATE RHEOLOGY AND SICKLING PARAMETERS COMPARABLE TO SICKLE CELL TRAIT (SCT)	Priya S. Chockalingam	Received

PF-1160	DENDRITIC CELL-BASED VACCINES (KSD-101) AGAINST EBV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASES: RESULTS FROM AN ONGOING PHASE I CLINICAL STUDY	chunrui li	Received

PF-1162	AUTOLOGOUS AND DONOR-DERIVED CD7-KNOCKOUT CD7-TARGETED CAR T THERAPY IN RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE 1/2 CLINICAL STUDY	Jing Pan	Received

PF-1164	A PHASE I STUDY OF GPRC5D TARGETING CAR T-CELL THERAPY CT071 FOR HIGH-RISK NEWLY DIAGNOSED MULTIPLE MYELOMA	Juan Du	Received

PF-1165	Integrated Editing and Manufacturing Process Design for BEAM-101, an Autologous CD34+ HSPC Therapy for Sickle Cell Disease, Results in Robust Process Yield and Increased HbF Induction	Paul Kopesky	Received

PF-1167	SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN PLUS GLOFITAMAB AS BRIDGING THERAPY PRIOR TO TALICABTAGENE AUTOLEUCEL FOR RELAPSED/ REFRACTORY B-CELL LYMPHOMA	Thomas Eipe	Received

PF-1168	COST-EFFECTIVENESS OF REAL-WORLD AXICABTAGENE CILOLEUCEL USE IN RELAPSED/REFRACTORY 2L LBCL BASED ON A MULTI-CENTER US REGISTRY	Olalekan Oluwole	Received

PF-1169	NEUROPATHIC CHRONIC PAIN IN SICKLE CELL DISEASE IS ASSOCIATED WITH WORSE QUALITY OF LIFE, HEMOLYSIS, AND TNF INFLAMMATION	Angela Liu	Received

PF-1171	LEFT VENTRICULAR STRAIN IN PEDIATRIC SICKLE CELL DISEASE: INSIGHTS INTO SUBCLINICAL MYOCARDIAL DYSFUNCTION	Miguel R. Abboud	Received

PF-1172	PREGNANCIES IN SICKLE CELL PATIENTS IN AN AREA OF HIGH SOCIO-ECONOMIC DEPRIVATION REVEAL HIGH LEVELS OF MATERNAL AND FETAL COMPLICATIONS	Louise Caldwell	Received

PF-1174	IDENTIFYING POTENTIAL BIOMARKERS OF CLINICAL RELEVANCE IN SICKLE CELL TRAIT: INTERIM FINDINGS FROM THE NATIONAL ALLIANCE OF SICKLE CELL CENTERS AUNT STUDY	Julie Kanter	Received

PF-1175	SICKLE CELL DISEASE AND IRON	Simone Villaboni	Received

PF-1176	OPTIMIZING HYDROXYUREA THERAPY IN SICKLE CELL DISEASE: INSIGHTS FROM METABOLITE DETECTION, TREATMENT RESPONSE AND CLINICAL OUTCOMES	Sigrid van der Veen	Received

PF-1178	MITOCHONDRIAL RETENTION IN SICKLE CELL DISEASE: CONNECTING RED BLOOD CELL BIOLOGY TO DISEASE HETEROGENEITY	Alkmini Anastasiadi	Received

PF-1179	OXIDATIVE METABOLISM IMPROVEMENT DURING EXERCISE IN SICKLE CELL DISEASE PATIENTS TREATED 12 MONTHS WITH VOXELOTOR. ANALYSIS OF HEMOPROVE TRIAL.	Thomas d´Humières	Received

PF-1181	TRANSFUSION AFTER PROPHYLACTIC ECULIZUMAB USE IN INDIVIDUALS WITH SICKLE CELL DISEASE AND A HISTORY OF DELAYED HEMOLYTIC TRANSFUSION REACTION: A SINGLE-CENTER CASE SERIES	Brittany McCrary	Received

PF-1184	SAFETY AND EFFICACY OF ADDITION OF FILGRASTIM TO CD34+ CELL HARVESTING IN FOUR CASES OF SICKLE CELL DISEASE PATIENTS FOR GENOME EDITING	Francesco Arcioni	Received

PF-1186	COMPUTATIONAL ANALYSIS OF IMMUNOPHENOTYPIC PERTURBATIONS OF PERIPHERAL BLOOD MONONUCLEAR CELLS IN SICKLE CELL DISEASE	Elisabeth Dovern	Received

PF-1187	THE IMPACT OF LUSPATERCEPT ON ERYTHROPOIESIS IN A REAL-WORLD COHORT OF TRANSFUSION-DEPENDENT ß-THALASSEMIA PATIENTS	Valentina Brancaleoni*	Received

PF-1191	ASSESSMENT OF SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) LEVELS IN PATIENTS WITH TRANSFUSION DEPENDENT ß-THALASSEMIA (TDT)	Elena Chatzikalil	Received

PF-1196	ROLE OF TERTIARY GENETIC MODIFIERS IN RESPONSE TO LUSPATERCEPT TREATMENT IN TRANSFUSION-DEPENDENT THALASSEMIA	Simona Leoni	Received

PF-1197	MULTI-CENTRE EVALUATION OF THE a-THALASSAEMIA EARLY ELUTING PEAK, IMMUNOCHROMATOGRAPHIC STRIP TEST AND HAEMOGLOBIN H INCLUSION TEST FOR a0-THALASSAEMIA SCREENING	Wing Kit Lam	Received

PF-1198	PREVALENCE AND CORRELATES OF DILATED AND NON-DILATED LEFT VENTRICULAR CARDIOMYOPATHY IN TRANSFUSION-DEPENDENT THALASSEMIA	Antonella Meloni	Received

PF-1200	EVALUATION OF MOLECULAR VARIANTS IN B THALASSEMIA CARRIERS AND CORRELATION WITH LABORATORY PARAMETERS IN AN ARGENTINIAN POPULATION	Estefania Rossetti	Received

PF-1202	EFFICACY AND SAFETY OF SUTIMLIMAB IN COLD AGGLUTININ DISEASE IN THE REAL WORLD	Bruno Fattizzo	Received

PF-1203	G6PDFR-1 STUDY : A FRENCH NATIONAL RETROSPECTIVE STUDY OF PATIENTS WITH CLASS A G6PD DEFICIENCY	Clara Rigaud	Received

PF-1204	A NOVEL ANK1 C.5096G>A (P.R1699K) MUTATION IN HEREDITARY SPHEROCYTOSIS: FROM DISCOVERY TO FUNCTIONAL VALIDATION IN A CRISPR/CAS9 KNOCK-IN MOUSE MODEL	Linglong Xu	Received

PF-1205	A PILOT STUDY OF ORELABRUTINIB TREATMENT IN REFRACTORY/RELAPSED AUTOIMMUNE HAEMOLYTIC ANAEMIA/EVANS SYNDROME	Rong Fu	Received

PF-1206	INCIDENCE, PREVALENCE, CLINICAL CHARACTERISTICS, AND TREATMENT PATTERNS OF PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA: A NATIONWIDE POPULATION-BASED STUDY IN TAIWAN, 2017-2022	Hsiao-Wen Kao	Received

PF-1207	MARKERS OF ERYTHROPOIESIS AND IRON METABOLISM RELATE TO THE WIDE SPECTRUM OF CLINICAL AND GENETIC CHARACTERISTICS OF PATIENTS WITH HEREDITARY SPHEROCYTOSIS	Vasiliki Chouliara	Received

PF-1208	A SYSTEMATIC REVIEW IN PRIMARY AND SECONDARY WARM AUTOIMMUNE HAEMOLYTIC ANEMIA: AN OUTCOME-FOCUSED ANALYSIS TO INFORM THE DESIGN OF FUTURE STUDIES	Tom Verbiest	Received

PF-1209	OXIDATIVE DAMAGE FROM MITOCHONDRIAL EXPANSION IN PYRUVATE KINASE DEFICIENCY (PKD): POTENTIAL BENEFITS OF VITAMIN C IN PKD AND G6PD DEFICIENCY	Jihyun Song	Received

PF-1210	INVESTIGATING THE DISTRIBUTION OF FERRITIN LEVELS AND THE PREVALENCE OF IRON DEFICIENCY IN PATIENTS WITH LONG TERM CHRONIC CONDITIONS: A RETROSPECTIVE ANALYSIS USING REAL-WORLD DATA FROM CPRD AURUM	Alvin Katumba	Received

PF-1211	THE ORAL SUCROSOMIAL IRON IS SUPERIOR TO IRON SULFATE IN THE IMPROVEMENT OF HEART FUNCTIONS IN A PRE-CLINICAL MODEL OF IRON DEFICIENCY ANEMIA	Francesca Vinchi	Received

PF-1212	DYSREGULATED IRON METABOLISM, ANEMIA OF INFLAMMATION, AND ALTERED MYELOPOIESIS AT SEPSIS ONSET AND 3 AND 6 MONTHS AFTER DISCHARGE.	Alice Vianello	Received

PF-1213	THE KEY ROLE OF PHOSPHORYLATION IN CERULOPLASMIN STABILITY	Giulio Magherini	Received

PF-1214	IDENTIFICATION OF NOVEL ACERULOPLASMINEMIA MISSENSE VARIANTS IN TYPE II AND III COPPER DOMAINS OF CERULOPLASMIN EXPLOITING AN IN-VITRO CELLULAR MODEL	Sara Lencioni	Received

PF-1215	CHARACTERISTICS AND CARE OF PATIENTS WITH JUVENILE HEMOCHROMATOSIS TYPE 2A	Elena Chatzikalil	Received

PF-1216	AN IRON PULSE STUDY TO ASSESS ORAL IRON ABSORPTION FOLLOWING TREATMENT WITH DISC-3405 IN HEALTHY VOLUNTEERS	Guowen Liu	Received

PF-1217	TARGETED MOLECULAR ASSAYS AND NOVEL BIOMARKERS IN THE EVALUATION OF PRIMARY HYPERFERRITINEMIA	Elena Chatzikalil	Received

PF-1218	EVALUATION OF CHELATION THERAPY EFFECTIVENESS IN TDT PATIENTS	Sophia Delicou	Received

PF-1219	A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL ON PREVENTING HBV REACTIVATION WITH HEPATITIS B VACCINE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WHO HAVE RESOLVED HBV INFECTION (PREVENT HBV)	Masahiro Onozawa	Received

PF-1220	A CLINICAL RISK SCORING SYSTEM FOR THE PREDICTION OF EARLY INFECTION AFTER CAR-T THERAPY	chunrui li	Received

PF-1222	PEDIATRIC ALLO-HSCT RECIPIENTS SHOW ETHNIC DIFFERENCES IN RESPONSE TO CMV IMMUNOTHERAPY USING INTRAVENOUS CMV HYPERIMMUNE GLOBULIN	Antimo Tessitore	Received

PF-1223	RESPIRATORY VIRUSES IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN BOREAL AUTUMN/WINTER 2023-2024	Jon Salmanton-García	Received

PF-1224	TARGETING INTERLEUKIN-1 DURING MUCOSITIS HAS NO EFFECT ON ORAL OR GUT MICROBIAL COMPOSITION IN MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION.	Eva Molendijk	Received

PF-1225	RATES OF INFLUENZA AND PNEUMOCOCCAL VACCINATION AND CORRELATION WITH SURVIVAL IN MULTIPLE MYELOMA PATIENTS: A REAL-LIFE SURVEY	Alessandra Romano	Received

PF-1226	PROPHYLAXIS, PREVENTION AND MANAGEMENT OF NEUTROPENIC FEVER IN AML AND MDS: AN INTERNATIONAL SURVEY OF PRACTICE	Aleece MacPhail	Received

PF-1227	TRANSFORMING ANTIFUNGAL PRESCRIPTIONS IN HEMATO-ONCOLOGY: THE IMPACT OF AN OPTIMIZATION PROGRAM	María Argüello Marina	Received

PF-1229	WORLDWIDE VARIABILITY IN THE USE OF IRRADIATED BLOOD IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCY – A VOX SANGUINIS INTERNATIONAL FORUM	Xiao-Yin Zhang	Received

PF-1231	CAR-T CELL THERAPY- CHALLENGES IN TRANSFUSION SUPPORT	Adriana Lukac	Received

PF-1232	BLOOD ON OUR HANDS: PREVENTABLE HAEMORRHAGES, REPEATED MISSED OPPORTUNITIES	Sarah Bassiony	Received

PF-1234	EVALUATION OF RED CELL SAVER IN CARDIAC SURGERY UNDER CARDIOPULMONARY BYPASS	Silvia Lovato	Received

PF-1235	TREATMENT OUTCOMES AND DISCONTINUATION PATTERNS IN PATIENTS RECEIVING THROMBOPOIETIN RECEPTOR AGONISTS: A EUROPEAN MULTICENTER ANALYSIS	MARIA LOZANO	Received

PF-1236	PLATELET RESPONSE TO AVATROMBOPAG AMONG PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA WHO SWITCHED FROM ELTROMBOPAG OR ROMIPLOSTIM: THE REAL-AVA 2.0 REAL-WORLD STUDY	Alexandra Greatsinger	Received

PF-1239	DURABILITY OF RESPONSE TO AVATROMBOPAG AMONG PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: THE REAL-AVA 2.0 REAL-WORLD STUDY	Alexandra Greatsinger	Received

PF-1241	IMPACT OF ETHNICITY ON RELAPSE FREE SURVIVAL AFTER RITUXIMAB TREATMENT IN IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA IN FRANCE	Júlia Weisinger	Received

PF-1243	EFFICACY AND SAFETY OF TPO-RA-BASED COMBINATION THERAPIES IN REFRACTORY IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTRE COMPARISON OF 3 TPO-RA BASED TREATMENT STRATEGIES.	Lucy Kamuriwo	Received

PF-1244	AUTOIMMUNE CYTOPENIAS ASSOCIATED WITH LYMPHOID HEMATOLOGICAL MALIGNANCIES: A 25-YEAR ANALYSIS OF A FRENCH PROSPECTIVE REGISTRY.	Sylvain Audia	Received

PF-1245	EVALUATION OF ARTERIAL THROMBOSIS FREQUENCY AND RISK FACTORS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA	Ufuk Demirci	Received

PF-1246	IMMATURE PLATELET FRACTION: A USEFUL TOOL TO DIFFERENTIATE IMMUNE THROMBOCYTOPENIA FROM MYELODYSPLASTIC SYNDROMES.	Sylvain Audia	Received

PF-1248	ATP-RELEASE IDENTIFIES PLATELET FUNCTION DISORDERS IN PATIENTS WITH BLEEDING DISORDER OF UNKNOWN CAUSE (BDUC) AND NORMAL LTA RESULTS	Amaury Monard	Received

PF-1250	FUNCTIONAL AND CLINICAL IMPACT OF ANKRD26 GENE VARIANT C.-140C>G IN INHERITED THROMBOCYTOPENIA	Paulina Likavcova	Received

PF-1251	CLINICALLY MEANINGFUL RESPONSE TO AVATROMBOPAG: A PHASE 3B TRIAL FOR TREATMENT OF CHILDREN WITH ITP	Rachael F. Grace	Received

PF-1253	TPO-RA COMBINED WITH SIROLIMUS IS EFFECTIVE IN THE TREATMENT OF RELAPSED IMMUNE THROMBOCYTOPENIA (ITP):A PROSPECTIVE, SINGLE-ARM CLINICAL STUDY	Yimei Feng	Received

PF-1255	PROSPECTIVE, OPEN-LABEL, PHASE I/III STUDY OF THE PHARMACOKINETICS, EFFICACY AND SAFETY OF A FIBRINOGEN CONCENTRATE FROM HUMAN PLASMA, FOR THE TREATMENT AND PROPHYLAXIS OF BLEEDING IN PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY	daniel zaldumbide	Received

PF-1256	PLATELET REACTIVITY IS VARIABLE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA AND CAN BE CORRECTED BY TREATMENT	Rocel Saputil	Received

PF-1257	MACHINE LEARNING MODEL FOR BLEEDING PREDICTION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Nikola Pantic	Received

PF-1258	AGE-RELATED DIFFERENCES IN COMORBIDITIES, RESPONSE AND ADVERSE EVENTS TO THROMBOPOIETIN RECEPTOR AGONISTS IN IMMUNE THROMBOCYTOPENIA	MARIA LOZANO	Received

PF-1261	STUDY DESIGN OF PHASE 3 PART IN A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SOVLEPLENIB IN WARM AUTOIMMUNE HAEMOLYTIC ANAEMIA (ESLIM-02)	Bing Han	Received

PF-1262	DISCOVERY OF NOVEL, REVERSIBLE AND ALLOSTERIC AKT1-ISOFORM SELECTIVE INHIBITORS FOR THE PURPOSE OF ADDRESSING ABERRANT ANGIOGENESIS IN HEREDITARY HEMORRHAGIC TELANGIECTASIAS AND VASCULAR MALFORMATIONS	Shomit Sengupta	Received

PF-1264	INTRINSIC ACTIVATION OF THROMBIN GENERATION IS A PROMISING TOOL TO MONITOR SEVERE HEMOPHILIA A PATIENTS ON EMICIZUMAB	Emma Urlings	Received

PF-1266	EFFICACY AND SAFETY OF IMMUNOSUPPRESSIVE THERAPY IN ACQUIRED HAEMOPHILIA A: A SYSTEMATIC REVIEW OF CLINICAL TRIALS	Nia Siregar	Received

PF-1268	THE IMPACT OF IMPROVED HEMOPHILIA CARE ON HOSPITALIZATION RATE IN CHILDREN WITH HEMOPHILIA: A SINGLE-CENTER EXPERIENCE	Alkistis Adramerina	Received

PF-1271	COMPARISON OF RIETE AND SOME SCORES FOR PREDICTING CANCER IN UNPROVOKED THROMBOSIS	Abdulrahman Al Raizah	Received

PF-1272	IGG AUTOANTIBODIES ON A COHORT OF 113 CONFIRMED ADQUIRED THROMBOTIC THROMOBOCYTOPENIC PURPURA (ATTP) PATIENTS.	Rafael L. Del Amo	Received

PF-1274	VISCOELASTIC TESTS VERSUS STANDARD-OF-CARE IN PATIENTS WITH CIRRHOSIS: A SYSTEMATIC REVIEW AND UPDATED META-ANALYSIS	Cilomar Martins de Oliveira Filho	Received

PF-1275	A NOVEL SCORE FOR PREDICTION OF CANCER IN UNPROVOKED VENOUS THROMBOEMBOLISM	Abdulrahman Al Raizah	Received

PF-1276	NATIONAL TRENDS IN VENOUS THROMBOEMBOLISM IN IRELAND (20152022): A RETROSPECTIVE ANALYSIS	Richard Daly	Received

PF-1278	A SINGLE CENTRE REVIEW OF POTENTIALLY PREVENTABLE HOSPITAL-ACQUIRED VENOUS THROMBOEMBOLISM: IDENTIFYING TARGETS FOR QUALITY IMPROVEMENT AND ENHANCED PATIENT SAFETY	Barry Kevane	Received

PF-1279	RETROSPECTIVE STUDY IN A LARGE COHORT OF SUSPECTED CASES TO IDENTIFY POTENTIAL CLINICAL AND BIOLOGICAL PREDICTIVE MARKERS OF LYSOSOMAL ACID LIPASE DEFICIENCY	Irene Serrano-Gonzalo	Received

PF-1280	THE PREDICTIVE VALUE OF TAT, PIC, TM AND TPAI-C FOR THROMBOTIC RISK IN CHINESE MULTIPLE MYELOMA PATIENTS	Yue Huang	Received

PF-1282	THE EFFECT OF UNADDRESSED SIDE EFFECTS ON PATIENT-REPORTED CONFIDENCE IN CARE PLANS AMONG PATIENTS WITH LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Natacha Bolanos	Received

PF-1283	UNDERSTANDING OF THE PERSPECTIVES AND PREFERENCES OF INFORMAL CARERS OF PEOPLE WITH ACUTE LEUKEMIA: INSIGHTS FROM A QUALITATIVE STUDY	Samantha Nier	Received

PF-1284	EARLY INTEGRATION OF PALLIATIVE CARE (PC) TO ENHANCE QUALITY OF LIFE AND SYMPTOM MANAGEMENT IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT)	María Argüello Marina	Received

PF-1285	EXPLORING SHORT-TERM PATIENT-REPORTED ADVERSE EVENTS (AES) AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) BY CAR T-CELL PRODUCT IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMAS: EVIDENCE FROM A REAL-WORLD STUDY BY THE GIMEMA	Fabio Efficace	Received

PF-1288	EXTERNAL VALIDATION OF THE FA-IPSS(H) FOR PREDICTING SURVIVAL IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES	Fabio Efficace	Received

PF-1289	ECONOMIC HARDSHIP IS A SIGNIFICANT FACTOR FOR DEPRESSION AND SURVIVAL FOUR YEARS AFTER ACUTE LEUKEMIA – A SWEDISH PATIENT REPORTED OUTCOME STUDY	Emma Lennmyr	Received

PF-1290	ASSOCIATIONS BETWEEN ILLNESS PERCEPTIONS AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: A CROSS-SECTIONAL GREEK STUDY	Charalampos Pontikoglou	Received

PF-1291	ASSOCIATION BETWEEN BASELINE PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY	Julia Garcia Mateo	Received

PF-1292	HEALTH-RELATED QUALITY OF LIFE PROFILE OF PATIENTS WITH VEXAS: PRELIMINARY ANALYSIS OF A REAL-LIFE STUDY BY THE GIMEMA	Fabio Efficace	Received

PF-1294	UNDERSTANDING CAREGIVER CHALLENGES IN MULTIPLE MYELOMA (MM): A SYSTEMATIC LITERATURE REVIEW (SLR) OF THE QUALITATIVE AND QUANTITATIVE LITERATURE	Doris Hansen	Received

PF-1295	QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS: REAL-WORLD STUDY IN KAZAKHSTAN	Azaliya Turgunova	Received

PF-1296	OUT-PATIENT INTENSIVE CHEMOTHERAPY FOR ACUTE LEUKEMIA: A STUDY SHOWING A SAFE AND COST-EFFECTIVE MODEL OF CARE AT THE LEEDS CANCER CENTER	Amy Todd	Received

PF-1298	IMPACT OF HAEMATOLOGICAL DISEASES ON EMPLOYMENT, ECONOMIC AND SOCIAL ASPECTS: PRELIMINARY RESULTS FROM A MULTI-REGIONAL SURVEY IN SPAIN	Celia Marín Rancel	Received

PF-1299	HEALTHCARE RESOURCE UTILIZATION AND COSTS IN THE MANAGEMENT OF PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE IN THE UNITED STATES	Ariela Noy	Received

PF-1302	A MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF BRECADD VS PET-GUIDED ABVD AND EBEACOPP IN ADVANCED HODGKIN LYMPHOMA	Alexa Molinari	Received

PF-1303	INDIRECT TREATMENT COMPARISON OF IPTACOPAN VS. PEGCETACOPLAN IN COMPLEMENT INHIBITOR NAÏVE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS	Anggie Wiyani	Received

PF-1306	TRANSFUSION-RELATED COST AND TIME BURDEN OFFSETS IN PATIENTS WITH MYELOFIBROSIS TREATED WITH PACRITINIB COMPARED TO BEST AVAILABLE THERAPY BASED ON PERSIST-2 TRIAL	Abiola Oladapo	Received

PF-1308	LINKING GUT MICROBIOME COMPOSITION AND METABOLOMIC PROFILES TO CLINICAL FEATURES: DEVELOPMENT OF PREDICTIVE MODELS IN MDS AND AML	Alessia Campagna	Received

PF-1309	SPATIAL TRANSCRIPTOMICS OF PAEDIATRIC AND ADULT ACUTE MYELOID LEUKAEMIA BONE MARROW REVEALS DIFFERENCES IN CELLULAR COMPOSITION AND SPATIAL NEIGHBOURHOODS	Merel van der Meulen	Received

PF-1310	HIGH ACCURACY OF PERIPHERAL BLOOD TESTING AND MACHINE LEARNING-DERIVED PREDICITIVE MODELS TO DISTINGUISH ADVANCED FROM INDOLENT SYSTEMIC MASTOCYTOSIS: ANALYSIS OF AVAPRITINIB AND ELENESTINIB TRIAL DATA	Daniel J. DeAngelo	Received

PF-1311	LYMPHOPATH: AI-DRIVEN DIGITAL PATHOLOGY PLATFORM FOR RISK STRATIFICATION IN DIFFUSE LARGE B-CELL LYMPHOMA	Manuel Piñeiro Fiel	Received

PF-1313	AI-BASED RISK SCORE FOR THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP): ENHANCING DIAGNOSTIC ACCURACY AND TREATMENT OPTIMIZATION.	Jorge M. Nieto	Received

PF-1314	MULTI-CENTRE VALIDATION OF A PREDICTIVE SCREENING TOOL TO IDENTIFY PATIENTS WITH A POTENTIAL MYELOPROLIFERATIVE NEOPLASM	Xavier Peer	Received

PF-1315	MITOCHONDRIAL DNA MUTATION ANALYSIS REVEALS DELAYED DONOR T CELL ENGRAFTMENT IN SKIN COMPARED TO PERIPHERAL BLOOD	Livius Penter	Received

PF-1316	A COST-EFFECTIVE LONG-READ GENOME SEQUENCING APPROACH FOR RAPID, COMPREHENSIVE, AND SCALABLE MOLECULAR CHARACTERIZATION OF HEMATOLOGIC MALIGNANCIES	Jens Schrezenmeier	Received

PF-1317	TH-17-DRIVEN NK-LIKE CYTOTOXIC CD8+ T CELLS IN MSC AND CAR-T CELL DUAL IMMUNOTHERAPY FOR SUPERIOR ANTI-TUMOR EFFICACY	Caidong Hu	Received

PF-1318	SPECTRAL FLOW CYTOMETRY-GUIDED SELECTION OF ALTERNATIVE TUMOR-ASSOCIATED MEMBRANE EXPRESSION ANTIGENS FOR CAR-T CELL RE-TREATMENT IN RELAPSED/REFRACTORY B-CELL MALIGNANCIES	yajing zhang	Received

PF-1320	IMPLEMENTATION OF A NOVEL HOSPITAL AT HOME PROGRAM FOR PATIENTS UNDERGOING ACUTE LEUKEMIA INDUCTION	Nikesh Shah	Received

PF-1321	IN THE DLBCL MICROENVIRONMENT, SIRT1 AND SIRT3 UPREGULATION IN MACROPHAGES IS CORRELATED WITH AUTOPHAGY-RELATED GENE EXPRESSION AND DIFFERENT INFLAMMATORY STATES.	Mounia S Braza	Received

PF-1324	LONG-READ SEQUENCING AS A RAPID AND RELIABLE DIAGNOSTIC METHOD FOR THE DETECTION OF ACTIONABLE MUTATIONS IN ACUTE MYELOID LEUKEMIA	Rebecka Östlund	Received

PF-1325	FEASIBILITY OF NANOPORE SEQUENCING FOR TP53 MUTATION DETECTION IN CLL AND MYELOID NEOPLASMS IN A RESOURCE-LIMITED SETTING	Yuliya Tsoy	Received

PF-1327	AI-DRIVEN STRUCTURING OF ELIGIBILITY CRITERIA TO ENHANCE PATIENT RECRUITMENT IN MULTIPLE MYELOMA CLINICAL TRIALS	Arturo Hurtado	Received

PF-1328	GLOBAL, REGIONAL, AND NATIONAL BURDEN OF ACUTE LEUKEMIA AND ITS RISK FACTORS FROM 1990 TO 2021 AND PREDICTIONS TO 2040: FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY 2021	Xinpu Han	Received

PF-1329	REAL-TIME PATIENT QUALITY OF LIFE AND WEARABLE BIOMETRIC TRACKING \| IMPLICATIONS FOR VASO-OCCLUSIVE CRISIS PREDICTION.	Kim Summers	Received

PS-1330	H3K4 TRIMETHYLATION IS A TARGETABLE DEPENDENCY IN T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL)	Gabriela Segat	Received

PS-1331	RESIDUAL DISEASE AND RELAPSE: HOW STOCHASTIC FOUNDER EFFECTS SHAPE PEDIATRIC ALL OUTCOMES	Virginia Turati	Received

PS-1332	MAPPING THE AKR1C3 CIS-REGULOME IN ACUTE LYMPHOBLASTIC LEUKEMIA TO ENHANCE TARGETED THERAPY WITH A NEW AKR1C3-ACTIVATED PRODRUG	Hansen Kosasih	Received

PS-1334	EPIGENETIC DETERMINANTS CONFERRING GLUCOCORTICOID RESISTANCE IN PAEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA	Yashna Walia	Received

PS-1335	DIGITAL DROPLET PCR FOR MINIMAL RESIDUAL DISEASE MONITORING IN PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT FROM THE PROSPECTIVE NORTHERN ITALY LEUKEMIA GROUP (NILG) ALL 10/07 STUDY	Francesco Ballardini	Received

PS-1336	DISCOVERY OF A NOVEL BCP-ALL MOLECULAR SUBGROUP DEFINED BY IGH::FENDRR GENE FUSION, FOXF1 OVEREXPRESSION AND KRAS A146 MUTATION	Sonja Bendig	Received

PS-1337	DNMT3A LIMITS MYELOID SIGNALING RESPONSES IN T-CELL PROGENITORS DURING NORMAL AND LEUKEMIC DEVELOPMENT	Marissa Foo	Received

PS-1339	DRUG-RESPONSE MODULATING GENES IN ETV6::RUNX1 CHILDHOOD LEUKEMIA	Laura Oksa	Received

PS-1340	CAPTURE PROFILING REVEALS AGE-RELATED IG/TR PROFILES, MUTATIONAL PATTERNS AND CLONAL HAEMATOPOIESIS SIGNATURES IN ADULT PATIENTS WITH ALL	Cecilia Bozzetti	Received

PS-1344	DEEP MOLECULAR PROFILING REVEALS PROGNOSTIC MARKERS FOR REFINED PATIENT STRATIFICATION AND TARGETABLE ALTERATIONS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA	Borbála Péterffy	Received

PS-1346	SENSITISATION AND ERADICATION OF DRUG-RESISTANT PAEDIATRIC ETP-ALL BY REPURPOSING DECITABINE	Yizhou Huang	Received

PS-1348	CLUSTERING ANALYSIS OF ALTERNATIVE SPLICING IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IDENTIFIED TARGETABLE SUBTYPE WITH GLOBAL SPLICING DEFECTS	Margaret Heung-Ling Ng	Received

PS-1349	ROLE OF TP53 MUTATIONS IN REFINING PROGNOSIS OF KTM2A-REARRANGED ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS	Mariangela Di Trani	Received

PS-1352	CD49F, A USEFUL MRD AND SUPPOSED PREDICTIVE MARKER OF LATE RELAPSE IN PEDIATRIC B-ALL	Gábor Barna	Received

PS-1354	TARGETING ONCOGENE-INDUCED SENESCENCE IN ETV6::RUNX1 PRE-LEUKEMIC CELLS	Mayla Bertagna	Received

PS-1358	CHEMORESISTANT ALL CELL LINES EXHIBIT REDUCED MITOCHONDRIAL DAMAGE AND INCREASED MITOCHONDRIAL BIOGENESIS UPON CHEMOTHERAPY.	Jenny Chatzigerou	Received

PS-1359	MUSASHI-2 PROMOTES CHEMOTHERAPY RESISTANCE OF INFANT KMT2A-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA VIA REGULATING THE BIOENERGETIC METABOLISM.	Luigia Valsecchi	Received

PS-1364	ROLE OF FRUCTOSE TRANSPORTER (GLUT5) EXPRESSION IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Serene Xavier	Received

PS-1366	B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA CAUSES PARACRINE SENESCENCE IN MESENCHYMAL STROMAL CELLS TO SUBVERT THE TREATMENT RESPONSE IN ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA	Aditi Dey	Received

PS-1368	REAL-WORLD OUTCOMES OF ADULT B-ALL PATIENTS WHO EXPERIENCE RELAPSED OR REFRACTORY DISEASE FOLLOWING BREXUCABTAGENE AUTOLEUCEL, A STUDY BY THE ROCCA CONSORTIUM	Rawan Faramand	Received

PS-1370	LEUKEMIC STEM CELL SIGNATURES IMPROVE RISK STRATIFICATION IN T-ALL PATIENTS	YI WEI Lee	Received

PS-1371	INOTUZUMAB OZOGAMICIN IN PEDIATRIC CD22-POSITIVE VERY HIGH RISK FIRST RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY RESULTS OF THE ITCC-059 STUDY	Erica Brivio	Received

PS-1372	COMBINATION OF OLVEREMBATINIB AND VP REGIMEN AS FIRST-LINE THERAPY FOR ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-ARM, MULTICENTRE, PHASE 2 TRIAL	Gaixiang Xu	Received

PS-1373	MUTATIONS IN GENES ASSOCIATED WITH CLONAL HEMATOPOIESIS IN PATIENTS WITH ACUTE T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA	Anastasia Vasilieva	Received

PS-1376	PEGASPARGASE ADMINISTRATION IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AGED 55 YEARS OR OLDER TREATED WITH THE PEDIATRIC-INSPIRED PROGRAM LAL1913. A SUBANALYSIS OF THE CAMPUS ALL STUDY	Davide Lazzarotto	Received

PS-1377	MULTICENTER REAL-WORLD STUDY ON INOTUZUMAB AS A BRIDGE TO CELLULAR THERAPY IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Alicia Aguirre	Received

PS-1378	CLINICAL EFFICACY ANALYSIS OF CAR-T THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH EXTRAMEDULLARY DISEASE	Zhao defeng	Received

PS-1379	COMPARATIVE EFFICACY OF THE GIMEMA LAL1913 STANDARD CHEMOTHERAPY PROTOCOL VERSUS THE STANDARD ARM OF THE E1910 TRIAL IN MRD-NEGATIVE PH-NEGATIVE ALL: A MAIC ANALYSIS	Alfonso Piciocchi	Received

PS-1380	PROGNOSTIC SCORE MODELING FOR ADULT PATIENTS WITH PHILADELPHIA CHROMOSSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA	Eduardo Chapchap	Received

PS-1383	T-ACUTE LYMPHOCYTIC LEUKEMIA: NEW PERSPECTIVES ON DIFFERENCES IN IMMUNOPHENOTYPES AND GENE PROFILES BETWEEN CHILDREN AND ADULTS	Ying Wang	Received

PS-1384	DEFIBROTIDE TREATMENT OUTCOMES IN PATIENTS WITH VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) OCCURRING AFTER EXPOSURE TO INOTUZUMAB (INO) OR GEMTUZUMAB (GO)	Trina Soluta	Received

PS-1386	VENETOCLAX, TUCIDINOSTAT, PEGASPARGASE, AND DEXAMETHASONE INDUCTION REGIMEN FOR NEWLY DIAGNOSED ADULT ETP-ALL: A CHEMOTHERAPY-FREE, LOW-TOXICITY, EFFECTIVE REGIMEN	Jieping Lin	Received

PS-1388	GENETIC CHARACTERISTICS OF BCR::ABL1-POSITIVE B-ACUTE LYMPHOBLASTIC LEUKEMIA WITH MULTILINEAGE INVOLVEMENT AND POST-HSCT SURVIVAL ANALYSIS	Tong Wang	Received

PS-1389	MRD-BASED TARGET THERAPY FOR PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULT PATIENTS BY THE RALL-2016M PROTOCOL: EFFECTIVE FOR BCP-ALL, SHOWS NO EFFICACY IN T-ALL	Olga Aleshina (Gavrilina)	Received

PS-1390	CLINICAL ANALYSIS OF SEQUENTIAL CAR-T CELL THERAPY COMBINED WITH VENETOCLAX, HYPOMETHYLATING AGENTS, AND PERSONALIZED TARGETED DRUGS IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY ACUTE B-CELL LYMPHOBLASTIC LEUKEMIA	Zhao defeng	Received

PS-1391	PROGNOSTIC CLASSIFICATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: INTEGRATED ANALYSIS OF CLINICAL AND GENETIC FEATURES	Kana Kato	Received

PS-1392	REAL-WORLD OUTCOMES OF PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS TREATED WITH A PEDIATRIC-INSPIRED PROTOCOL: A COMPARISON ACROSS TWO TIME PERIODS	Maria Agustina Perusini	Received

PS-1393	COMBINATION OF VENETOCLAX AND DARATUMUMAB PLUS CAG REGIMEN IS AN EFFECTIVE TRANSPLANT BRIDGING REGIMEN IN ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH POSITIVE MINIMAL RESIDUAL DISEASE	Li-Jun Peng	Received

PS-1395	NOVEL EUROFLOW QUALITY ASSESSMENT ON B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA MINIMAL RESIDUAL DISEASE. PROGRAM DEVELOPMENT AND FOUR ROUNDS OF IMPLEMENTATION	Michaela Reiterová	Received

PS-1397	CO-OCCURRENCE OF CHILDHOOD ACUTE LEUKEMIA AND TYPE 1 DIABETES MELLITUS: A FINNISH CASE-CONTROL STUDY	Julia Ventelä	Received

PS-1403	GATA2 N-TERMINAL ZINC FINGER DOMAIN MUTATIONS PROMOTE ERYTHROID CLONAL EXPANSION IN ACUTE MYELOID LEUKEMIA	Tianhui Liu	Received

PS-1405	SINGLE-CELL DISSECTION OF SELF-DERIVED VERSUS DONOR-DERIVED T-CELL EXHAUSTION IN BONE MARROW NICHES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA	Chunzi Yu	Received

PS-1406	CXCR4 EXPRESSION IN AML BLASTS AND ITS IMPACT ON CXCR4 INHIBITOR EFFICACY DURING CONSOLIDATION THERAPY: RESULTS FROM THE SAL BLAST TRIAL	Enise Ceran	Received

PS-1408	SINGLE-CELL PROFILING IDENTIFIES LEUKEMIC STEM CELL SUBTYPES LINKED TO ATRA SENSITIVITY IN RAS MUTANT ACUTE MYELOID LEUKEMIA	Diego A Pereira-Martins	Received

PS-1409	PEDIATRIC AML BLASTS PROMOTE AN IMMUNOSUPPRESSIVE M2-LIKE PHENOTYPE BY REPROGRAMMING MACROPHAGE METABOLISM.	Alicia Perzolli	Received

PS-1410	MICROBIOTA-INSPIRED COMPOUNDS AS NOVEL DRUG CANDIDATES TARGETING NPM1-MUTATED ACUTE MYELOID LEUKEMIA	Miguel Ángel Navarro Aguadero	Received

PS-1411	DEEP IMMUNOPHENOTYPING BY MASS CYTOMETRY ELUCIDATES THE PROGENITOR TRAJECTORY OF ERYTHROID-DERIVED ACUTE MYELOID LEUKEMIA	Inga KF Motzfeldt	Received

PS-1413	CD180 IS A TARGETABLE MARKER FOR SENESCENCE ASSOCIATED CHEMORESISTANT IN PAEDIATRIC KMT2A-REARRANGED ACUTE MYELOID LEUKAEMIA	Aya Gouma	Received

PS-1415	OXPHOS-DRIVEN M2-POLARIZED MACROPHAGES SUPPORT LEUKEMIC CELL GROWTH THROUGH MITOCHONDRIAL TRANSFER	Wendy Boschloo	Received

PS-1419	HIGH THROUGHPUT DRUG SCREEN COUPLED TO PROTEO-GENOMIC DATA IDENTIFIES EPIGENETIC VULNERABILITIES IN AML SUBTYPE-SPECIFIC PATIENT GROUP	Shanna Hogeling	Received

PS-1422	P16INK4A SUPPRESSION BY FLT3-ITD ENHANCES AML PROGRESSION: MECHANISTIC INSIGHTS AND THERAPEUTIC TARGETING OF EPIGENETIC REGULATORS	jiarui zheng	Received

PS-1424	RGT-61159, A POTENT AND SELECTIVE SMALL MOLECULE MYB RNA INHIBITOR, SHOWED SIGNIFICANT ANTI-TUMOR ACTIVITY AS MONOTHERAPY OR IN COMBINATION WITH STANDARDS OF CARE IN SEVERAL LEUKEMIA DISEASE MODELS HARBORING AML MOST COMMON GENETIC LESIONS	Patricia Soulard	Received

PS-1427	ACTIVIN A INHIBITION IMPAIRED IN VITRO AML CELL MIGRATION AND IN VIVO BONE MARROW ENGRAFTMENT IN MICE	Blake Moses	Received

PS-1429	COMPLEMENTARITY OF HIGH-THROUGHPUT SEQUENCING AND FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE IN AML: A REAL LIFE STUDY FROM THE HAUTS-DE-FRANCE OBSERVATORY	Augustin Boudry	Received

PS-1431	TARGETING METABOLIC ALTERATIONS IN PML::RARa+ MYELOID CELLS TO OVERCOME RESISTANCE AND RELAPSE IN ACUTE PROMYELOCYTIC LEUKEMIA.	Nelida I. Noguera	Received

PS-1432	GLUCOSE METABOLIC CHANGES DRIVE DISEASE PROGRESSION AND RELAPSE IN RUNX1::ETO ACUTE MYELOID LEUKEMIA	Nuria Tubio Santamaria	Received

PS-1436	INTEGRATIVE SYSTEMS BIOLOGY APPROACH UTILIZING TRANSCRIPTOMIC AND MUTATIONAL PROFILES TO UNVEIL PROGNOSIS-ASSOCIATED MOLECULAR PATHWAYS IN ACUTE MYELOID LEUKEMIA	Xiaoxue Wang	Received

PS-1438	DEEP TARGETED SEQUENCING TO MONITOR MEASURABLE RESIDUAL DISEASE AND CHIMERISM IN MIELOID MALIGANCIES AFTER ALLOGENIC STEM CELL TRANSPLANT	Irene Zamanillo	Received

PS-1439	SELECTIVE THERAPEUTIC TARGETING ON MNX1-DRIVEN PROGRAMS IN INFANT AML	Ylenia Cicirò	Received

PS-1440	AVPR2-DRIVEN NEUROHYPOPHYSEAL DYSFUNCTION IN ADVERSE-RISK CYTOGENETIC AML: MECHANISTIC INSIGHTS AND SURVIVAL IMPLICATIONS	Diyaer Abuduaini	Received

PS-1443	GUICAOBAIDU DECOCTION ALLEVIATES DOXORUBICIN-INDUCED MYOCARDIAL CARDIOTOXICITY VIA AMELIORATION OF TRDMT1/BNIP3 MEDIATED MITOPHAGY IN MICE	Xing Cui	Received

PS-1444	(LEUKEMIA-SPECIFC) B-CELLS IN AML PATIENTS CAN BE INDUCED BY IMMUNE MODULATORY THERAPY (KIT M: GM-CSF AND PGE-1) AND CONTRIBUTE TO IMPROVE ANTILEUKEMIC RESPONSE	Helga Schmetzer	Received

PS-1445	TRANSCRIPTOMIC AND CELLULAR DECONVOLUTION ANALYSIS REVEALS DISTINCT PROFILES ASSOCIATED WITH CYTARABINE RESISTANCE IN ACUTE MYELOID LEUKEMIA	Alba Mora	Received

PS-1449	ADVANCING NK CELL IMMUNOTHERAPY IN AML AND OVERCOMING CYTOKINE-DRIVEN ADAPTIVE RESISTANCE	Monika Sponheimer	Received

PS-1450	MOLECULAR CHARACTERISTICS OF AML DEFINED BY DIFFERENTIATION	Christoph Kornauth	Received

PS-1452	VENETOCLAX INDUCES MITOCHONDRIAL APOPTOSIS AND AUTOPHAGY TO OVERCOME ARSENIC TRIOXIDE RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA	Syed Hasan	Received

PS-1455	ANTI-LEUKEMIC ACTIVITY OF MITOTIC CHECKPOINT INHIBITOR BAL0891 AS MONOTHERAPY AND IN COMBINATION WITH TARGETED AGENTS	Mi Ji Choi	Received

PS-1456	CHARACTERISTICS AND PROGNOSTIC IMPACT OF IDH MUTATIONS IN A REAL-LIFE COHORT OF 217 PATIENTS WITH ACUTE MYELOID LEUKEMIA	Giovanna Piras	Received

PS-1457	SPHINGOSINE-1-PHOSPHATE (S1P) MODULATOR FTY720 SYNERGIZES WITH VENETOCLAX IN AML THROUGH MTOR PATHWAY SUPPRESSION, MITOCHONDRIAL DAMAGE, AND LYSOSOMAL STRESS INDUCTION	Katia Beider	Received

PS-1460	ACUTE MYELOID LEUKEMIA WITH 7Q DELETION: INCIDENCE, PROGNOSTIC, AND IMPACT ON RESPONSE TO BORTEZOMIB IN COMBINATION WITH AZACITIDINE OF EZH2 ALTERATIONS.	Iván Martín	Received

PS-1461	EXPLORATION OF MUTATIONAL PATTERNS AND THEIR IMPACT ON THE IMMUNE MICROENVIRONMENT IN ACUTE MYELOID LEUKEMIA THROUGH IN SILICO ANALYSES	Allana Carvalho	Received

PS-1464	REGULATORY T CELL-PREDOMINANT TUMOR MICROENVIRONMENT (TME) PREDICTS POOR OUTCOMES IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN).	Claudia Tobar Cabrera	Received

PS-1465	PAEONIFLORIN TARGETING M6A RNA METHYLATION IMPROVES BNIP3 ASSOCIATE MITOPHAGY IN DOXORUBICIN-INDUCED MYOCARDIAL CARDIOTOXICITY	Xing Cui	Received

PS-1467	PATIENTS WITH RELAPSED OR REFRACTORY (R/R) NUCLEOPHOSMIN 1–MUTATED (NPM1M) ACUTE MYELOID LEUKEMIA (AML): UPDATED RESULTS FROM THE PHASE 2 AUGMENT-101 STUDY	Martha L Arellano	Received

PS-1469	HYPOMETHYLANTS IN MONOTHERAPY OR COMBINED WITH VENETOCLAX: REAL-LIFE EXPERIENCE IN 1964 PATIENTS REPORTED TO THE PETHEMA-GPLA REGISTRY	Eliana Aguiar	Received

PS-1470	RISK STRATIFICATION OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX IN COMBINATION WITH INTENSIVE CHEMOTHERAPY	Wei-Ying Jen	Received

PS-1471	A PHASE IB/2 TRIAL OF AN ALL-ORAL „TRIPLET" REGIMEN FOR IDH-MUTATED MYELOID MALIGNANCIES: DECITABINE/CEDAZURIDINE AND VENETOCLAX IN COMBINATION WITH IVOSIDENIB/ENASIDENIB	Jennifer Marvin-Peek	Received

PS-1472	PROGNOSTIC VALUE OF MOLECULAR MEASURABLE RESIDUAL DISEASE MONITORED BY DIGITAL PCR BEFORE AND AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TP53-MUTATED AML/MDS COHORT: A TROPHY STUDY	Yanmin Zhao	Received

PS-1473	UPDATED RESULTS AND LONGER FOLLOW-UP FROM THE AUGMENT-101 PHASE 2 STUDY OF REVUMENIB IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) KMT2AR ACUTE LEUKEMIA	Ibrahim Aldoss	Received

PS-1474	CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES IN 405 ADULT PATIENTS WITH MIXED PHENOTYPE ACUTE LEUKEMIA: A STUDY FROM THE PETHEMA AND PALG GROUPS	Marta Sobas	Received

PS-1475	IS MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENT BY MULTIPARAMETER FLOW CYTOMETRY (MFC) A VALID EARLY ENDPOINT OF TREATMENT EFFICACY IN ACUTE MYELOID LEUKEMIA (AML): A PETHEMA STUDY IN 2,819 PATIENTS	Bruno Paiva	Received

PS-1478	RESULTS FROM A CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 (ORAL AZACITIDINE) AND VENETOCLAX FOR NEWLY DIAGNOSED AND RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA	Maria Amaya	Received

PS-1479	THE PROGNOSTIC IMPACT OF TRISOMY 8 IN ACUTE MYELOID LEUKEMIA	Daniel Tuyet Kristensen	Received

PS-1480	PHASE II STUDY OF CLADRIBINE WITH LOW DOSE CYTARABINE AND VENETOCLAX ALTERNATING WITH AZACYTIDINE AND VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA	Alex Bataller	Received

PS-1481	SECOND INDUCTION CYCLE BEFORE ALLOHSCT DOES NOT IMPROVE SURVIVAL IN ADVERSE-RISK AML PATIENTS IN COMPLETE REMISSION AFTER FIRST INDUCTION	Lukas Haaksma	Received

PS-1484	CIRCULATING TUMOR DNA BETTER DISCRIMINATES TRUE MRD POSITIVITY FOR THE RISK STRATIFICATION OF CHILDHOOD ACUTE MYELOID LEUKEMIA	Lipeng Liu	Received

PS-1485	HIGH REMISSION RATES IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH QHRD107 (CDK9 INHIBITOR), VENETOCLAX, AND AZACITIDINE COMBINATION THERAPY (107VA REGIMEN): PRELIMINARY RESULTS FROM A PHASE 2A STUDY	Yunxiang Zhang	Received

PS-1486	OUTCOMES IN PATIENTS YOUNGER THAN 50 YEARS OLD WITH TREATMENT-NAÏVE BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATED WITH TAGRAXOFUSP: SUBANALYSIS OF A PHASE 1/2 TRIAL	Anthony Stein	Received

PS-1488	DECITABINE COMBINED WITH HAAG FOR NEWLY DIAGNOSED PARENTS WITH POOR-RISK ACUTE MYELOID LEUKEMIA: A PROSPECTIVE, PHASE 3, RANDOMIZED, MULTI-CENTER STUDY	wei cui	Received

PS-1491	IMPACT OF DAY 14 MEASURABLE RESIDUAL DISEASE IN NEWLY DIAGNOSED UNFIT ACUTE MYELOID LEUKEMIA PATIENTS DURING THE AZACITIDINE PLUS VENETOCLAX REGIMEN AS THE INDUCTION THERAPY	Ying Lu	Received

PS-1494	NUCLEOSIDE ANALOGUE-BASED INDUCTION (CLAG-M OR FLAGIDA) RESULTS IN HIGHER REMISSION RATES THAN STANDARD AML OR ALL-LIKE INTENSIVE INDUCTION REGIMENS IN MIXED PHENOTYPE ACUTE LEUKAEMIA. A STUDY FROM THE PETHEMA/PALG REGISTRIES.	Magdalena Karasek	Received

PS-1495	CONSTRUCTION OF A PROGNOSTIC MODEL FOR ACUTE MYELOID LEUKEMIA BASED ON FLOW CYTOMETRY IMMUNOPHENOTYPING USING MACHINE LEARNING METHODS.	Qing Ma	Received

PS-1496	OUTCOMES OF ADULT PATIENTS WITH NEWLY DIAGNOSED IDH-MUTATED ACUTE MYELOID LEUKEMIA RECEIVING INTENSIVE CHEMOTHERAPY PLUS VENETOCLAX	Jennifer Croden	Received

PS-1497	PROGNOSTIC VALUE OF IDH1 AND IDH2 MUTATIONS MEASURABLE RESIDUAL DISEASE MARKERS IN ACUTE MYELOID LEUKEMIA	Guillermo Ramil	Received

PS-1498	THE IMPACT OF ALLOGENIC STEM CELL TRANSPLANTATION ON NPM1MUTFLT3MUT AML PATIENTS IN FIRST REMISSION DEPENDS ON MRD STATUS AFTER CONSOLIDATION CHEMOTHERAPY: A RETROSPECTIVE MULTICENTRIC ITALIAN STUDY	Sara Consolo	Received

PS-1499	PROGNOSTIC SIGNIFICANCE OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA: IMPACT OF CONCURRENT GENETIC ALTERATIONS ON SURVIVAL	Hsin-Yu Lu	Received

PS-1500	A NOVEL RANDOM SURVIVAL FOREST MODEL FOR ADULT NPM1-MUTATED ACUTE MYELOID LEUKEMIA PATIENTS	Yiyi Yao	Received

PS-1501	REVUMENIB ACTIVITY IN PATIENTS WITH ACUTE LEUKEMIA WITH NUP98R: RESULTS FROM THE AUGMENT-101 PHASE 1 STUDY	Ghayas Issa	Received

PS-1502	VENETOCLAX-AZACITIDINE PLUS IDARUBICIN IN OLDER AML PATIENTS: A PHASE II TRIAL EVALUATING FEASIBILITY AND EARLY OUTCOMES	Xinjie Chen	Received

PS-1503	COMPARABLE SURVIVAL OUTCOMES FOR SECONDARY AND DE NOVO ACUTE MYELOID LEUKEMIA AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION	Kehan Zhang	Received

PS-1504	IMPACT OF TYROSINE KINASE INHIBITORS ON OUTCOMES IN PHILADELPHIA CHROMOSOME-POSITIVE MIXED PHENOTYPE ACUTE LEUKEMIA: DATA FROM THE PETHEMA/PALG REGISTRY	Marta Sobas	Received

PS-1505	GENETIC ABNORMALITIES PREDICT OUTCOMES IN ACUTE MYELOID LEUKEMIA PATIENTS WITH CEBPA IN-FRAME MUTATIONS	Qian Jiang	Received

PS-1506	NGS VS DIGITAL PCR FOR MRD MONITORING IN ACUTE MYELOID LEUKEMIA: A COMPARATIVE STUDY	Guillermo Ramil	Received

PS-1507	LONG TERM SURVIVAL AND VACCINE-INDUCED IMMUNE RESPONSES ARE COMPARABLE BETWEEN NPM1 MUTATED VS NPM1 WILD TYPE AML PATIENTS AFTER IMMUNOTHERAPY WITH VIDIDENCEL	Arjan van de Loosdrecht	Received

PS-1508	REAL-WORLD PATTERNS AND OUTCOMES IN AML PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: DATA FROM THE PETHEMA REGISTRY	Laura Torres Miñana	Received

PS-1510	MITOXANTRONE HYDROCHLORIDE LIPOSOME-BASED INDUCTION REGIMENS FOR UNTREATED DE NOVO ACUTE MYELOID LEUKEMIA: AN OPEN-LABEL, MULTICENTER, RANDOMIZED, MULTICOHORT STUDY	Shaowei Qiu	Received

PS-1512	EVALUATION OF THE 2022 ELN RISK CLASSIFICATION IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: IDENTIFICATION OF A VERY POOR PROGNOSIS SUBGROUP	Huixian Wu	Received

PS-1513	COMPARING OUTCOMES OF PATIENTS WITH DE NOVO AND SECONDARY AML, TREATED FRONTLINE WITH VENETOCLAX AND HYPOMETHYLATING AGENTS: A MULTICENTER RETROSPECTIVE STUDY.	Ilaria Tanasi	Received

PS-1514	REAL WORLD OUTCOMES OF ADULT PATIENTS WITH NUP98 GENE REARRANGED ACUTE MYELOID LEUKEMIA	Laura Torres Miñana	Received

PS-1516	A PHASE I STUDY OF VENETOCLAX, AZACITIDINE, AND MITOXANTRONE HYDROCHLORIDE LIPOSOME IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA	Wenxiang Ren	Received

PS-1517	OUTCOMES OF THE ACUTE MYELOID LEUKEMIA-DEFINING MECOM REARRANGEMENT DIFFER BASED ON BLAST COUNT AT DIAGNOSIS	Wei-Ying Jen	Received

PS-1519	PROGNOSTIC IMPACT OF EXTRAMEDULLARY DISEASE IN ACUTE MYELOID LEUKEMIA: A META-ANALYSIS	Hongyan Tong	Received

PS-1522	TREATMENT AND SURVIVAL OF MIXED PHENOTYPE ACUTE LEUKAEMIA – A POPULATION-BASED COHORT	Lisa-Maj Christensen	Received

PS-1523	TREATMENT INTENSITY IS ASSOCIATED WITH DISTINCT LONGITUDINAL TRAJECTORIES OF FRAILTY IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)	Victoria Ling	Received

PS-1524	THE EFFICACY AND PROGNOSTIC EVALUATION OF BTG1 IN HYPOMETHYLATING AGENTS TREATMENT FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA	Shuai Su	Received

PS-1525	VENETOCLAX PLUS MITOXANTRONE HYDROCHLORIDE LIPOSOME AND AZACITIDINE AS FIRST-LINE TREATMENT FOR ADULTS WITH ACUTE MYELOID LEUKEMIA	Weiwei Qin	Received

PS-1527	CD4+ T CELLS, GRANZYME B+ NK, MZ B CELLS AND DIFFERENTIATED/SENESCENT CD4+CD28- T CELLS AFTER INDUCTION TREATMENT PREDICT AML PATIENT´S OUTCOME	Xin Huang	Received

PS-1528	THE RESULTS OF TREATMENT OF ACUTE LEUKEMIA DIAGNOSED DURING PREGNANCY	Vera Troitskaya	Received

PS-1530	PERI-TRANSPLANT KMT2A-REARRANGED MRD DYNAMICS AS A PROGNOSTIC MARKER IN ADULT ACUTE MYELOID LEUKEMIA	Lulu Wang	Received

PS-1531	FEASIBILITY AND SAFETY OF OUTPATIENT CONSOLIDATION CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA	Laura Curras Sanchez	Received

PS-1533	MEASURABLE MINIMAL RESIDUAL DISEASE BY AN ULTRA-SENSITIVE NGS METHOD TO EVALUATE THE RESPONSE IN ACUTE MYELOID LEUKEMIA, THE VENAQUI CLINICAL TRIAL	Rosa María Ayala Díaz	Received

PS-1534	TOWARDS THE USE OF ARTIFICIAL INTELLIGENCE MODELS IN THE ASSESSMENT OF ACUTE PROMYELOCYTIC LEUKEMIA - SYSTEMATIC REVIEW	Mihnea-Alexandru Gaman	Received

PS-1535	VEN-BASED SCHEMES, ARE THEY BETTER THAN "3 + 7"?	Pedro Amorim Machado	Received

PS-1536	ALLOGENEIC TRANSPLANTATION VS. CHEMOTHERAPY AS CONSOLIDATION STRATEGIES IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS AFTER FIRST COMPLETE REMISSION: A SYSTEMATIC REVIEW AND META-ANALYSIS	Cilomar Martins de Oliveira Filho	Received

PS-1537	REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH AML FROM 65 TO 74 YEARS UNFIT FOR FIRST-LINE INTENSIVE CHEMOTHERAPY IN JAPAN.	Masahiro Onozawa	Received

PS-1538	THE FUS::ERG FUSION IN ACUTE MYELOID LEUKEMIA: INSIGHTS INTO MOLECULAR PROFILES AND PROGNOSTIC IMPLICATIONS	Bingbing Han	Received

PS-1539	HEALTHCARE RESOURCE UTILIZATION IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX COMPARED TO HIGH- AND LOW-INTENSITY NON-VENETOCLAX THERAPIES	Pinkal Desai	Received

PS-1540	PROGNOSTIC IMPACT OF THE AML60+ SCORE FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS	Tobias Silzle	Received

PS-1542	SURVIVAL ANALYSIS OF LONG-TERM TREATMENT WITH VENETOCLAX-AZACITIDINE IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: MULTICENTRE REAL-WORLD OUTCOMES IN CHINA	Jing Zou	Received

PS-1543	CLINICAL EXPERIENCE WITH HDAC INHIBITOR-BASED PROTOCOLS IN MECOM-REARRANGED ACUTE MYELOID LEUKEMIA	Eitan Kugler	Received

PS-1544	REAL-LIFE STUDY ON GILTERITINIB RELATED INFECTIONS (GILTERINF): AN ITALIAN SEIFEM STUDY	Elisa Buzzatti	Received

PS-1545	OUTCOMES OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN ACUTE MYELOID LEUKEMIA: THE THREE-SITE MAYO CLINIC CANCER CENTER EXPERIENCE.	Jabra Zarka	Received

PS-1546	VA COMBINED WITH LIPOSOMAL MITOXANTRONE: A NOVEL AND SAFE INDUCTION THERAPY FOR NEWLY DIAGNOSED AML	Yan Yu	Received

PS-1547	EFFECT OF OBESITY ON OVERALL SURVIVAL IN ELDERLY PATIENTS (>65 YEARS OLD) WITH ACUTE MYELOID LEUKEMIA – SINGLE-CENTER EXPERIENCE.	Karolina Beldzinska-Gadek	Received

PS-1549	THE PREDICTIVE ROLE OF HEMATOLOGIC RECOVERY IN THE PROGNOSIS OF ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH AZACITIDINE-VENETOCLAX	Yan Li	Received

PS-1551	IN-DEPTH IMMUNE AND METABOLIC PROFILING OF GAIA/CLL13 PATIENTS TO UNCOVER TREATMENT-SPECIFIC CHANGES TO THE T-CELL COMPARTMENT [CJ1]	Chaja F Jacobs	Received

PS-1553	GUT MICROBIOME IMBALANCE DRIVES IMMUNE EXHAUSTION VIA SHORT-CHAIN FATTY ACIDS IN CLL	Monika Szelest	Received

PS-1554	THE LANDSCAPE OF CLONAL HEMATOPOIESIS IN CHRONIC LYMPHOCYTIC LEUKEMIA	Othman Al-Sawaf	Received

PS-1555	EGR2 MUTATIONS COOPERATE IN ACTIVATING NOTCH-1 PATHWAY AND LEAD TO BTK INHIBITORS RESISTANCE IN CLL	Alessia Morabito	Received

PS-1556	DIAGNOSTIC CRITERIA FOR NK-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA: VALIDATION THROUGH A MULTICENTRIC INTERNATIONAL STUDY	Daniel Zaldumbide	Received

PS-1557	A CLINICAL-MOLECULAR MODEL FOR A PERSONALISED PREDICTION OF TIME TO FIRST TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA	Aleix Real	Received

PS-1561	GENOMIC CHARACTERIZATION OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ALTERATIONS FROM A SPANISH REAL-WORLD COHORT TREATED WITH TARGETED AGENTS	Joanna Kamaso	Received

PS-1563	VENETOCLAX-ACALABRUTINIB FOR CLL PATIENTS RELAPSING AFTER VENETOCLAX-ANTICD20 TREATMENT: HIGHLY EFFECTIVE AND LOW TOXICITY. INTERIM ANALYSIS OF HOVON 159/REVEAL PHASE 2 TRIAL	Sabina Kersting	Received

PS-1564	ALLOGENEIC STEM CELL TRANSPLANTATION IS EFFECTIVE AFTER PATHWAY INHIBITOR TREATMENTS IN CLL; A RETROSPECTIVE STUDY ON BEHALF OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT	Michel van Gelder	Received

PS-1567	MRD GUIDED MESUTOCLAX PLUS ORELABRUTINIB FOR CLL/SLL DEMONSTRATES HIGH RESPONSE AND EARLY MRD CLEARANCE WITH GOOD TOLERABILITY: PRELIMINARY ANALYSIS FROM AN ONGOING PHASE II DOSE OPTIMIZATION STUDY	Yang Liang	Received

PS-1568	USING MINIMAL RESIDUAL DISEASE STATUS TO GUIDE VENETOCLAX TREATMENT DURATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: INTERIM RESULTS FROM THE PHASE II VENETOSTOP STUDY	Leora Boussi	Received

PS-1570	10-YEAR FOLLOW-UP OF A RANDOMIZED PHASE-2 STUDY OF IBRUTINIB OR IBRUTINIB PLUS RITUXIMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Jan Burger	Received

PS-1572	REAL-WORLD COMPARATIVE EFFECTIVENESS OF VENETOCLAX-OBINUTUZUMAB VERSUS SECOND-GENERATION BRUTON TYROSINE KINASE INHIBITORS IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Beenish Manzoor	Received

PS-1573	TREATMENT EFFECTIVENESS IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING VENETOCLAX-BASED THERAPY AFTER PROGRESSION ON A COVALENT BRUTON TYROSINE KINASE INHIBITOR (CBTKI)	Beenish Manzoor	Received

PS-1574	ANALYSIS OF COVID-19 INFECTIONS WITH FIXED-DURATION ACALABRUTINIB-VENETOCLAX COMBINATIONS IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA IN THE PHASE 3 AMPLIFY TRIAL	Jennifer R. Brown	Received

PS-1575	PHASE 1 STUDY OF FCN-338, A NOVEL BCL-2 INHIBITOR IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY	Huiqiang Huang	Received

PS-1577	DEVELOPMENT OF A CLINICAL MACHINE LEARNING TOOL FOR THE PREDICTION OF AUTOIMMUNE HEMOLYTIC ANEMIA IN CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION BASED MULTILAYER PERCEPTRON MODEL	Rayan Ramadan	Received

PS-1578	REAL-WORLD COMPARATIVE EFFECTIVENESS OF FIRST-LINE BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Ryan Jacobs	Received

PS-1579	FIRST WORLDWIDE REAL-LIFE DATA ON FIXED-DURATION IBRUTINIB+VENETOCLAX TREATMENT FOR PREVIOUSLY UNTREATED CLL/SLL PATIENTS: INITIAL INTERIM ANALYSIS OF SPAIN´S LI+VE OBSERVATIONAL STUDY	María Yuste	Received

PS-1580	FIXED-DURATION BTKI-VENETOCLAX COMBINATIONS IN CLL: AN INDIRECT COMPARISON OF AMPLIFY AND CAPTIVATE TRIALS	Stefano Molica	Received

PS-1585	GERMLINE VARIANTS IN PEDIATRIC CHRONIC MYELOID LEUKEMIA	Tabita Ghete	Received

PS-1586	EARLY PREDICTION OF MR4.5 ATTAINMENT AND SUSTAINED RESPONSE IN CHRONIC MYELOID LEUKEMIA TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS: ANALYSIS FROM THE JALSG CML212 ROAD TO MR4.5 STUDY	TAKAAKI ONO	Received

PS-1588	IMPROVED PATIENT-REPORTED OUTCOMES (PROS) WITH ASCIMINIB (ASC) VS INVESTIGATOR-SELECTED TYROSINE KINASE INHIBITORS (IS-TKIS) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML): ASC4FIRST WK 48 ANALYSIS	Andreas Hochhaus	Received

PS-1590	ASSESSMENT OF TRANSITIONING FROM HIGH-POTENCY TO LOW-POTENCY INHIBITORS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: THE DOWNGRADING-IMPACT (D-IMPACT) PROJECT, A CML CAMPUS STUDY	Simona Bernardi	Received

PS-1591	THE FRONTLINE SECOND GENERATION TYROSINE KINASE INHIBITORS BRING TREATMENT-FREE REMISSION TO MORE PATIENTS WITH CHRONIC MYELOID LEUKEMIA	Naoto Takahashi	Received

PS-1592	MYELOPROLIFERATIVE NEOPLASMS WITH CONCOMITANT CHRONIC MYELOID LEUKAEMIA ARE ASSOCIATED WITH TKI RESISTANCE AND POOR OUTCOMES: A REVIEW OF 46 CASES	Laura Li Gagnon	Received

PS-1593	ASC4OPT STUDY: HIGH EFFICACY AND FAVORABLE TOLERABILITY OF ASCIMINIB ONCE OR TWICE DAILY IN CML PATIENTS WITH SUBOPTIMAL RESPONSE, RESISTANCE OR INTOLERANCE OF 2 OR MORE TYROSINE KINASE INHIBITORS	Andreas Hochhaus	Received

PS-1594	UPDATED RESULTS OF MANAGED-ACCESS PROGRAM (MAP) OF ASCIMINIB USE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN 3 CLINICAL CENTERS.	Ekaterina Chelysheva	Received

PS-1595	IMPACT OF ADVERSE EVENTS ON QUALITY OF LIFE IN CHRONIC MYELOID LEUKEMIA (CML) – RESULTS FROM THE PATIENT SURVEY ON HUMANISTIC BURDEN OF INTOLERANCE TO FIRST OR SECOND TKIS (SHIFT) STUDY IN THE US	David Wei	Received

PS-1596	CLINICAL FEATURES AND T CELL REPERTOIRE OF CHRONIC MYELOID LEUKEMIA PATIENTS WHO ATTEMPT DISCONTINUATION OF TYROSINE KINASE INHIBITORS: THE ISAC-TFR STUDY	Mai Fujita	Received

PS-1597	DEVELOPMENT OF A NOVEL SCORING TOOL TO PREDICT OPTIMAL RESPONSE IN CHRONIC MYELOID LEUKEMIA FOR IMPROVING TREATMENT EFFICACY BEYOND CURRENT RISK CLASSIFICATIONS	Kohjin Suzuki	Received

PS-1598	IMPACT OF PONATINIB TREATMENT ON PREGNANCY OUTCOMES	Haley Maire	Received

PS-1599	ANALYSIS OF FACTORS INFLUENCING TREATMENT-FREE REMISSION OUTCOMES AFTER IMATINIB DISCONTINUATION IN PAEDIATRIC CHRONIC MYELOID LEUKEMIA	Yanli Zhang	Received

PS-1600	SINGLE-CELL DERIVED TRANSCRIPTIONAL SIGNATURE OF DYSERYTHROPOIESIS STRATIFIES MDS WITH DIFFERENTIAL OUTCOMES AND RESPONSE TO LUSPATERCEPT	Kristian Gurashi	Received

PS-1602	GALECTIN-1 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN CHRONIC MYELOMONOCYTIC LEUKAEMIA	Laura Guest	Received

PS-1604	SOMATIC RUNX1 DELETIONS IN MYELODYSPLASTIC SYNDROME: A NOVEL RARE RECURRENT GENETIC ABERRATION ASSOCIATED WITH HIGH-RISK FOR TRANSFORMATION TO ACUTE MYELOID LEUKEMIA	Ahmed Al-Djaber	Received

PS-1605	ADAR1-MEDIATED RNA EDITING IN RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)	Ioannis Kotsianidis	Received

PS-1607	SINGLE-CELL TRANSCRIPTOMICS REVEALS BONE MARROW CHANGES IN MDS PATIENTS RESPONDING TO BEXMARILIMAB AND AZACYTIDINE	Jesper Mickos	Received

PS-1608	PROGENITOR IMBALANCE AND TRANSCRIPTIONAL DYSREGULATION AS POTENTIAL DRIVERS OF ABERRANT HEMATOPOIESIS IN MDS	Carmen Rodriguez-Res	Received

PS-1609	TRANSCRIPTIONAL REMODELING OF THE NON-IMMUNE BONE MARROW MICROENVIRONMENT IN MDS PATIENTS WITH SF3B1 MUTATIONS: INSIGHTS INTO BIOLOGY AND THERAPEUTIC IMPLICATIONS	Isabel A. Calvo	Received

PS-1612	ARSENIC SULFIDE NANOCRYSTAL FORMULATION INCREASES EFFECTIVE ERYTHROPOIESIS OF MDS THROUGH SCAVENGING REACTIVE OXIDATIVE SPECIES AND STRESS GRANULES FORMATION	Tao Wang	Received

PS-1613	UTILITY OF SNP-ARRAY FOR DETECTING NUMERICAL ALTERATIONS AND LOSS OF HETEROZYGOSITY IN SMD AND CMML PATIENTS WITH NORMAL KARYOTYPE	Carmen Loredo Alvarez	Received

PS-1614	PATHOPHYSIOLOGICAL ABNORMALITIES OF RED BLOOD CELLS IN MYELODYSPLASTIC SYNDROMES AS POTENTIAL DIAGNOSTIC AND THERAPEUTIC MARKERS	Pinelopi Vryttia	Received

PS-1615	LUSPATERCEPT MODULATES THE TRANSCRIPTIONAL PROGRAM OF HSPCS OF MDS PATIENTS AT THE SINGLE CELL LEVEL.	Ioannis Kotsianidis	Received

PS-1616	ANALYSIS OF PREANALYTICAL VARIABILITY ON PLASMA MIRNA EXPRESSION PROFILE BY NEXT GENERATION SEQUENCING TO REVEAL SPECIFIC POTENTIAL DIAGNOSTIC BIOMARKERS OF MYELODYSPLASTIC SYNDROME.	Alessandra Giannella	Received

PS-1618	RISK STRATIFICATION IN HYPOMETHYLATING AGENT-TREATED PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A MULTIVARIATE MODEL (MDS-HOPE)	Kelly Chien	Received

PS-1621	INVESTIGATION OF CHANGE IN IPSS-M AND MOLECULAR REMISSION STATUS AS PREDICTORS OF POST-TRANSPLANTATION OUTCOME - A NORDIC MULTICENTRE STUDY	Joel Wiggh	Received

PS-1622	OUTCOMES OF IMETELSTAT THERAPY IN PATIENTS WITH RING SIDEROBLAST–NEGATIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES FROM THE POOLED IMERGE STUDY POPULATIONS	Valeria Santini	Received

PS-1624	MEASURABLE RESIDUAL DISEASE IN CD34+ CELLS IN MYELODYSPLASTIC SYNDROME AFTER ALLOGENIC STEM CELL TRANSPLANTATION	Carolin Lindholm	Received

PS-1625	THE ROLE OF THE ADENOSINERGIC PATHWAY IN THE RESPONSE TO AZACYTIDINE IN HR-MDS PATIENTS	Ioannis Kotsianidis	Received

PS-1627	ALLOGENEIC TRANSPLANTATION OUTCOMES OF MDS/AML: RISK VERIFICATION AND MATCHED ANALYSIS WITH AML—A MULTICENTER STUDY	Jia Chen	Received

PS-1628	A PHASE 2 PROSPECTIVE STUDY EVALUATING LOW-DOSE DEFERASIROX IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROME RESISTANT OR RELAPSING AFTER ERYTHROPOIETIN STIMULATING AGENTS (LODEFI)	Mathieu Meunier	Received

PS-1629	OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR SECONDARY MYELODYSPLASTIC SYNDROME EVOLVED FROM APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Machiko Fujioka	Received

PS-1630	A PHASE I DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF F182112, BCMA X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA	Junyuan Qi	Received

PS-1631	A PHASE 2, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF OB756, A NOVEL JAK2 INHIBITOR, IN JAK INHIBITOR-NAÏVE PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA	Jian Huang	Received

PS-1632	UPSTAGED RISK FROM THE REVISED TO THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM PREDICTS ADVERSE OUTCOMES IN MYELODYSPLASTIC SYNDROMES	Alexandre Bazinet	Received

PS-1633	TP53 MUTATIONS DISTINGUISH A CLASS OF HIGHLY HOMOGENOUS MYELOID NEOPLASMS WITHIN MDS AND AML IN THE CONTEXT OF COMPLEX KARYOTYPE	Ye Yang	Received

PS-1634	ASSESSING AVAILABLE RISK SCORES FOR DISEASE PROGRESSION AND SURVIVAL IN CCUS: A SINGLE-INSTITUTION STUDY	Aref Al-Kali	Received

PS-1635	SPECTRUM, PREVALENCE AND CLINICAL CORRELATES OF PPM1D MUTATIONS IN PATIENTS WITH THERAPY RELATED CLONAL HEMATOPOIESIS AND CLONAL CYTOPENIAS	Talha Badar	Received

PS-1636	PHASE 2 RANDOMISED TRIAL, REPURPOSING DANAZOL AND VBAP IN LOW RISK MYELODYSPLASTIC SYNDROME: REPAIR-MDS	Manoj Raghavan	Received

PS-1637	A PHASE I OPEN LABEL STUDY OF FOSTAMATINIB, A SYK INHIBITOR, IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA	Jennifer Croden	Received

PS-1638	PHASE I/II TRIAL OF AZACITIDINE AND VENETOCLAX IN PREVIOUSLY UNTREATED AND HYPOMETHYLATING AGENT FAILURE MYELODYSPLASTIC SYNDROME: AN INTERIM EFFICACY ANALYSIS	Ian Bouligny	Received

PS-1639	HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH IMETELSTAT IN THE IMERGE TRIAL	María Díez Campelo	Received

PS-1640	OUTCOMES WITH IMETELSTAT BY SERUM ERYTHROPOIETIN LEVELS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES WHO WERE TREATMENT NAIVE OR WHO HAD PRIOR TREATMENT WITH ERYTHROPOIESIS-STIMULATING AGENTS	Rami S. Komrokji	Received

PS-1642	THERAPEUTIC INTERVENTION IN BONE MARROW FAILURES: TARGETING NUCLEOLAR AND RIBOSOME STRESS INDUCED BY HNRNPK OVEREXPRESSION	Miguel Gallardo	Received

PS-1643	METABOLIC DYSREGULATION IN ERCC6L2 DISEASE: IMPLICATIONS FOR ERYTHROPOIESIS THROUGH GLUTAMINE, GLUTATHIONE, AND FERROPTOSIS PATHWAYS	Ilse Kaaja	Received

PS-1644	SOMATIC PRE-MALIGNANT CLONES IN THE ORAL MUCOSA OF FANCONI ANEMIA PATIENTS, WITH AND WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION	Tamar Berger	Received

PS-1646	BOTH RARE PNH CELLS AND MINOR PNH CLONES SHOULD BE CONSIDERED AS GENUINE PNH CLONES: INSIGHTS FROM ANALYSIS OF THE 5-YEAR FRENCH NATION-WIDE MULTICENTER OBSERVATIONAL STUDY	Orianne Wagner-Ballon	Received

PS-1647	THE ROLE OF CD8+CD28-REGULATORY T CELLS IN ACQUIRED APLASTIC ANEMIA	Meili Ge	Received

PS-1648	THE SUBGROUP OF APLASTIC ANEMIA PATIENTS IS CHARACTERIZED BY IMPAIRED MESENCHYMAL STROMAL CELLS PROLIFERATION AND ADIPOGENIC DIFFERENTIATION	Alena Dorofeeva	Received

PS-1649	ACCURATE QUANTIFICATION OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONE IN NEUTROPHILS: ADDED VALUE OF ANTI-CD16 ANTIBODY IN ELIMINATING EOSINOPHIL CONTAMINATION	Bouchra BADAOUI	Received

PS-1651	HETROMBOPAG COMBINED WITH CYCLOSPORINE A AS FIRST-LINE TREATMENT IN PATIENTS WITH NON-SEVERE APLASTIC ANEMIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY	Xin Zhao	Received

PS-1652	DANICOPAN ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS STRATIFIED BY BONE MARROW FAILURE HISTORY	Morag Griffin	Received

PS-1653	BUSULFAN, LOW DOSE CYCLOPHOSPHAMIDE, AND FLUDARABINE VERSUS BUSULFAN PLUS STANDARD-DOSE CYCLOPHOSPHAMIDE CONDITIONING REGIMEN IN HAPLOIDENTICAL CELL TRANSPLANTATION FOR PATIENTS WITH ACQUIRED APLASTIC ANEMIA: A PROPENSITY SCORE MATCHED CONTROLLED STUDY.	Fan Lin	Received

PS-1654	EVALUATING THE SAFETY AND EFFICACY OF MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH CHRONIC NEUTROPENIC DISORDERS: RESULTS FROM THE PHASE 2 STUDY	Julia Warren	Received

PS-1657	THE SURVIVAL ADVANTAGE OF REDUCED-TOXICITY CONDITIONING WITH BUSULFAN/FLUDARABINE/LOW-DOSE CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS WITH PRE-TRANSPLANT COMORBIDITIES.	Fan Lin	Received

PS-1658	SPECTRUM AND PREVALENCE OF NON-HEMATOLOGICAL MALIGNANCIES IN PATIENTS WITH TELOMERE BIOLOGY DISORDERS	Madeline Franke	Received

PS-1659	IMMUNE-DRIVEN SELECTION AND FREQUENT DETECTION OF PNH CLONES IN POST-CAR-T THERAPY HEMATOPOIETIC FAILURE	Yuki Nukii	Received

PS-1660	COMPARISON OF OF HETROMBOPAG VERSUS ELTROMBOPAG COMBINED WITH ANTI-THYMOCYTE GLOBULIN AND CYCLOSPORINE A AS FIRST-LINE THERAPY FOR SEVERE APLASTIC ANEMIA: SIMILAR EFFICACY AND SAFETY	Jingnan Sun	Received

PS-1661	DUAL PLATFORM GENOMIC TESTING FROM DIRECT SKIN BIOPSY FOR DETECTION OF GERMLINE PREDISPOSITION IN BONE MARROW FAILURE AND HEMATOLOGIC MALIGNANCY	Enrico Attardi	Received

PS-1662	A BENEFIT ASSESSMENT OF PEGCETACOPLAN DOSE INCREASE IN THE PHASE 3 PEGASUS TRIAL OF PNH PATIENTS WITH DIFFICULT-TO-CONTROL DISEASE	Morag Griffin	Received

PS-1663	IMPACT OF FRONT-LINE ALLOGENEIC HSCT OR IMMUNOSUPPRESSIVE THERAPY ON SURVIVAL IN APLASTIC ANEMIA PATIENTS	Alfadil Haroon	Received

PS-1664	MOLECULAR AND CLINICAL FEATURES OF ACQUIRED APLASTIC ANEMIA WITH DDX41 MUTATIONS	Xin Zhao	Received

PS-1665	BENEFIT OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IRRESPECTIVE OF BASELINE TRANSFUSION STATUS	Britta Höchsmann	Received

PS-1669	MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, ALLOWS FOR GRANULOCYTE-COLONY STIMULATING FACTOR DOSE DE-ESCALATION IN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA AND CONGENITAL NEUTROPENIA	Julia Warren	Received

PS-1670	ANELLOVIRUS-ASSOCIATED SUBOPTIMAL HEMATOLOGICAL RECOVERY IN SEVERE APLASTIC ANEMIA AFTER IMMUNOSUPPRESSIVE THERAPY	Guangsheng He	Received

PS-1673	SELECTIVE DEPLETION OF B-CELL LINEAGE SUBSETS DURING TREATMENT WITH ANTI-BCMA VS ANTI-GPRC5D BISPECIFIC ANTIBODIES (BSABS) UNDERLIES DIFFERENT RISK OF INFECTIONS IN PATIENTS WITH MULTIPLE MYELOMA (MM)	Tomas Jelinek	Received

PS-1675	MOLECULAR INSIGHTS INTO MULTIPLE MYELOMA BONE DISEASE: SINGLE-NUCLEUS RNA-SEQ ANALYSIS OF OSTEOCLAST DIFFERENTIATION	Melika Bakharzi	Received

PS-1676	ZMYND8 READS H3K36ME2 TO ACTIVATE CEBPE TRANSCRIPTION AND SUPPRESS MULTIPLE MYELOMA PROGRESSION THROUGH THE INHIBITION OF ADAPTIVE UPR PATHWAYS	Bing Chen	Received

PS-1678	CCR4 MODULATES MALIGNANT PROGRESSION OF MULTIPLE MYELOMA VIA PI3K/AKT/MTOR SIGNALING AXIS: MECHANISTIC INSIGHTS AND TARGETED THERAPEUTIC STRATEGY	Yonghuai Feng	Received

PS-1680	HP-001, AN ORAL IKZF 1/3 MOLECULAR GLUE, DEMONSTRATED SUPERIOR DEGRADATION POTENCY AND SPECIFITY IN THE PRE-CLINICAL MODEL	Dihuang Wang	Received

PS-1682	THE MECHANISM OF EXOSOMAL CIRC-G042080 PROMOTING MYELOMA BONE DISEASE THROUGH MIR-6791-3P/HDAC4/RANKL AXIS	Xing Cui	Received

PS-1683	IMMUNOMMAP: INSIGHTS INTO IMMUNE AND GENOMIC ALTERATIONS UNDERLYING THE RESISTANCE TO BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA BY FULL SPECTRUM CYTOMETRY AND EXOME SEQUENCING	Daniel Bilek	Received

PS-1684	EPIGENETIC DRIVERS OF IMMUNOTHERAPY RESISTANCE IN MULTIPLE MYELOMA: ADVANCED MULTI-OMIC PROFILING IDENTIFIES BCMA AND FCRL5 SILENCING VIA LONG-RANGE DNA HYPERMETHYLATION	Larissa Haertle	Received

PS-1686	MECHANISM OF BUTYRATE-REMODELED FATTY ACID OXIDATION IN NK CELLS IN THE TREATMENT OF MULTIPLE MYELOMA WITH DARATUMUMAB	Tingting Li	Received

PS-1687	ROLE AND MECHANISM OF PIM-2 KINASE INHIBITOR-INDUCED IMMUNOGENIC CELL DEATH IN MULTIPLE MYELOMA	Hongli Shen	Received

PS-1688	ACQUIRED PYRIDOXAL PHOSPHATE (VITAMIN B6) DEFICIENCY AS MECHANISM FOR NEUROPATHY IN POEMS SYNDROME	Oliver Tomkins	Received

PS-1689	INCREASING TUMOR DENSITIES ARE ASSOCIATED WITH REMODELING OF THE BONE MARROW MYELOID AND STROMAL MICROENVIRONMENT IN NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS	Marnix Koops	Received

PS-1690	COMPLEMENT AND AMYLOID SIGNATURE PROTEIN UPREGULATION IN POST- TREATMENT AL AMYLOID PROTEOMES PROVIDES NOVEL INSIGHTS INTO DISEASE BIOLOGY	Matthew Rees	Received

PS-1694	PAEONIFLORIN INHIBITS THE ANGIOGENESIS OF MULTIPLE MYELOMA VIA DECREASING MEF2A LEVEL TO DOWNREGULATE THE EXPRESSION OF EXOSOMAL LNCRNA MALAT1	Xing Cui	Received

PS-1695	IDENTIFICATION OF TRANSLOCATION-INDUCED ENHANCER HIJACKING IN MULTIPLE MYELOMA BY TRANSFINDER	Jin Lu	Received

PS-1696	DI-(2-ETHYLHEXYL) PHTHALATE (DEHP) AND ITS METABOLITE PROMOTE MULTIPLE MYELOMA PROGRESSION AND BORTEZOMIB RESISTANCE	Wenxia Li	Received

PS-1697	GENOMIC LANDSCAPE OF PARA-SKELETAL AND EXTRAMEDULLARY PLASMACYTOMAS IN MULTIPLE MYELOMA PATIENTS	Martin Stork	Received

PS-1698	IMPAIRED BONE MARROW AND CIRCULATING ?? T CELLS WERE LINKED TO AN INCREASED RISK OF PROGRESSING FROM PRE-MALIGNANT PLASMA CELL CONDITIONS TO SYMPTOMATIC MULTIPLE MYELOMA	ANNA MARIA CORSALE	Received

PS-1699	DEFINING A NOVEL CYTOKINE COMBINATION TO OPTIMIZE IN VITRO CULTURE CONDITIONS FOR PRIMARY MULTIPLE MYELOMA PATIENT CELLS	Ariene Cabantog	Received

PS-1700	THE BIOLOGICAL RELEVANCE OF UPREGULATED NONO PROTEIN IN MULTIPLE MYELOMA THROUGH THE REGULATION OF CELL CYCLE PROGRESSION AND DRUG TREATMENT RESPONSE	Giuseppina Fabbiano	Received

PS-1701	TARGETING MAT2A ALTERS THE METHYLATION LANDSCAPE AND DNA DAMAGE RESPONSE IN MULTIPLE MYELOMA, REVEALING NOVEL COMBINATION STRATEGIES.	Lien Van Hemelrijck	Received

PS-1702	THE STORY OF THE GUT MICROBIOME AND MULTIPLE MYELOMA: THE CHICKEN OR THE EGG?	Sylvia Faict	Received

PS-1703	PYGO2 IS OVEREXPRESSED BY CD138+ CELLS IN MULTIPLE MYELOMA PATIENTS WITH 1Q AMPLIFICATION IRRESPECTIVE OF CYTOGENETIC HETEROGENEITY: A NEW POSSIBLE DRUGGABLE TARGET	Nicolas Thomas Iannozzi	Received

PS-1704	PAEONIFLORIN ATTENUATES MOUSE MYELOMA BONE DISEASE BY REDUCING ERK 1 LEVELS IN THE EXOSOMES OF MULTIPLE MYELOMA CELLS	Xing Cui	Received

PS-1705	PERCENTAGE OF ACTIVATED CD4+ T LYMPHOCYTES AMONG T LYMPHOCYTES PREDICT HEMATOLOGIC RESPONSE TO IMMUNOSUPPRESSIVE THERAPY IN APLASTIC ANEMIA	Youzhen Xiong	Received

PS-1706	IN SILICO-IDENTIFIED PUTATIVE INHIBITORS OF PARASPECKLE ASSEMBLY INDUCE CELL DEATH BY APOPTOSIS IN MULTIPLE MYELOMA CELLS AND LEAD TO THE ACTIVATION OF THE CGAS/STING PATHWAY.	Valentina Traini	Received

PS-1707	EXPLORING THE ROLE OF NONO IN TRANSCRIPTIONAL REGULATION OF CELLULAR PATHWAYS IN MULTIPLE MYELOMA: INSIGHTS INTO ITS PARASPECKLE-DEPENDENT AND INDEPENDENT REGULATORY MECHANISMS	Elisa Taiana	Received

PS-1709	MYELOMA-ASSOCIATED MACROPHAGES INDUCE DRUG-RESISTANCE THROUGH SREBP1-DEPENDENT LIPID METABOLIC DYSREGULATION IN MULTIPLE MYELOMA	Xing Guo	Received

PS-1710	RISK RECLASSIFICATION IN MULTIPLE MYELOMA: ASSESSING THE SHIFT FROM MSMART V3.0 TO V4.0	Arturo Hurtado	Received

PS-1711	UPDATED RESULTS OF A PHASE I OPEN-LABEL SINGLE-ARM STUDY OF DUAL TARGETING BCMA AND CD19 FASTCAR-T (GC012F/AZD0120) AS FIRST-LINE THERAPY FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED HIGH-RISK MULTIPLE MYELOMA	Juan Du	Received

PS-1713	ELEVATED PROPORTIONS OF RESIDUAL BONE MARROW CLONAL PLASMA CELLS IN S-PHASE PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IS ASSOCIATED WITH HIGH RISK OF EARLIER RELAPSE IN MULTIPLE MYELOMA PATIENTS	Tamer Hellou	Received

PS-1714	ISATUXIMAB WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOLLOWED BY ISATUXIMAB AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: A PHASE 2 STUDY BY THE GREEK MYELOMA STUDY GROUP	Evangelos Terpos	Received

PS-1717	NARLUMOSBART COMPARED WITH DENOSUMAB IN THE TREATMENT OF BONE DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: A MULTICENTER, RANDOMIZED, CONTROLLED, NON-INFERIORITY STUDY	Fei Li	Received

PS-1720	DELETION 17P, AND IGH HIGH RISK TRANSLOCATIONS ALONG WITH CHROMOSOME 1 ABNORMALITIES ARE THE STRONGEST SURVIVAL PREDICTORS IN MULTIPLE MYELOMA: A REAL-WORLD VALIDATION BY THE GREEK MYELOMA STUDY GROUP	Eirini Katodritou	Received

PS-1722	POSITRON EMISSION TOMOGRAPHY WITH COMPUTED TOMOGRAPHY AND MINIMAL RESIDUAL DISEASE FOR EFFICACY ASSESSMENT IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: IMROZ ANALYSIS	Elena Zamagni	Received

PS-1724	EFFICACY AND SAFETY OF FRONTLINE ALTERNATING BORTEZOMIB-BASED REGIMENS PLUS DARATUMUMAB IN PRIMARY PLASMA CELL LEUKEMIA: INTERIM RESULTS OF EUMELEIA PHASE 2 TRIAL BY THE GREEK MYELOMA STUDY GROUP.	Eirini Katodritou	Received

PS-1725	EFFICACY OF RADIOTHERAPY AND ROLE OF ADJUNCTIVE IMMUNOCHEMOTHERAPY IN POEMS SYNDROME WITH SOLITARY PLASMACYTOMA	Wai Nga Grace Lau	Received

PS-1726	EFFICACY AND SAFETY OF ISATUXIMAB SUBCUTANEOUS (SC) PLUS CARFILZOMIB AND DEXAMETHASONE (ISA-KD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE PHASE 2 STUDY IZALCO	Gurdeep Parmar	Received

PS-1729	SIMULTANEOUS WHOLE-BODY MULTI-PARAMETRIC 2-[18F]FDG-PET/MRI IN SMOLDERING MULTIPLE MYELOMA ASSESSMENT : DIAGNOSTIC AND PROGNOSTIC IMPACT	Bastien JAMET	Received

PS-1731	AUTOLOGOUS B CELL MATURATION ANTIGEN (BCMA) AND CD19 DUAL TARGETING FASTCAR-T CELLS (GC012F/AZD0120) AS FIRST-LINE THERAPY FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS	Juan Du	Received

PS-1732	BCMA-TARGETING BISPECIFIC T-CELL ENGAGERS WITH PROPHYLACTIC TOCILIZUMAB USE ARE SAFE AND INDUCE DEEP AND RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY STAGE 3 AL AMYLOIDOSIS	Romain Gounot	Received

PS-1741	REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN (BELAMAF) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED IN EUROPE	Michele Cavo	Received

PS-1743	POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN NDMM PATIENTS WITH RENAL INJURY(RI): A MULTICENTER, RANDOMIZED CONTROLLED, OPEN-LABEL TRIAL	Jian Hou	Received

PS-1744	THE PHASE I/II TG01-STUDY - VACCINATING AGAINST RAS-MUTATED MULTIPLE MYELOMA	Hanne Marie Liddle Norseth	Received

PS-1746	MULTICENTER PHASE 2 STUDY OF SUBCUTANEOUS ISATUXIMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA SC-VRD) IN NEWLY DIAGNOSED TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA (NDMM TI): RESULTS FROM ISASOCUT (IFM 2022-05)	Arthur Bobin	Received

PS-1748	INCREASED RISK OF INFECTIONS IN INDIVIDUALS WITH SMOLDERING MULTIPLE MYELOMA: RESULTS FROM THE SCREENED ISTOPMM STUDY	Lærke Sloth Andersen	Received

PS-1749	CARFILZOMIB AND LENALIDOMIDE FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: LONG-TERM FOLLOW-UP OF THE EMN12/HOVON-129 STUDY	Niels W C J van de Donk	Received

PS-1750	CARFILZOMIB-POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MYELOMA IN THE ERA OF QUADRUPLET THERAPY : A MULTICENTER REAL-WORLD STUDY	Pierre-Edouard Debureaux	Received

PS-1752	CLINICAL MANAGEMENT OF BELANTAMAB MAFODOTIN-ASSOCIATED OCULAR EVENTS: PRACTICAL GUIDANCE FROM THE BELAMAF EXPERT EXPERIENCE PROGRAM	Evangelos Terpos	Received

PS-1753	COMPARATIVE ANALYSIS OF TREATMENT PATTERNS AND OUTCOMES IN 2,202 OCTOGENARIANS VS. 5,823 ELDERLY PATIENTS (70-	Irit Avivi Mazza	Received

PS-1754	THE IMPACT OF CHROMOSOME 1Q21 ABNORMALITIES ON FRONTLINE TREATMENT OUTCOMES IN CHINESE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: INSIGHTS FROM A MULTICENTER RETROSPECTIVE COHORT STUDY	Jian Cui	Received

PS-1756	A SINGLE-ARM, MULTI-CENTER, OBSERVATIONAL CLINICAL STUDY OF SELINEXOR COMBINED BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE REGIMEN FOR NEWLY DIAGNOSED MULTIPLE MYELOMA(NDMM) WITH HIGH-RISK FACTORS	Yuping Zhong	Received

PS-1758	DIFFERENCES IN INCIDENCE OF CYTOKINE RELEASE SYNDROME (CRS) AND IMPACT ON OVERALL SURVIVAL (OS) IN MULTIPLE MYELOMA PATIENTS TREATED WITH ANTI-BCMA VS. ANTI-GCPR5D BISPECIFIC ANTIBODIES: A REAL-WORLD ANALYSIS	Heidi Cho	Received

PS-1762	CHARACTERIZATION OF INFECTIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF)-BASED REGIMENS FROM DREAMM-7 AND DREAMM-8 TRIALS	Pawel Robak	Received

PS-1765	PROGNOSTIC IMPACT OF DYNAMIC CHANGES OF TYPE I MELANOMA ANTIGEN GENE PROTEINS CT7 (MAGE-C1/CT7) TRANSCRIPTS IN MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS	Jin Lu	Received

PS-1767	ADVANCED RISK PREDICTION FOR SMOLDERING MULTIPLE MYELOMA (SMM) PATIENTS THROUGH THE COMBINATION OF MAYO CLINICS 2/20/20 MODEL WITH TELOVIEW SMM RISK ASSESSMENT.	Atacenk Baslik	Received

PS-1769	EVALUATION OF A NOVEL PATIENT-REPORTED TOOL GUIDING EXTENDED DOSING SCHEDULE OF BELANTAMAB MAFODOTIN IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; UPDATED OPHTHALMIC SAFETY FROM A PHASE 1/2 TRIAL OF THE G	Evangelos Terpos	Received

PS-1772	UNDERSTANDING THE BIOLOGY OF FRAILTY IN MYELOMA: JOINING SERUM PROTEOMICS WITH CLINICAL DATA USING MACHINE LEARNING	Adam Jones	Received

PS-1773	IMPACT OF 1Q GAIN AND AMPLIFICATION IN PATIENTS TREATED WITH ANTI-CD38 MONOCLONAL ANTIBODIES. REAL WORLD DATA FROM A SINGLE CENTER IN SPAIN.	María Sánchez Tabernero	Received

PS-1775	AUTOLOGOUS STEM CELL TRANSPLANT - DOES IT BENEFIT MULTIPLE MYELOMA PATIENTS IN ERA OF CD38 MONOCLONAL ANTIBODIES?	Lay Khandwala	Received

PS-1778	A REAL-WORLD STUDY OF LENALIDOMIDE REFRACTORY MULTIPLE MYELOMA PATIENTS IN FINLAND: TREATMENT AND OUTCOMES	Marika Waltari	Received

PS-1779	HEPATIC RESPONSE DYNAMICS IN NEWLY DIAGNOSED LIGHT-CHAIN AMYLOIDOSIS PATIENTS	Chengyang Xu	Received

PS-1781	INCIDENCE OF INFECTIONS AND MICROBIOLOGICAL PATTERN IN PATIENTS WITH MULTIPLE MYELOMA IN A REAL-WORLD POPULATION IN NORWAY	Juni Songe Paulsen	Received

PS-1782	IN-CLASS TRANSITION (ICT) FROM PARENTERAL BORTEZOMIB (V) TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF US MM-6 BY RACE/ETHNICITY, RENAL FUNCTION, AND AREA INCOME	Ruemu Birhiray	Received

PS-1785	A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF SECONDARY IMMUNODEFICIENCY AND RISK OF INFECTION IN PATIENTS WITH AL AMYLOIDOSIS TREATED WITH DARATUMAMAB-BASED INDUCTION REGIMENS. A MULTICENTER ITALIAN EXPERIENCE	Anna Furlan	Received

PS-1786	IMPACT OF CORTICOSTEROIDS ON THE EFFICACY AND TOXICITY OF BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	Cristian Gutierrez-Padilla	Received

PS-1787	INCIDENCE AND SURVIVAL OF MULTIPLE MYELOMA IN ENGLAND: AN UNSELECTED COHORT STUDY FROM THE UNCOVER STUDY GROUP AND UKMRA FRAILTY GROUP.	Thea Chandler	Received

PS-1789	RENAL RESPONSE AND PROGNOSIS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT APPLYING VRD AND AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION	Chengcheng Fu	Received

PS-1790	THROMBOPROPHYLAXIS PRESCRIBING PATTERN AND RATES OF THROMBOEMBOLIC EVENTS AMONG PATIENTS WITH MULTIPLE MYELOMA IN THE LARGEST HEALTHCARE SYSTEM IN NEW YORK	Phyu Thin Naing	Received

PS-1792	THE EFFICACY AND SAFETY OF DARATUMUMAB-BASED REGIMENS IN THE INITIAL TREATMENT OF AMYLOID LIGHT-CHAIN AMYLOIDOSIS	Kai Ding	Received

PS-1793	PHASE 3 DREAMM-10 STUDY DESIGN: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE VS DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE NEWLY-DIAGNOSED MULTIPLE MYELOMA	Meletios A. Dimopoulos	Received

PS-1796	DECIPHERING BONE MARROW ENDOTHELIAL DYSFUNCTION IN MYELOPROLIFERATIVE NEOPLASMS THROUGH SPATIAL TRANSCRIPTOMICS	Jimena CASTORENA RODRIGUEZ	Received

PS-1797	CHARACTERIZATION OF CD9 AS A NOVEL MARKER FOR DISEASE-PROPAGATING STEM CELLS IN MYELOFIBROSIS	Lara Tavernari	Received

PS-1798	THE IMMUNE-MODULATORY FUNCTION OF MEGAKARYOCYTES IN THE HEMATOPOIETIC NICHE OF MYELOPROLIFERATIVE NEOPLASMS	Huichun Zhan	Received

PS-1800	MED12L: A COMPONENT OF THE MEDIATOR COMPLEX AS A POTENTIAL NOVEL ORCHESTRATOR OF PLATELET DYSFUNCTION IN MYELOPROLIFERATIVE NEOPLASMS	Matteo Brindisi	Received

PS-1801	EMBRYONIC HEMATOPOIETIC STEM AND PROGENITOR CELLS SHOW DIFFERENTIAL SUSCEPTIBILITY TO LEUKEMIC TRANSFORMATION UPON ACQUISITION OF JMML-ASSOCIATED KRASG12D MUTATION	Emanuele Azzoni	Received

PS-1802	GERMLINE VARIANTS IN MYELOPROLIFERATIVE NEOPLASMS WITH EARLY ONSET OR FAMILIAL HISTORY	Elisa Rumi	Received

PS-1804	TARGETED INHIBITION OF ACTIVATED NEUTROPHIL TRANSMIGRATION AMELIORATES MYELOPROLIFERATIVE NEOPLASM IN MICE	Sarolta Bojtiné Kovács	Received

PS-1805	INCB057643, A BROMODOMAIN AND EXTRA-TERMINAL PROTEIN INHIBITOR, HAS NOVEL ROLES IN MYELOID CELL REGULATION AND IMMUNOSUPPRESSIVE TUMOUR ENVIRONMENT REMODELLING IN MYELOFIBROSIS	Hamza Celik	Received

PS-1806	A MOLECULAR SIGNATURE PREDICTS HEMATOLOGIC EVOLUTION IN POLYCYTHEMIA VERA PATIENTS, A FIM STUDY	Damien Luque Paz	Received

PS-1808	CLINICAL AND GENE EXPRESSION PATTERNS ASSOCIATED WITH DISEASE PROGRESSION IN PATIENTS WITH LOW-RISK MYELOFIBROSIS ENROLLED IN THE MYELOFIBROSIS AND ESSENTIAL THROMBOCYTHEMIA OBSERVATIONAL STUDY (MOST)	Abdulraheem Yacoub	Received

PS-1809	IDENTIFICATION AND VALIDATION OF A NOVEL FERROPTOSIS-RELATED GENE SIGNATURE FOR PREDICTION OF THE PROGNOSIS IN PRIMARY MYELOFIBROSIS : BASED ON SINGLE-CELL ANALYSIS AND MACHINE LEARNING	Jian Huang	Received

PS-1810	THE COOPERATION BETWEEN CALRDEL52 AND TP53 MUTATIONS INCREASES THE NUMBER OF IMMATURE HEMATOPOIETIC PROGENITORS AND ENHANCES THROMBOPOIETIN-INDEPENDENT MEGAKARYOPOIESIS	Suzana Benedito	Received

PS-1811	ALLELIC POLYMORPHISMS IN KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) GENES MODULATE THE RISK FOR DEVELOPMENT OF PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS	Velizar Shivarov	Received

PS-1812	THERAPEUTIC STRATEGIES TARGETING SRSF2 AND KIT MUTATIONS IN SYSTEMIC MASTOCYTOSIS	Ken-Hong Lim	Received

PS-1813	GLUTAMATE OVERLOAD IN THE MYELOFIBROSIS MICROENVIRONMENT RESHAPES MESENCHYMAL STROMAL CELLS´ EPIGENETIC ARCHITECTURE TOWARD SENESCENCE.	Sebastiano Giallongo	Received

PS-1814	ANTI-HEMOJUVELIN MONOCLONAL ANTIBODY FURTHER ENHANCES HEMATOLOGIC RESPONSE TO ESA AND/OR LUSPATERCEPT IN MICE	Min Wu	Received

PS-1815	NOVEL INSIGHTS INTO THE INNATE IMMUNE LANDSCAPE OF MUTANT CALRETICULIN-DRIVEN MPN	Agnieszka Witalisz-Siepracka	Received

PS-1816	PRESENCE OF PERIPHERAL BLASTS PREDICT WORSE CLINICAL OUTCOMES IN PATIENTS WITH POLYCYTHEMIA VERA IRRESPECTIVE OF STANDARD RISK FACTORS	Lucia Masarova	Received

PS-1818	MOLECULAR DETERMINANTS OF RESISTANCE TO ROPEGINTERFERON ALFA-2B IN PV AND ET	Jihyun Song	Received

PS-1819	T CELL MATURATION SHIFT TOWARD A SENESCENT PROFILE AND ENHANCED INHIBITORY SIGNALING VIAREGULATORY T CELLS ARE ASSOCIATED WITH ADVANCED MYELOFIBROSIS	Camila Garcia	Received

PS-1822	SAFETY AND EFFICACY OF BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY	Pankit Vachhani	Received

PS-1824	CLINICAL TRAJECTORIES AND GENOMIC HETEROGENEITY IN AYA VERSUS NON-AYA ESSENTIAL THROMBOCYTHEMIA: A COMPARATIVE STUDY INTEGRATING CLINICAL PROFILES, OUTCOMES, AND NEXT-GENERATION SEQUENCING	Jian Huang	Received

PS-1825	DYNAMIC ELEVATIONS OF EARLY-STAGE MYELOID-DERIVED SUPPRESSOR CELLS PREDICT LEUKEMIC TRANSFORMATION IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOTILNIB: A REAL-WORLD, PROSPECTIVE, LONGITUDINAL STUDY	Jian Huang	Received

PS-1826	DECODING THE MYELOPROLIFERATIVE NEOPLASM CONTINUUM: A MACHINE LEARNING APPROACH TO DISEASE EVOLUTION AND PROGNOSTIC STRATIFICATION	Yu-Hung Wang	Received

PS-1827	REAL-WORLD EFFECTIVENSS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS WHO HAVE THROMBOCYTOPENIA AND ANEMIA	Raajit K Rampal	Received

PS-1828	EXPLORATORY ANALYSIS OF GECACITINIB IN RUXOLITINIB-INTOLERANT MYELOFIBROSIS PATIENTS: IMPACT OF BASELINE ANEMIA AND PRIOR RUXOLITINIB TREATMENT DURATION ON RESPONSE TO GECACITINIB	Yi Zhang	Received

PS-1829	IMPACT OF DUAL SPLEEN RESPONSE AND TRANSFUSION INDEPENDENCE ON SURVIVAL IN JAK INHIBITOR–NAIVE PATIENTS WITH MYELOFIBROSIS AND ANEMIA TREATED WITH MOMELOTINIB: A SUBGROUP ANALYSIS OF SIMPLIFY-1	Francesca Palandri	Received

PS-1831	RETROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH PRIMARY AND SECONDARY MYELOFIBROSIS TREATED WITH RUXOLITINIB: JUMP STUDY	Emma Richards-Sirianni	Received

PS-1832	A PHASE 1/2A TRIAL OF PXS-5505, A NOVEL PAN-LYSYL OXIDASE INHIBITOR, IN PATIENTS WITH ADVANCED MYELOFIBROSIS	Anne-Marie Watson	Received

PS-1834	DEVELOPMENT AND VALIDATIONTION OF A MODEL FOR PREDICTING LEUKEMIC TRANSFORMATION IN MYELOFIBROSIS PATIENTS A MULTI-CENTER RETROSPECTIVE STUDY	Jian Huang	Received

PS-1836	EFFICACY OF LUSPATERCEPT IN TREATING ANEMIA IN SF3B1-POSITIVE MYELOPROLIFERATIVE NEOPLASMS	Minghui Duan	Received

PS-1837	FACTORS ASSOCIATED WITH GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS: A MULTICENTER RETROSPECTIVE STUDY	Yuqian Sun	Received

PS-1839	INDIRECT TREATMENT COMPARISON OF GECACITINIB VS RUXOLITINIB IN MYELOFIBROSIS	Yi Zhang	Received

PS-1840	IMPACT OF THROMBOSIS ON DISEASE PROGRESSION, CANCER AND MORTALITY IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA	Anna Angona Figueras	Received

PS-1841	RELATIONSHIP BETWEEN HEMOGLOBIN AND QUALITY OF LIFE IN NON-TRANSFUSION-DEPENDENT PATIENTS WITH MYELOFIBROSIS TREATED WITH LUSPATERCEPT	Haifa Kathrin Al-Ali	Received

PS-1843	CLINICAL AND MOLECULAR DIAGNOSTIC CHALLENGES IN MYELOPROLIFERATIVE NEOPLASMS WITH LOW JAK2V617F ALLELIC BURDEN.	Erika Morsia	Received

PS-1844	THE ECONOMIC BURDEN OF MYELOFIBROSIS TREATED WITH RUXOLITINIB IN FRANCE	Jean-Jacques Kiladjian	Received

PS-1845	DISC-0974 (AN ANTI-HEMOJUVELIN ANTIBODY) IN NON-TRANSFUSION-DEPENDENT PATIENTS WITH MYELOFIBROSIS: LABORATORY CORRELATES OF MAJOR ANEMIA RESPONSE	Ayalew Tefferi	Received

PS-1846	IMPACT OF INDIVIDUALIZED DOSING PROFILES OF MIDOSTAURIN ON SAFETY, RESPONSE AND SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS	Johannes Lübke	Received

PS-1847	DEEP MOLECULAR RESPONSES WITH LOW-FIXED DOSE OF ROPEGINTERFERON ALFA-2B IN A ROLLOVER COHORT OF THE LOW-PV TRIAL	Tiziano Barbui	Received

PS-1849	THE APPLICABILITY OF CLINICAL, CYTOGENETIC, AND MOLECULAR PREDICTORS OF OUTCOME IN PATIENTS WITH MYELOFIBROSIS IN THE ERA OF JAK INHIBITORS	Haifa Kathrin Al-Ali	Received

PS-1851	QRISK3 SCORE IDENTIFIES ESSENTIAL THROMBOCYTHAEMIA AND POLYCYTHAEMIA VERA PATIENTS WHO BENEFIT FROM CYTOREDUCTIVE THERAPY	Andrea Duminuco	Received

PS-1854	AN EXPLORATORY ANALYSIS OF SYMPTOMATIC BENEFIT IN PATIENTS TREATED WITH GECACITINIB: A FOCUS ON THOSE INTOLERANT OR REFRACTORY/RELAPSED TO RUXOLITINIB	Yi Zhang	Received

PS-1855	DIFFERENTIAL IMPACTS OF GRAFT-VERSUS-HOST DISEASE ON SURVIVAL IN CHRONIC MYELOMONOCYTIC LEUKEMIA ACCORDING TO TRANSPLANT MODALITIES	Hidehiro Itonaga	Received

PS-1857	OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER CHECKPOINT INHIBITORS IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS: A RETROSPECTIVE ANALYSIS OF THE EBMT-LWP (CHECK-AUTO STUDY)	Carmen Martínez	Received

PS-1858	THE CHANGE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES OF HODGKIN LYMPHOMA IN NOVEL AGENT ERA.	Yukiko Misaki	Received

PS-1859	IMPACT OF AGE, FRAILTY AND COMORBIDITIES IN THE SURVIVAL OF OLDER PATIENTS WITH HODGKIN LYMPHOMA: A RETROSPECTIVE, MULTICENTER STUDY IN SPAIN FROM THE SPANISH LYMPHOMA REGISTRY (RELINF) OF THE SPANISH GROUP OF LYMPHOMA (GELTAMO)	Raul Cordoba	Received

PS-1860	REAL-LIFE EVALUATION OF EFFICACY AND TOLERANCE OF A PET-GUIDED DE-ESCALATION FROM BRECADD TO BRAVD IN FIRST-LINE TREATMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA	Maxime Delforge	Received

PS-1863	METABOLIC TUMOR VOLUME IN OLDER PATIENTS WITH ADVANCED-STAGE CLASSIC HODGKIN LYMPHOMA: RESULTS FROM THE GHSG HD21 TRIAL	Paul J. Bröckelmann	Received

PS-1867	A SURVIVAL UPDATE ON A PHASE II TRIAL USING CONVENTIONAL CHEMOTHERAPY PLUS NIVOLUMAB IN ADVANCED STAGE HODGKIN DISEASE (HD)	Maher Salamoon	Received

PS-1870	PD-1-BASED SALVAGE THERAPY FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER REAL-WORLD ANALYSIS	Hishan Tharmaseelan	Received

PS-1871	ZR STUDY: A PROSPECTIVE PHASE II CLINICAL TRIAL EVALUATING ZANUBRUTINIB-RITUXIMAB INDUCTION THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN TREATMENT-NAÏVE MANTLE CELL LYMPHOMA	Chang-Ju Qu	Received

PS-1873	OBINUTUZUMAB SINGLE AGENT FOR THE FIRST LINE TREATMENT OF MARGINAL ZONE LYMPHOMA: RESULTS OF THE PROSPECTIVE MULTICENTER PHASE II OLYMP-1 TRIAL OF THE GERMAN LYMPHOMA ALLIANCE (GLA)	Christian Buske	Received

PS-1874	GOLDILOX: FIRST EXPERIENCE OF SAFETY AND ACTIVITY OF TWO DOSING STRATEGIES OF PIRTOBRUTINIB AND GLOFITAMAB FOR MANTLE CELL LYMPHOMA IN PATIENTS PREVIOUSLY TREATED WITH COVALENT BTK INHIBITORS - AN ALLG STUDY	Chan Cheah	Received

PS-1875	THE IMPACT OF TIRABRUTINIB, A SECOND-GENARATION BRUTON´S TYROSINE KINASE INHIBITOR, FOR BING-NEEL SYNDROME: A MULTICENTER RETROSPECTIVE STUDY	Naohiro Sekiguchi	Received

PS-1876	LONG-TERM SURVIVAL TRENDS IN ADVANCED-STAGE MANTLE CELL LYMPHOMA: A POOLED ANALYSIS OF SIX RANDOMIZED PHASE III TRIALS FROM 1996 TO 2020	Linmiao Jiang	Received

PS-1877	TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A POST HOC ANALYSIS OF OUTCOMES BY POD24 STATUS FROM THE INMIND STUDY	Haley Maire	Received

PS-1879	GOLCADOMIDE (GOLCA), A CEREBLON E3 LIGASE MODULATOR (CELMOD™) AGENT ± RITUXIMAB (R), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): UPDATED PHASE 1/2 STUDY RESULTS	Raul Cordoba	Received

PS-1880	BARRIERS FOR TRIAL INCLUSION AND IMPACT ON SURVIVAL FOR MANTLE CELL LYMPHOMA PATIENTS WITHIN AND OUTSIDE OF THE RANDOMIZED PHASE II/III TRIAL ENRICH	Leila Boukharta	Received

PS-1882	REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH TREATMENT-NAIVE MANTLE CELL LYMPHOMA IN THE UK, SWEDEN, AND FRANCE	Morgane Cheminant	Received

PS-1884	PROGNOSTIC IMPACT OF POD24 AND MALT-IPI ON OVERALL SURVIVAL IN EXTRANODAL MARGINAL ZONE LYMPHOMA RECEIVING SYSTEMIC CHEMOTHERAPY: ANALYSIS FROM THE THAI LYMPHOMA STUDY GROUP (TLSG)	Kannadit Prayongratana	Received

PS-1885	DETERMINING THE PROGNOSTIC SIGNIFICANCE OF THE KI67 PROLIFERATION INDEX IN TREATMENT-NAÏVE FOLLICULAR LYMPHOMA: AN AUSTRALASIAN LYMPHOMA AND RELATED DISEASES REGISTRY (LARDR) STUDY	Eliza Chung	Received

PS-1888	CHIDAMIDE IN COMBINATION WITH ANTI-CD20 MONOCLONAL ANTIBODY PLUS CHOP FOR TREATING NEWLY DIAGNOSED B-CELL NON-HODGKIN LYMPHOMA WITH EPIGENETIC MUTATIONS: PRELIMINARY ANALYSIS FROM A PHASE II STUDY	Hongmei Jing	Received

PS-1889	ZANUBRUTINIB COMBINED WITH BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA: A PROSPECTIVE OPEN-LABEL SINGLE-ARM PHASE II CLINICAL STUDY	He Huang	Received

PS-1890	LONG-TERM OUTCOMES IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS WHO DISCONTINUE BRUTON´S TYROSINE KINASE INHIBITOR (BTKI) THERAPY	Karan Chohan	Received

PS-1891	SPANISH IMCD REGISTRY EPIDEMIOLOGY OF IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE IN SPAIN (ARCANA) - PREVALENCE COHORT	Jose Tomás Navarro Ferrando	Received

PS-1892	PHASE II INVESTIGATOR-INITIATED TRIAL OF EPCORITAMAB-LENALIDOMIDE IN TREATMENT NAÏVE FOLLICULAR LYMPHOMA	Swetha Thiruvengadam	Received

PS-1893	RITUXIMAB, LENALIDOMIDE AND ZANUBRUTINIB CHEMO-FREE REGIMEN FOLLOWED BY IMMUNOCHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA: AN INVESTIGATOR INITIATED, SINGLE ARM, PHASE 2 TRIAL	Xi Chen	Received

PS-1894	THE EXPRESSION INTENSITY OF KI-67 WAS ASSOCIATED WITH PROGNISIS IN FOLLICULAR LYMPHOMA GRADE 3A	Wenjuan Yu	Received

PS-1895	BALANCING SAFETY AND EFFICACY OF BENDAMUSTINE PLUS ANTI CD20 REGIMENS IN ELDERLY PATIENTS (>70 Y) WITH FOLLICULAR LYMPHOMA: A TERTIARY ACADEMIC CENTER EXPERIENCE	Mattia D´Antiga	Received

PS-1896	RISK STRATIFICATION IN ASYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA – VALIDATION AND COMPARISON OF THE DFCI AND SPANISH MODELS	Theresia Akhlaghi	Received

PS-1897	A PHASE 1 STUDY OF BI-1206, A MONOCLONAL ANTIBODY TO CD32B (FC?RIIB), IN COMBINATION WITH RITUXIMAB AFTER A BI-1206 SAFETY RUN-IN PHASE IN SUBJECTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA	Jianyong Li	Received

PS-1898	PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA TREATED WITH EPCORITAMAB WITHIN THE ENTIRE STUDY COHORT AND IN PATIENTS WITH SYMPTOMS AT BASELINE	P. Connor Johnson	Received

PS-1899	DETECTION OF RECURRENT GENOMIC ALTERATIONS AND MINIMAL RESIDUAL DISEASE WITH CELL-FREE DNA AND BONE MARROW IN WALDENSTRÖM´S MACROGLOBULINEMIA.	Signy Chow	Received

PS-1900	ASSESSING SECONDARY IMMUNODEFICIENCY IN A COHORT OF PATIENTS WITH WALDENSTRÖM MACROGLOBULINAEMIA	Nicole Japzon	Received

PS-1902	THE RATIONALITY, EFFICACY AND SAFETY OF ORELABRUTINIB PLUS OBINUTUZUMAB (O2) IN SYSTEMIC TREATMENT-NAÏVE MARGINAL ZONE LYMPHOMA: A PROSPECTIVE COHORT STUDY	Jiadai Xu	Received

PS-1903	OBINUTUZUMAB COMBINED WITH BENDAMUSTINE IN THE TREATMENT OF MATURE B-CELL LYMPHOMA: AN OPEN-LABEL, MULTICENTER STUDY	Yuting Yan	Received

PS-1904	CAR T-CELL VS BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS	Hao Yao	Received

PS-1905	EFFICACY AND SAFETY OF ORELABRUTINIB IN COMBINATION WITH OBINUTUZUMAB AND LENALIDOMIDE IN PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA: PRELIMINARY RESULTS FROM A PROSPECTIVE, SINGLE-ARM, MULTICENTER, PHASE II STUDY	Wei Wang	Received

PS-1907	LENALIDOMIDE AND OBINUTUZUMAB FOR TREATMENT OF CHEMORESISTANT RELAPSED FOLLICULAR LYMPHOMA: A SINGLE-CENTER STUDY	Maria Sannikova	Received

PS-1910	BASELINE INFLAMMATION PREDICTS RESPONSE TO CD3XCD20 BISPECIFIC T CELL ENGAGERS IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA	Giulia Magno	Received

PS-1911	INITIAL RESULTS FROM LOTIS-7: A PHASE 1B STUDY OF LONCASTUXIMAB TESIRINE PLUS GLOFITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)	Samantha Farghaly	Received

PS-1912	CIRCULATING TUMOUR DNA-DIRECTED INTERVENTION WITH EPCORITAMAB ALONE OR IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IS FEASIBLE IN THE EARLY POST-CAR-T POPULATION AT HIGH RISK OF RELAPSE: PRELIMINARY DATA FROM EPLCART	Mark Dowling	Received

PS-1914	MULTICENTER REAL-WORLD OUTCOMES OF FRONTLINE POLA-R-CHP IN TREATMENT NAÏVE DLBCL	Swetha Thiruvengadam	Received

PS-1915	RELAPSE PATTERNS AND CLINICAL CHARACTERISTICS OF PATIENTS WITH PRIMARY TESTICULAR LYMPHOMA (PTL) OR TESTICULAR INVOLVEMENT IN THE FLYER, UNFOLDER AND RICOVER-60 TRIALS IN AGGRESSIVE B-CELL-LYMPHOMA	Igor Age Kos	Received

PS-1916	OPTIMIZING POST–CHIMERIC ANTIGEN RECEPTOR T CELL MONITORING: EVIDENCE ACROSS LISOCABTAGENE MARALEUCEL PIVOTAL CLINICAL TRIALS AND REAL-WORLD EXPERIENCE	Alex Verdeur	Received

PS-1917	ORELABRUTINIB, RITUXIMAB COMBINED WITH HIGH-DOSE METHOTREXATE AS INDUCTION THERAPY IN NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA	Xibin Xiao	Received

PS-1919	TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY	Chris Geraci	Received

PS-1920	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH CAR-T CELL THERAPY SIGNIFICANTLY IMPROVES PROGRESSION-FREE SURVIVAL IN RELAPSED REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA	Liu Rui	Received

PS-1922	OUTCOMES WITH CAR-T IN PATIENTS WITH T CELL HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, UK EXPERIENCE	Dima El-Sharkawi	Received

PS-1923	PLASMABLASTIC LYMPHOMA: POPULATION-BASED TREATMENT STRATEGIES AND OUTCOME	Diana Al-Sarayfi	Received

PS-1925	18F-FDG PET RADIOMICS SCORE CONSTRUCTION BY AUTOMATIC MACHINE LEARNING FOR TREATMENT RESPONSE PREDICTION IN ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTER STUDY	Jingyan Xu	Received

PS-1927	SAFETY AND EFFICACY OF AZD0486, A CD19XCD3 T-CELL ENGAGER, IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA	Dok Hyun Yoon	Received

PS-1928	REDEFINING MAINTENANCE STRATEGIES IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: A DUAL-CENTER RETROSPECTIVE COMPARISON OF BTK INHIBITORS AND LENALIDOMIDE	Xiaoli Chang	Received

PS-1929	A PHASE I/II STUDY OF ORELABRUTINIB COMBINED WITH ANTI-PROGRAMMED CELL DEATH PROTEIN-1 ANTIBODY AND FOTEMUSTINE FOR PATIENTS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)	Wanyue Zhao	Received

PS-1931	GOLCADOMIDE (GOLCA), A CEREBLON E3 LIGASE MODULATOR (CELMOD™) AGENT, ± RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): UPDATED PHASE 1/2 STUDY RESULTS	Jean Marie Michot	Received

PS-1933	ANTI-PD-1 ANTIBODY (TISLELIZUMAB) COMBINED WITH R-CHOP FOR THE TREATMENT OF PREVIOUSLY UNTREATED PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER PHASE II STUDY	Shujuan Wen	Received

PS-1934	AZACYTIDINE COMBINED WITH CHOP REGIMEN FOR THE TREATMENT OF NEWLY DIAGNOSED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA	Wenjuan Yu	Received

PS-1939	ORELABRUTINIB, RITUXIMAB, AND THIOTEPA (ORT) IN COMBINATION WITH ORWITHOUT HIGH-DOSE METHOTREXATE IN UNTREATED PRIMARY CENTRAL NERVOUSSYSTEM LYMPHOMA	Wenjuan Yu	Received

PS-1941	LINPERLISIB COMBINED WITH CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION AND LINPERLISIB MAINTENANCE IN PATIENTS WITH NEWLY DIAGNOSED NODAL T FOLLICULAR HELPER CELL LYMPHOMA: INTERIM ANALYSIS OF A PHASE II TRIAL	Weiping Liu	Received

PS-1943	ORELABRUTINIB ADDITION TO R-CHOP-LIKE REGIMEN ADAPTED TO RESPONSE IN TREATMENT-NAÏVE NON-GCB DLBCL: UPDATE RESULTS OF ORIENT STUDY	Chang-Ju Qu	Received

PS-1944	PATIENT PREFERENCES FOR ATTRIBUTES OF BISPECIFIC ANTIBODIES INDICATED FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES	Erin Mulvey	Received

PS-1946	PREEMPTIVE TMP-SMX/N-ACETYLCYSTEINE PROPHYLAXIS MITIGATES THE INCIDENCE OF INTERSTITIAL PNEUMONIA IN DLBCL IMMUNOCHEMOTHERAPY: A DUAL-CENTER COHORT STUDY ON RISK STRATIFICATION AND CLINICAL OUTCOMES	wenwen wang	Received

PS-1947	EFFECTIVENESS AND GENE PROFILE OF FRONT-LINE POLA-BASED REGIMEN FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A REAL-WORLD, SINGLE-CENTER STUDY INCLUDING DATA ON TP53 MUTATED PATIENTS	Jia Liu	Received

PS-1948	PERSISTING THROMBOCYTOPENIA AFTER CD19-DIRECTED CAR-T CELL THERAPY IS A PREDICTOR OF WORSE SURVIVAL IN RELAPSED / REFRACTORY LBCL PATIENTS	Akhil Behringer	Received

PS-1949	RAPID RAMP-UP OF BI-SPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA	Yucai Wang	Received

PS-1950	NOVEL SMALL MOLECULAR TARGET AGENTS WITH HD-MTX-BASED REGIMENS IMPROVED REMISSION RATES WITHOUT PROLONGING PFS IN NEWLY DIAGNOSED PCNSL	Yan Zhang	Received

PS-1954	LATEST UPDATE RESULTS OF P-GEMD REGIMEN IN NEWLY DIAGNOSED EARLY NON-UPPER AERO-DIGESTIVE TRACT OR ADVANCED STAGE EXTRANODAL NK/T CELL LYMPHOMA	Jinhua Liang	Received

PS-1955	DIAGNOSTIC DISCREPANCY OF CT AND FDG PET-CT AT INTERIM STAGING AND END OF TREATMENT IN FRAIL PATIENTS WITH LBCL TREATED WITH R-MINICHOP+/-ACALABRUTINIB	Igor Age Kos	Received

PS-1956	INTERIM ANALYSIS OF POMALIDOMIDE PLUS RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE (PR-ICE) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE I/II STUDY (PRIDE STUDY)	WeiLi Zhao	Received

PS-1957	UPDATED SAFETY RUN-IN RESULTS FROM LOTIS-5: A PHASE 3, RANDOMIZED TRIAL OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL/HGBL	Samantha Farghaly	Received

PS-1959	COMPARISON OF 18F-FDG PET/CT AND BONE MARROW BIOPSY IN DETECTION OF BONE MARROW INVOLVEMENT IN DIFFUSE LARGE B-CELL LYMPHOMA	Fahong Yan	Received

PS-1960	A COMBINED EASIX-IPI (E-IPI) SCORE IMPROVES THE PROGNOSTIC STRATIFICATION OF NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)	Jing Yuan Tan	Received

PS-1961	CLADRIBINE AND VENETOCLAX FOR TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA	Caitlin Rausch	Received

PS-1963	GLOFITAMAB COMBINED WITH SALVAGE THERAPY FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A REAL-WORLD PROSPECTIVE OBSERVATIONAL STUDY IN CHINESE PATIENTS	Haiwen Huang	Received

PS-1964	CLINICAL FEATURES AND OUTCOMES OF EXTRANODAL NK/T-CELL LYMPHOMA INCLUDING EXTRANASAL DISEASE	Yuka Morita	Received

PS-1965	PEGFILGRASTIM VS. FILGRASTIM FOR FEBRILE NEUTROPENIA PREVENTION IN THE FIRST CYCLE OF POLATUZUMAB VEDOTIN-R-CHP (POLA-R-CHP): A NATIONWIDE COHORT STUDY IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA	NOBUYUKI KABASAWA	Received

PS-1967	EFFECTIVENESS AND SAFETY OF POLA-R-CHP REGIMEN IN PREVIOUSLY UNTREATED LOW-RISK DLBCL: A NATIONWIDE MULTICENTER RETROSPECTIVE STUDY OF IPI 0-1 PATIENTS IN CHINA	Yuhong Ren	Received

PS-1969	ORELABRUTINIB PLUS BENDAMUSTINE-RITUXIMAB (OBR) VERSUS BENDAMUSTINE-RITUXIMAB (BR) IN TRANSPLANT-INELIGIBLE, INTERMEDIATE- TO HIGH-RISK MANTLE CELL LYMPHOMA (MCL)	Li Wang	Received

PS-1970	MAINTAINING R-CHOP INTENSITY IS ASSOCIATED WITH PROLONGED DURATION OF COMPLETE REMISSION IN LARGE B-CELL LYMPHOMA: A MULTI-CENTER REAL-LIFE DATA OF 953 PATIENTS FROM TÜRKIYE	Umut Yilmaz	Received

PS-1975	CHIDAMIDE IN COMBINATION WITH AZACITIDINE, MITOXANTRONE LIPOSOMES, AND PREDNISONE (CAMP REGIMEN) FOR TREATMENT-NAÏVE TFH-DERIVED PERIPHERAL T-CELL LYMPHOMA	Huimin Liu	Received

PS-1977	ASSOCIATION OF DYNAMIC CHANGES IN METABOLIC SYNDROME COMPONENTS WITH CLINICAL OUTCOMES IN DIFFUSE LARGE B-CELL LYMPHOMA	Dewan Zhao	Received

PS-1978	SUBDIAPHRAGMATIC DISEASE AND HIGH FIL SCORE PERFORM BETTER THAN IPI IN IDENTIFYING A SUBGROUP OF PATIENTS WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA WITH A LESS FAVOURABLE PROGNOSIS	Simone Maifredi	Received

PS-1980	ADVANCING PROGNOSIS: A ROBUST PREDICTIVE MODEL FOR LONG-TERM SURVIVAL IN R/R LBCL PATIENTS TREATED WITH CD19 CAR-T THERAPY	Hu Qian	Received

PS-1981	DISSECTING THE HELLS GENE SIGNATURE IN ANAPLASTIC LARGE CELL LYMPHOMA: IMPLICATIONS FOR DRUG REPURPOSING AND COMBINATION THERAPY	Valentina Fragliasso	Received

PS-1982	LONG-TERM FOLLOW-UP REVEALS CURATIVE POTETIAL AND FAVORABLE SAFETY OF CD19/22 CAR-T THERAPY, ALONE OR IN COMBINATION WITH ASCT, IN TP53-ALTERED RELAPSED/REFRACTORY B-NHL	Juan Peng	Received

PS-1985	NR4A1 LOSS PROMOTES AN IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT AND ENHANCES LYMPHOMA PROGRESSION	Katrin Pansy	Received

PS-1986	DC-SIGN LOCALIZATION AND CONTRIBUTION TO TUMOUR CELL FUNCTION IN FOLLICULAR LYMPHOMA	Giorgia Chiodin	Received

PS-1987	LONG NONCODING RNA MTAAT REGULATES PD-L1 SUBCELLULAR TRAFFICKING IN T-CELL LYMPHOMA THROUGH ARF6	Selene Mallia	Received

PS-1988	CD4+ CADM1+ T CELL POPULATION EMERGES AS A MALIGNANCY-ASSOCIATED BIOMARKER IN EBV-RELATED LYMPHOPROLIFERATIVE DISORDERS	Qinhuan Luo	Received

PS-1989	CLONAL HEMATOPOIESIS IN FOLLICULAR LYMPHOMA: ANALYSIS OF THE PHASE III FIL FOLL12 TRIAL	Riccardo Moia	Received

PS-1990	PROTEOMIC PROFILING USING HIGH-DIMENSIONAL MULTIPLEX PLATFORMS TO IDENTIFY PROSPECTIVE RISK FACTORS FOR LYMPHOID MALIGNANCIES ACROSS MULTIPLE COHORTS	Pieter Martijn Kolijn	Received

PS-1993	EMBRYONIC ECTODERM DEVELOPMENT (EED) INHIBITOR APG-5918 EXHIBITS POTENT ANTITUMOR ACTIVITY AND SYNERGIZES WITH HISTONE DEACETYLASE INHIBITOR TUCIDINOSTAT IN PRECLINICAL T-CELL LYMPHOMA (TCL) MODELS	Eric Liang	Received

PS-1994	A GENOME-WIDE CRISPR SCREEN IDENTIFIES UBE2A LOSS-OF-FUNCTION TO CONFER BORTEZOMIB SENSITIVITY IN DIFFUSE LARGE B-CELL LYMPHOMA	Hanne Due	Received

PS-1995	ADVANTIG-101: A PHASE 1B/2 STUDY OF OCIPERLIMAB (ANTI-TIGIT) PLUS TISLELIZUMAB (ANTI-PD-1) OR RITUXIMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA	Yuqin Song	Received

PS-1997	DISTINCT T-CELL PROFILES AND INSIGHTS INTO T-CELL RESPONSES IN SPLENIC SMALL B-CELL MALIGNANCIES	Elisavet Vlachonikola	Received

PS-1998	COMPREHENSIVE ANALYSIS OF MUTATIONAL SIGNATURES IN PATIENTS WITH RELAPSED/REFRACTORY LBCL BY CIRCULATING TUMOR DNA SEQUENCING	Sophie Heidenreich	Received

PS-1999	TRANSLATIONAL FINDINGS FROM THE PHASE 2 LUMINICE-203 STUDY OF ACIMTAMIG (AFM13) IN COMBINATION WITH ALLONK® (AB-101) IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)	Joseph Maakaron	Received

PS-2001	PEMBROLIZUMAB THERAPY INDUCES AN INFLAMMATORY RESPONSE IN LYMPHOMA PATIENTS BY RESHAPING MONOCYTES RESULTING IN HYPERPROGRESSIVE DISEASE	Zhi-Zhang Yang	Received

PS-2002	ENDOCYTIC MODULATION UNVEILS A NOVEL MECHANISM OF NOTCH1 ACTIVATION IN DIFFUSE LARGE B-CELL LYMPHOMA	Paolo Sportoletti	Received

PS-2004	ANTITUMOR CHARACTERIZATION OF IPH6501, A NOVEL IL2V-ARMED TETRASPECIFIC NK CELL ENGAGER TARGETING CD20 B CELLS, IN DLBCL AND FL PATIENT SAMPLES, AND IN PRECLINICAL COMBINATION WITH R-CHOP	Florent Carrette	Received

PS-2005	LCP2 MEDIATES SUV39H1-DRIVEN CELLULAR SENESCENCE-RELATED CHEMORESISTANCE IN NATURAL KILLER/T CELL LYMPHOMA	Yue Zhang	Received

PS-2006	EXPERT-INDEPENDENT CLASSIFICATION OF T-CELL CHRONIC LYMPHOPROLIPHERATIVE DISORDERS USING STANDARDIZED FLOW CYTOMETRY	Sonia Carretero-Domínguez	Received

PS-2007	GENOMIC TESTING IN PATIENTS WITH LARGE CELL AND FOLLICULAR LYMPHOMA TREATED WITH T-CELL ENGAGERS BI-SPECIFIC ANTIBODIES AND CORRELATION WITH TREATMENT RESPONSE	Rita Tavarozzi	Received

PS-2008	A DELICATE BALANCE BETWEEN EPSTEIN-BARR VIRUS (EBV) INDUCED MUTAGENESIS AND DNA REPAIR DICTATES STABILIZED LATENCY OR LYTIC POTENTIATION: IMPLICATIONS FOR EBV ASSOCIATED LYMPHOMAGENESIS	Tom Howard	Received

PS-2009	IMPACT OF LARGE B-CELL LYMPHOMA (LBCL) GENOMICS ON CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) TREATMENT OUTCOMES	Marc Bosch Schips	Received

PS-2013	ABERRANT EXPRESSION AND ONCOGENIC ACTIVITY OF SPP1 IN HODGKIN LYMPHOMA	Nagel Stefan	Received

PS-2014	NOVEL IMMUNOPHENOTYPIC APPROACHES TO IMPROVE THE DIAGNOSTIC CLASSIFICATION OF MATURE T-CELL NEOPLASMS	Daniel Zaldumbide	Received

PS-2015	COMPREHENSIVE EVALUATION OF OTHER IATROGENIC IMMUNODEFICIENCY-ASSOCIATED LYMPHOPROLIFERATIVE DISEASE ELUCIDATES THE UNIQUE IMPACT OF METHOTREXATE-BASED IMMUNOSUPPRESSION AND EBV INFECTION	Yuki Furukawa	Received

PS-2016	PRE-INFUSION CD57+ CAR-T CELL FREQUENCY AND EARLY POST-INFUSION PD-1 EXPRESSION CORRELATE WITH CLINICAL OUTCOMES FOLLOWING CAR-T CELL THERAPY FOR HEMATOLOGICAL MALIGNANCIES	yajing zhang	Received

PS-2021	POLYMORPHONUCLEAR MYELOID-DERIVED SUPPRESSOR CELLS REPROGRAM FATTY ACID METABOLISM TO INDUCE IMMUNOSUPPRESSION IN PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Yujun Wei	Received

PS-2023	THE SIGNIFICANCE OF HLA PHYLOGENETICALLY RELATED COUNTRIES IN THE CREATION OF IPSC HAPLOBANKS AGAINST THE REGIONAL HLA HETEROGENEITY.	Helen Papadaki	Received

PS-2024	BONE MARROW SELENOP+ MACROPHAGES PROMOTE HEMATOPOIETIC RECONSTITUTION AFTER TRANSPLANTATION VIA GAS6-AXL SIGNALING PATHWAY	Mengzhu Shen	Received

PS-2025	GENETIC POLYMORPHISMS OF ENZYMES METABOLIZING CYCLOPHOSPHAMIDE IS ASSOCIATED WITH THE CLINICAL OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION	Huai-Chueh Gem Wu	Received

PS-2027	A RANDOMIZED TRIAL OF THREE GVHD PROPHYLAXIS REGIMENS IN HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANT: ANTITHYMOCYTE GLOBULIN, POSTTRANSPLANT CYCLOPHOSPHAMIDE, AND LOW-DOSE COMBINATION THERAPY	Yannan Jia	Received

PS-2028	DYNAMIC IMMUNE RECONSTITUTION AND CLINICAL OUTCOMES OF THREE DIFFERENT PROTOCOLS FOR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION	Xiao-Di Ma	Received

PS-2029	THE EFFECTS OF PRIOR LINES OF THERAPY ON CLINICAL OUTCOMES FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE RECEIVING AXATILIMAB: A POST HOC ANALYSIS OF AGAVE-201	Valkal Bhatt	Received

PS-2030	DROPLET DIGITAL PCR FOR MRD MONITORING STANDS AS A PROMISING APPROACH IN PREDICTING RELAPSE AT THE EARLIEST FOR PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Xiao Zhou	Received

PS-2031	MAAT033 TO ENSURE OPTIMAL GUT MICROBIOTA TO IMPROVE SURVIVAL IN PATIENTS? RECEIVING ALLOGENEIC HCT: PHOEBUS TRIAL	Natalia Gemperle Ortiz	Received

PS-2032	CHIDAMIDE MONOTHERAPY PREVENTS THE RELAPSE OF HIGH-RISK MYELOID MALIGNANCIES POST-ALLO-HSCT: A PROSPECTIVE, SINGLE-CENTER, PHASE I/II TRIAL	Qiushi Liang	Received

PS-2035	THE ROLE OF MAINTENANCE THERAPY FOLLOWING CAR T-CELL THERAPY IN LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS	bingling guo	Received

PS-2036	G-CSF-PRIMED PERIPHERAL BLOOD STEM CELL HAPLOIDENTICAL TRANSPLANTATION COULD ACHIEVE SATISFACTORY CLINICAL OUTCOMES FOR SEVERE APLASTIC ANEMIA PATIENTS	Xiao-Di Ma	Received

PS-2038	UNRELATED CORD BLOOD THERAPY: A PROMISING ALTERNATIVE FOR SEVERE APLASTIC ANEMIA	Fang Zhou	Received

PS-2039	EFFICACY ANALYSIS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 140 PEDIATRIC PATIENTS WITH KMT2A REARRANGEMENTS ACUTE MYELOID LEUKEMIA	Rui-juan sun	Received

PS-2041	GERIATRIC ASSESSMENT SCORE FOR PREDICTING DISEASE RELAPSE IN OLDER ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS: RESULTS FROM A PROSPECTIVE ITALIAN SINGLE-CENTER STUDY.	Eugenia Accorsi Buttini	Received

PS-2042	ITALIAN RETROSPECTIVE REAL-LIFE ANALYSIS ON BELUMOSUDIL FOR TREATMENT-RESISTANT/REFRACTORY CHRONIC GVHD	Francesca Bonifazi	Received

PS-2043	THE STUDY ON THE CORRELATION BETWEEN DONOR CHEMOKINE RECEPTOR GENE POLYMORPHISM AND ACUTE GRAFT-VERSUS-HOST DISEASE	Tao Wu	Received

PS-2045	MEASURABLE CYCLOPHOSPHAMIDE ON DAY 0 OF ALLOGENEIC STEM CELL TRANSPLANTATION ADVERSELY IMPACTS GRAFT-VERSUS-HOST DISEASE AND SURVIVAL OUTCOMES	Ray Mun Koo	Received

PS-2046	SAFETY AND EFFICACY OF GCSF ALONE WITH PRE-EMPTIVE PLERIXAFOR FOR AUTOLOGOUS PERIPHERAL BLOOD HEMATOPOIETIC STEM CELL MOBILIZATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA	Mohamed Elemary	Received

PS-2048	THE HAPLOID HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH UMBILICAL CORD BLOOD TRANSFUSION IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES: A MULTICENTER, SINGLE-ARM PROSPECTIVE TRIAL	Xianbo Huang	Received

PS-2050	DYNAMIC IMMUNE RECONSTITUTION IN MIXED CHIMERISM: MECHANISMS LINKING TO GRAFT STABILITY AND CLINICAL OUTCOMES IN SEVERE APLASTIC ANEMIA AFTER HLA-MATCHED TRANSPLANTATION	Zheng-Li Xu	Received

PS-2052	ASSESSMENT OF CIRCULATING CELL FREE DNA AND CYTOKINE LEVELS IN HEMATOPOIETIC STEM CELL DONORS	Tatyana Rybolovleva	Received

PS-2054	A NOVEL CONDITIONING REGIMEN COMBINING SELINEXOR WITH MELPHALAN IMPROVES SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA:A PROSPECTIVE STUDY	Liangliang Ma	Received

PS-2056	COMPARISON OF THE 25 VS 50 MG/KG POST-TRANSPLANTATION CYCLOPHOSPHAMIDE DOSES IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES	Turgay Ulas	Received

PS-2057	REDUCED TOXICITY CONDITIONGING REGIMEN CONTAINING DECITABINE IS FEASIBLE AND ACHIEVES COMPARABLE CLINICAL OUTCOME IN ELDERLY AND FRAGILE MDS PATIETNS RECEIVED STEM CELL TRANSPLATATION: A RETROSPECTIVE, SINGLE-CENTER ANALYSIS	yanling Ren	Received

PS-2058	AMBULATORY DELIVERY OF AUTOLOGOUS STEM CELL TRANSPLANT WITH BEAM CONDITIONING IS SAFE AND RESULTS IN REDUCED INPATIENT STAYS	Pierre McCarthy	Received

PS-2060	CLINICAL EFFECTS OF RUNX1 MUTATIONS ON THE OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION	WeiJie Ran	Received

PS-2062	CHARACTERISTICS AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ERCC6L2-ASSOCIATED BONE MARROW FAILURE AND MYELOID MALIGNANCIES: SINGLE-CENTER REPORT OF 9 CASES	Alfadil Haroon	Received

PS-2064	CONVALESCENT PLASMA THERAPY FOR COVID-19 PROPHYLAXIS IN ADULTS EARLY POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION: ONE-YEAR OUTCOMES FROM A RANDOMIZED CONTROLLED TRIAL	Yigeng Cao	Received

PS-2066	DYNAMIC OUTCOME PREDICTION BY NT-PROBNP KINETICS FOLLOWING POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS	Niek van der Maas	Received

PS-2067	ANALYSIS OF THE DIAGNOSTIC VALUE OF METAGENOMIC NEXT-GENERATION SEQUENCING (MNGS) FOR INFECTIONS FOLLOWING THE HEMATOPOIETIC STEM CELL TRANSPLANTATION	Yang Yan	Received

PS-2068	EFFICACY AND SAFETY OF RUXOLITINIB COMBINED WITH STEROIDS FOR FIRST-LINE TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER, REAL-WORLD EXPERIENCE	Yang Yan	Received

PS-2069	LONG TERM OUTCOME OF aßTCR/CD19 DEPLETED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA. A SINGLE CENTER EXPERIENCE.	Lucia Prezioso	Received

PS-2070	ESTABLISHING A NOVEL GI-GVHD PREDICTION MODEL BASED ON MAIT CELLS AND DONOR-RECIPIENT CLINICAL CHARACTERISTICS	Mengge Gao	Received

PS-2072	EXPOSURE RESPONSE OF RAVULIZUMAB TO TREAT PEDIATRIC PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY	Jonathan Monteleone	Received

PS-2075	SPLENOMEGALY AND LOW CD34+ CELL DOSE ARE ASSOCIATED WITH POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS	Portia Smallbone	Received

PS-2078	BREAKING AGE BARRIERS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: EXPLORING THE SAFETY AND EFFICACY OF POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED PROPHYLAXIS IN ADULTS ACCORDING TO AGE RANGES	Gorka Pinedo Martín	Received

PS-2080	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIAMOND-BLACKFAN ANEMIA: FAVORABLE OUTCOMES FROM A SINGLE CENTER	Lan He	Received

PS-2081	EXPANSION OF CYTOTOXIC T LYMPHOCYTES POST-ALLOGENEIC TRANSPLANT: FACTORS INVOLVED IN THEIR DEVELOPMENT AND IMPACT ON TRANSPLANT OUTCOMES	Jaime Ortiz Andrade	Received

PS-2082	SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN THE ERA OF IMMUNOTHERAPY: OUTCOMES AND PROGNOSTIC RISK FACTORS	Rui Wang	Received

PS-2083	SINGLE-CENTER RETROSPECTIVE ANALYSIS OF THE PROGNOSIS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MLL-AF6 FUSION GENE POSITIVE ACUTE MYELOID LEUKEMIA	Xingyu Cao	Received

PS-2084	CLINICAL STUDY OF CLADRIBINE-CONTAINING CONDITIONING REGIMEN IN HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMES	Yi Zhu	Received

PS-2087	SEQUENTIAL ALLOGENEIC STEM CELL TRANSPLANTATION FOR VENETOCLAX-EXPOSED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2	Andrius Žucenka	Received

PS-2092	PARTIAL REPLACEMENT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH BENDAMUSTINE AS GVHD PROPHYLAXIS IN HAPLOIDENTICAL STEM CELL TRANSPLANTS IN PEDIATRIC PATIENTS:EXPERIENCE FROM A TERTIARY CARE CENTER	Ranjith CS	Received

PS-2093	THE FIRST ALLOGENEIC STEM CELL TRANSPLANT IN KENYA: A CASE REPORT	Rohini Radia	Received

PS-2094	S100A8/A9 SIGNALING CAUSES MITOCHONDRIAL DYSFUNCTION AND MEGAKARYOCYTE APOPTOSIS IN ACUTE MYELOID LEUKEMIA	Xiaohui Zhang	Received

PS-2096	LOSS OF HEPCIDIN IMPAIRS 5-FU-INDUCED HEMATOPOIETIC STEM CELL REGENERATION	Marta Lopes	Received

PS-2097	MAINTENANCE OF QUIESCENT HEMATOPOIETIC STEM CELLS ACROSS DEVELOPMENT IN SINGLE GROWTH FACTOR-BASED CULTURE	Margarita MacAldaz	Received

PS-2098	PHARMACOLOGICAL ACTIVATION OF CAMP PATHWAY PROTECTS HUMAN HEMATOPOIETIC STEM CELLS FROM CAR-T INDUCED HEMATO-TOXICITY	Siva Sai Naga Anurag Muddineni	Received

PS-2102	EXPRESSION OF KIT D814V IN MURINE HEMATOPOIETIC STEM CELLS RESULTS IN AN ADVANCED SYSTEMIC MASTOCYTOSIS PHENOTYPE WITH ASSOCIATED MYELOID NEOPLASM	Simona Stivala	Received

PS-2103	SPECIFIC GENETIC ALTERATIONS IN BCMA POSITIVE CELLS UNCOVER MYELOPROLIFERATIVE PHENOTYPES AND AN IMMUNOSUPPRESSIVE NICHE IN MURINE HEMATOPOIETIC MODELS	Álvaro Otero-Sobrino	Received

PS-2104	RAPID RESPONSE OF NEUTROPHILS DETERMINED BY THE SHORTEST LINEAGE COMMITMENT TRAJECTORY AND MINIMAL SIGNALING CHANGES	Yongjian Yue	Received

PS-2105	CH-MUTATED MACROPHAGES CONTRIBUTE TO A PERMISSIVE BONE MARROW NICHE FOR MALIGNANT TRANSFORMATION.	Sarah Mackie	Received

PS-2106	MACROPHAGE DEPLETION ALTERS MSC FUNCTION AND DIFFERENTIATION UNDER CHRONIC STRESS CONDITIONS	Sanja Momcilovic	Received

PS-2107	SINGLE-CELL MAPPING OF HUMAN BONE MARROW STROMAL CELLS REVEALS SUBPOPULATION DIVERSITY AND STRESS-INDUCED REMODELING	Charles Bataclan	Received

PS-2109	CELL DIVISION IS ABSENT DURING LINEAGE COMMITMENT OF HEMATOPOIETIC PROGENITOR CELLS	Yongjian Yue	Received

PS-2110	THERAPY RELATED CLONAL HEMATOPOESIS IS ASSOCIATED WITH INCREASED EPIGENETIC AGE ACCELERATION, INCREASED PACE OF AGING AND SHORTED ESTIMATED TELOMERE LENGTHS	Marissa Li	Received

PS-2113	PARP INHIBITORS IMPAIR ERYTHROPOIESIS THROUGH P53 ACTIVATION	Charlotte Chambrion	Received

PS-2114	B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA-INDUCED ADIPOGENIC BIAS OF BONE MARROW MESENCHYMAL STROMAL CELLS: EVIDENCE OF SKEWED FATE AND VARIABLE REPROGRAMMING	Bexultan Kazybay	Received

PS-2117	DISRUPTED GLUTAMINE METABOLISM ALTERS MACROPHAGE FUNCTION IN THE BONE MARROW.	Maddie Bristow	Received

PS-2122	ENHANCED LEUKEMIA IMMUNOTHERAPY WITH EXPANDED NKG2C+ NATURAL KILLER CELLS	Manja Wobus	Received

PS-2123	HIGHLY EFFICIENT AND SEAMLESS IN VIVO SELECTION OF LONG-RANGE GENE-EDITED HSPCS BY TARGETING HAPLOINSUFFICIENT GENES	Alessandra Weber	Received

PS-2125	ENGINEERING ROR1-SPECIFIC CAR T CELLS AGAINST LOW ANTIGEN DENSITY TUMORS	Federico Mario Aletti	Received

PS-2126	BEYOND EXPANSION: CIRCULATING TUMOR DNA AS A PROGNOSTIC BIOMARKER IN CAR T-CELL THERAPY FOR HIGH GRADE B-CELL LYMPHOMAS	Cristiana Carniti	Received

PS-2127	CAR-T CELLS FROM PATIENTS WITH NON-HODGKIN LYMPHOMAS SECRETE FACTORS ABLE TO ACTIVATE THE MONOCYTIC-MACROPHAGIC TRANSITION: AN IN VITRO MODEL	Besjana Xhahysa	Received

PS-2131	IMPROVING CAR-T CELL THERAPY FOR PDAC BY GENERATION OF VHH-BASED BINDERS	Alexander Seitz	Received

PS-2132	CMV SEROPOSITIVITY INFLUENCES T CELL RECONSTITUTION FOLLOWING CAR-T THERAPY	Jared Darcy	Received

PS-2134	ATRA INCREASES INKT CELL-MEDIATED TARGETING IN HEMATOLOGICAL MALIGNANCIES BY INDUCING CD1D EXPRESSION	Eliska Jandova	Received

PS-2137	EVALUATION OF MESENCHYMAL STEM CELL INTERMEDIATES IN 2015-2023	Hana Gmucova	Received

PS-2139	INKT-BASED CELLULAR PRODUCT FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE	Monika Holubova	Received

PS-2140	MAXIMIZING SAFETY AND EFFICACY IN HEMATOPOIETIC STEM CELLS GENE THERAPY	Valeriya Olevska	Received

PS-2141	ENHANCING CAR-T CELL HOMING TO AML BONE MARROW VIA CHEMOKINE RECEPTOR ENGINEERING	Alice Pievani	Received

PS-2142	EXPERIENCE OF USING A MICRONUCLEUS TEST TO CONTROL GENETIC INSTABILITY OF CAR-T LYMPHOCYTES AFTER TRANSDUCTION WITH LENTIVIRUS PARTICLES	Svetlana Popova	Received

PS-2145	NCG-X: A NOVEL MOUSE MODEL FOR PRECLINICAL STUDIES EVALUATING HUMANIZED ERYTHROID RECONSTITUTION	Hongyan Sun	Received

PS-2148	REDUCED OUTCOMES WITH PROTON PUMP INHIBITOR USE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH CD19-DIRECTED CAR T-CELL THERAPY: A POPULATION-BASED ANALYSIS FROM THE DUTCH CAR T-CENTERS	Jaap Van Doesum	Received

PS-2149	MANAGEMENT OF IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME FOLLOWING CAR-T CELL THERAPY IN CLINICAL PRACTICE: A MULTICENTRIC, RETROSPECTIVE, REAL-WORLD ANALYSIS OF TREATMENT APPROACHES AND OUTCOMES	Katharina J. Müller	Received

PS-2150	4-YEAR UPDATE OF PHASE 2 ELARA TRIAL: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH-RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)	Catherine Thieblemont	Received

PS-2152	DIAGNOSIS, PREDICTORS AND OUTCOMES FOR IMMUNE EFFECTOR CELL ASSOCIATED ENTEROCOLITIS IN MULTIPLE MYELOMA PATIENTS RECEIVING CILTA-CEL	Kenneth Jin Chang Lim	Received

PS-2153	EMAPALUMAB IN PEDIATRIC PATIENTS WITH HIGH-GRADE CYTOKINE RELEASE SYNDROME (CRS) FOLLOWING CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY	Jing Zhang	Received

PS-2154	HYPOXIA-RESPONSIVE CEA CAR-T CELLS THERAPY FOR RELAPSED STAGE IV NON-SMALL CELL LUNG CANCER: A SINGLE-ARM, OPEN-LABEL, PHASE I TRIAL	Shuang Wei	Received

PS-2155	IMPACT OF PRE-LYMPHODEPLETION (PRE LD) AND DAY 30 (M1) IMMUNE CELL COUNTS ON OUTCOMES OF CAR T THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL)	Suheil Albert Atallah-Yunes	Received

PS-2157	SINGLE-CELL IMMUNOPHENOTYPING OF CD19-CAR T CELLS IN PEDIATRIC BCP-ALL: INSIGHTS INTO CYTOKINE RELEASE SYNDROME AND TOCILIZUMAB-DRIVEN IMMUNE MODULATION.	Aleksandra Oszer	Received

PS-2158	PREGNANCY AND INFANT OUTCOMES POST–CD19-DIRECTED CAR-T THERAPY: TISAGENLECLEUCEL (TISA-CEL) AND/OR HUCAR19 (CTL119)	Marianne Ifversen	Received

PS-2161	INCIDENCE OF CARDIOTOXICITY IN OUTPATIENT CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES; A SINGLE CENTRE RETROSPECTIVE STUDY	Aminah Tayyab	Received

PS-2162	HIGH EFFICACY AND SAFETY OF A NOVEL ANTI-CD20 CAR-T CELL THERAPY, LY007 IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA	Lingshuang Sheng	Received

PS-2163	A MULTI-CENTER REAL-LIFE ANALYSIS ON PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FAILURE OF CAR-T CELLS THERAPY.	Mirko Farina	Received

PS-2167	A COMPUTATIONAL ANALYSIS OF IMMUNE RECONSTITUTION DYNAMICS IN ADULTS WITH SICKLE CELL DISEASE UNDERGOING HLA-IDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION	Elisabeth Dovern	Received

PS-2168	ESTABLISHING CONSENSUS ON THE KEY COMPONENTS OF OPTIMAL TRANSITION FROM PAEDIATRIC TO ADULT CARE IN SICKLE CELL DISEASE ACROSS EUROPE	Sylvie Farrow	Received

PS-2169	REAL WORLD DATA ON PREVALENCE, CHARACTERISTICS AND OUTCOME OF MONOCLONAL GAMMOPATHIES IN ADULT SICKLE CELL DISEASE PATIENTS: A SINGLE CENTER EXPERIENCE.	Maria Dimopoulou	Received

PS-2171	MARKERS OF HEMOLYSIS AND CARDIAC FUNCTION IN SICKLE CELL DISEASE: A GENOTYPE-BASED ANALYSIS	Arman Sarshoghi	Received

PS-2173	SEROPREVALENCE OF SARS-COV-2 AND VACCINE EFFECTIVENESS IN INDIVIDUALS WITH SICKLE CELL DISEASE: COVIDODREP THE FRENCH MULTICENTER PROSPECTIVE STUDY.	Luu-Ly Pham	Received

PS-2176	IMPROVEMENT IN CEREBRAL OXYGEN SATURATIONS AND VASOREACTIVITY AFTER 12 MONTHS OF VOXELOTOR MEASURED BY NEAR-INFRARED SPECTROSCOPY (NIRS) IN SICKLE CELL DISEASE PATIENTS	Gonzalo De Luna	Received

PS-2177	MEEXCALC APP, A CALCULATOR FOR MANUAL ERITHROEXCHANGE IN SCD	Gian Luca Forni	Received

PS-2180	INVESTIGATING THE RELATIONSHIP BETWEEN HIGH-SENSITIVITY TROPONIN, CLINICAL OUTCOMES AND HEMOLYTIC MARKERS IN ADULTS WITH SICKLE CELL DISEASE.	Najibah Galadanci	Received

PS-2181	UPDATED SAFETY AND EFFICACY RESULTS OF RM-001, AUTOLOGOUS HBG1/2 PROMOTER-MODIFIED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS, IN TREATING TRANSFUSION-DEPENDENT ß-THALASSEMIA	Hui Xu	Received

PS-2184	LUSPATERCEPT UNDER AN ´ EARLY ACCESS PROGRAM´: AN ITALIAN MULTICENTRE EXPERIENCE	Raffaella Origa	Received

PS-2187	CHANGES IN TRANSFUSION BURDEN AND IRON OVERLOAD PARAMETERS IN TRANSFUSION-DEPENDENT ß-THALASSEMIA PATIENTS TREATED WITH LUSPATERCEPT: A REAL-LIFE STUDY	Yesim Aydinok	Received

PS-2188	IMPACT OF GENE THERAPY ON PHYSICAL GROWTH OF PEDIATRIC PATIENTS WITH ß-THALASSEMIA: A PROSPECTIVE COHORT STUDY	Jingyu Zhao	Received

PS-2189	LEFT VENTRICULAR DIASTOLIC AND SYSTOLIC FUNCTIONS BY CARDIAC MAGNETIC RESONANCE IN TRANSFUSION-DEPENDENT BETA THALASSEMIA: CLINICAL AND OUTCOME CORRELATES	Antonella Meloni	Received

PS-2190	SURVIVAL OF PATIENTS WITH CONGENITAL RED BLOOD CELL DISORDERS IN COMPARISON WITH AGE, SEX AND ORIGIN MATCHED POPULATIONS: A DANISH REGISTER-BASED ANALYSIS	Dana Lawrie	Received

PS-2194	A NEW METHOD FOR ANALYZING BONE MARROW CELL POPULATIONS BY SPECTRAL FLOW CYTOMETRY	Laura BRAUD	Received

PS-2197	IMPACT OF RILZABRUTINIB ON BIOMARKERS OF INFLAMMATION AND COMPLEMENT FACTORS IN WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA): RESULTS FROM THE PHASE 2 STUDY	Nichola Cooper	Received

PS-2198	THE CDIN1-CODANIN-1 COMPLEX, DEFECTIVE IN CONGENITAL DYSERYTHROPOIETIC ANAEMIA TYPE I, IS A RNA NUCLEASE	Sanja Brolih	Received

PS-2199	RED BLOOD CELL AGE DISTRIBUTION AND METABOLIC FEATURES IN HEREDITARY SPHEROCYTOSIS, HEREDITARY XEROCYTOSIS AND CONGENITAL DYSERYTHROPOIETIC ANEMIA – BASELINE RESULTS OF EXPLORATORY ANALYSIS FROM THE SATISFY STUDY	Richard van Wijk	Received

PS-2204	ELLAGIC ACID ALLEVIATES IRON OVERLOAD-INDUCED LIVER DAMAGE BY MITIGATING FERROPTOSIS THROUGH MODULATION OF THE TGFß/SMAD SIGNALING PATHWAY	Hangjie Fu	Received

PS-2205	IMPROVEMENT OF ANEMIA AND KIDNEY STATUS BY SEVUPARIN TREATMENT IN A MOUSE MODEL OF CHRONIC KIDNEY DISEASE	Michela Asperti	Received

PS-2206	DIFFERENTIAL ROLES FOR CELL CYCLE REGULATIONS BETWEEN TRANSFERRIN AND FERRITIN JUSTIFY THE DEVELOPMENT OF TRANSFERRIN RECEPTOR 1 BLOCKERS AS ANTINEOPLASTIC AGENTS OVER IRON CHELATORS	Ryo Yanagiya	Received

PS-2207	SINGLE- AND MULTIPLE-ASCENDING DOSES OF DISC-3405, A RECOMBINANT HUMANIZED ANTIBODY TARGETING TMPRSS6, INCREASED HEPCIDIN AND REDUCED IRON AND HEMATOCRIT IN HEALTHY VOLUNTEERS	Marcus Carden	Received

PS-2208	STRIKE THE IRON WHILE IT´S LOW: REDEFINING IRON DEFICIENCY IN WOMEN	Ayesha Shameem	Received

PS-2210	RESULTS FROM THE HELIOS STUDY: A PHASE 2, OPEN-LABEL, LONG-TERM EXTENSION STUDY OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA	Melanie Chin	Received

PS-2211	INTRAVENOUS IRON RELATED HYPOPHOSPHATEMIA AND POTENTIAL PREVENTING ROLE OF VITAMIN D SUPPLEMENTATION:„REAL LIFE" DATA FROM AN OUTPATIENTS CLINIC IN NORTH ITALY	Giovanni Inghilleri	Received

PS-2213	PREDICTIVE MACHINE LEARNING MODEL FOR SCREENING IRON DEFICIENCY WITHOUT ANEMIA USING AVAILABLE DATA FROM ELECTRONIC HEALTH RECORDS	Shelly Soffer	Received

PS-2214	NATIONWIDE STUDY OF SECONDARY CARE INFECTIONS AND INFECTION-RELATED DEATH IN PATIENTS WITH MULTIPLE MYELOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA	Ingrid Glimelius	Received

PS-2216	MVA-BASED GEO-CM04S1 VACCINE RESULTS IN IMPROVED CELLULAR IMMUNE RESPONSE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) COMPARED WITH MRNA-BASED VACCINE: INITIAL RESULTS OF A PHASE II RANDOMIZED STUDY	Alexey Danilov	Received

PS-2217	CLINICAL IMPACT OF METAGENOMIC NEXT-GENERATION SEQUENCING (MNGS) OF PLASMA CELL-FREE DNA FOR THE DIAGNOSIS OF INFECTIOUS DISEASES IN PATIENTS WITH HEMATOLOGICAL DISORDERS	shanfeng hao	Received

PS-2219	WORLDWIDE EXPERIENCE OF CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION: A MULTINATIONAL RETROSPECTIVE COHORT STUDY	chunrui li	Received

PS-2220	AGGRESSIVE CLINICAL FEATURES AND POOR OUTCOME MAY ASSOCIATE WITH DECREASED IMMUNE FUNCTION IN HIV POSITIVE HL IN THE CART ERA: A MULTICENTER STUDY FROM CHINA	Chaoyu Wang	Received

PS-2223	CLINICAL JOURNEY AND IMMUNOGLOBULIN-REPLACEMENT THERAPY IN PATIENTS WITH MULTIPLE MYELOMA AND SEVERE OR RECURRENT INFECTIONS	Elisabet Viayna	Received

PS-2224	MATCHED COHORT STUDY COMPARING THE IMPACT OF RSV, INFLUENZA, AND SARS-COV-2 INFECTIONS IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES	Francesco MARCHESI	Received

PS-2225	IMMATURE PLATELET FRACTION AS A PREDICTOR OF PLATELET COUNT RECOVERY AND BLEEDING OCCURRENCE IN PATIENTS UNDERGOING INTENSIVE INDUCTION THERAPY FOR ACUTE LEUKEMIA.	Maha EL AMANI	Received

PS-2226	IMPACT OF IMMUNE PLATELET REFRACTORINESS IN THE TREATMENT COURSE OF ACUTE LEUKEMIA ADULT PATIENTS AT A TERTIARY CENTER	Anna Arrufat Bel	Received

PS-2227	UPFRONT TRANSFUSION OF NON-LEUKOREDUCED LOW-TITER GROUP O+ WHOLE BLOOD IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED 30-DAY SURVIVAL IN SEVERELY INJURED CIVILIAN TRAUMA PATIENTS	Eldad Dann	Received

PS-2228	AUDIT ON THE ADHERENCE TO BRITISH SOCIETY OF HAEMATOLOGY GUIDELINES IN A TERTIARY CARE CENTRE	Sanjali Dahiya	Received

PS-2229	MONITORING THE HEMODYNAMIC QUALITY OF STORED BLOOD UNITS FOR IMPROVED TRANSFUSION OUTCOME, BY DETERMINING RED CELL MEMBRANE COMPONENTS	Saul Yedgar	Received

PS-2230	TO TRANSFUSE OR NOT TO TRANSFUSE A BABY: THAT IS THE QUESTION!	Filipa Fonseca-Dias	Received

PS-2231	EFFECTIVENESS AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF ADULTS WITH NEWLY DIAGNOSED, PERSISTENT, OR CHRONIC IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS FROM THE PHASE 4 ADOPT STUDY	Waleed Ghanima	Received

PS-2234	EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF PEDIATRIC IMMUNE THROMBOCYTOPENIA IN THE OPEN-LABEL EXTENSION OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	Rachael F. Grace	Received

PS-2235	INBORN ERRORS OF IMMUNITY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA	Nehal Joshi	Received

PS-2237	IANALUMAB´ S DUAL MECHANISM OF ACTION: TARGETING B CELLS THROUGH ENHANCED B-CELL DEPLETION AND BLOCKADE OF B CELL-ACTIVATING FACTOR RECEPTOR SIGNALING	Christoph Burkhart	Received

PS-2238	CLINICAL IMPACT OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) IN PATIENTS WITH SOLID TUMORS	Austin Nuschke	Received

PS-2239	REAL-WORLD TREATMENT PATTERNS & CLINICAL OUTCOMES IN THROMBOPOIETIN RECEPTOR AGONIST NAIVE PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH AVATROMBOPAG: INTERIM RESULTS FROM THE REAL-AVA 3.0 STUDY	Sandhya Panch	Received

PS-2240	CLINICAL FACTORS ASSOCIATED WITH RESPONSE TO RILZABRUTINIB, A BRUTON TYROSINE KINASE (BTK) INHIBITOR, IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) TREATED IN THE PHASE 3 LUNA3 STUDY	David Kuter	Received

PS-2241	CLINICAL CHARACTERISTIC OF ISOLATED THROMBOCYTOPENIA IN PATIENTS WITH BONE MARROW FAILURE-RELATED GERMLINE VARIANTS: A RETROSPECTIVE STUDY FROM A SINGLE CENTRE	Diijong Wu	Received

PS-2242	EFFECTIVENESS AND SAFETY OF AVATROMBOPAG FOR TREATMENT OF IMMUNE THROMBOCYTOPENIA IN OLDER PATIENTS AND THOSE WITH COMORBIDITIES OR PRIOR TPO-RA EXPOSURE: INTERIM RESULTS FROM THE PHASE 4 ADOPT STUDY	Aileen Echeverry	Received

PS-2244	RESPONSE TO AVATROMBOPAG AMONG PATIENTS WITH CHRONIC AND ACUTE/PERSISTENT PRIMARY IMMUNE THROMBOCYTOPENIA: THE REAL-AVA 2.0 REAL-WORLD STUDY	Alexandra Greatsinger	Received

PS-2245	RNA SEQUENCING CONFIRMS PATHOGENICITY OF A NOVEL HOMOZYGOUS INTRON VARIANT IN NBEAL2 CAUSING GREY PLATELET SYNDROME	Eva Leinoe	Received

PS-2246	RIPERTAMAB, A NOVEL ANTI-CD20 MONOCLONAL ANTIBODY FOR TREATING REFRACTORY/RELAPSED IMMUNE THROMBOCYTOPENIA:A PROSPECTIVE, MULTICENTER CLINICAL STUDY	Yimei Feng	Received

PS-2247	EFFICACY AND SAFETY OF HETROMBOPAG FOR PARP INHIBITOR-INDUCED THROMBOCYTOPENIA: A PHASE II OPEN-LABEL, PROSPECTIVE TRIAL	Qinhao GUO	Received

PS-2248	SIROLIMUS TREATMENT FOR ITP WITH ABNORMAL ANTINUCLEAR ANTIBODY SPECTRUM CAN ACHIEVE LONG-LASTING EFFICACY	Yimei Feng	Received

PS-2250	EVALUATION OF EFFICACY AND SAFETY OF AVATROMBOPAG IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA BASED ON DISEASE DURATION: RESULTS FROM THE AVATROMBOPAG PHASE 3-B PEDIATRIC TRIAL	Rachael F. Grace	Received

PS-2251	THE ROLE OF SYMPATHETIC NERVE REGULATION IN MEGAKARYOCYTE FUNCTION AND PLATELET PRODUCTION IN IMMUNE THROMBOCYTOPENIA	Menglin Li	Received

PS-2254	PHASE I AND III STUDY RESULTS OF RECOMBINANT HUMAN COAGULATION FACTOR VIIA (TQG203):PHARMACOKINETICS/PHARMACODYNAMICS,EFFICACY AND SAFETY OF TQG203 IN HEMOPHILIA PATIENTS WITH INHIBITORS	Lei Zhang	Received

PS-2257	EFFICACY OF IANALUMAB IN A MOUSE MODEL OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)	Karina Yazdanbakhsh	Received

PS-2258	THE MAASTRICHT BLEEDING COHORT: PHENOTYPIC AND GENOTYPIC INSIGHTS INTO GENDERED PATTERNS OF BLEEDING DISORDERS	Nienke Meskes	Received

PS-2259	FACTORS INFLUENCING THE CHOICE OF ROMIPLOSTIM OR ELTROMBOPAG IN IMMUNE THROMBOCYTOPENIA: INSIGHTS FROM A REAL-WORLD EUROPEAN COHORT	MARIA LOZANO	Received

PS-2261	ASSESSMENT OF NOVEL POINT-OF-CARE WHOLE BLOOD COAGULATION ASSAY TO EVALUATE COAGULATION RESPONSE TO BIAB FVIIIA MIMETIC AND FVIII THERAPY	Christina Higgins	Received

PS-2263	ONLINE MEDICAL EDUCATION RESULTS IN PRACTICE CHANGES AND IDENTIFIES BARRIERS IN CONSIDERING PROPHYLAXIS FOR PATIENTS WITH MODERATE HEMOPHILIA A WITH A SEVERE BLEEDING PHENOTYPE	S Christy Rohani-Montez	Received

PS-2267	A RISK ASSESSMENT MODEL THAT INCORPORATES THROMBOINFLAMMATION BIOMARKERS ENHANCES THE ABILITY TO PREDICT EARLY DISEASE PROGRESSION IN ADVANCED-STAGE NON-SMALL CELL LUNG CANCER PATIENTS	Patricia Gomez Rosas	Received

PS-2268	EFFECTS OF THROMBOPOIETIN AND THROMBOPOIETIN RECEPTOR AGONISTS ON PLATELET ACTIVATION AND THROMBOSIS	Fan Zhou	Received

PS-2270	HIGH RISK OF RECURRENT VENOUS THROMBOEMBOLISM WITHIN TWO YEARS OF THE FIRST EPISODE IN PATIENTS WITH LYMPHOMA DESPITE ANTICOAGULATION	Ingrid Lundahl	Received

PS-2271	IDENTIFICATION OF NEW MOLECULAR MECHANISMS OF ANTITHROMBIN DEFICIENCY: RESULTS FROM A POLISH COHORT	Anetta Undas	Received

PS-2272	EASIX, A NEW TOOL TO PREDICT RESPONSE AND REFRACTORINESS IN IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA?	Maria Queralt Salas	Received

PS-2273	PHENOTYPING THE INTRINSIC THROMBIN GENERATION IN PLASMA SAMPLES CONTAINING HEPARIN: THE CASE OF TINZAPARIN NEUTRALIZATION.	Emilie Chalayer	Received

PS-2274	FACTORS RELATED TO ADHERENCE TO DIRECT ORAL ANTICOAGULANTS: IMPACT OF CLINICAL OUTPATIENT FOLLOW-UP	Maricel Subira	Received

PS-2275	EFFECT OF PROC GENE VARIANTS ON VENOUS THROMBOSIS: A RETROSPECTIVE CASE-CONTROL STUDY IN TAIWANESE POPULATION	Chi-yen Chen	Received

PS-2276	RELATIONSHIP BETWEEN PODOPLANIN EXPRESSION IN COVID-19 INFECTED PATIENTS AND THE INCIDENCE OF THROMBOTIC EVENTS	Ibtesam Khalifa	Received

PS-2278	FEASIBILITY OF IV EPOPROSTENOL FOR ACUTE LIMB ISCHEMIA IN ANTIPHOSPHOLIPID SYNDROME: A COMPARATIVE REVIEW OF SAFETY OUTCOMES	George Mason	Received

PS-2279	MULTICENTER MIXED METHODS RANDOMIZED CONTROLLED TRIAL OF FEASIBILITY AND EFFICACY OF A SUPERVISED PHYSICAL ACTIVITY INTERVENTION IN MYELOPROLIFERATIVE NEOPLASMS: THE MPN-FIT TRIAL	Marie Ouellet	Received

PS-2280	HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM BURDEN IN PRE-FIBROTIC AND OVERT MYELOFIBROSIS COMPARED TO THE GENERAL POPULATION AND PHYSICIAN PERCEPTIONS: RESULTS FROM THE GIMEMA-PROPHECY STUDY	Giovanni Caocci	Received

PS-2281	HEALTH-RELATED QUALITY OF LIFE BENEFITS OF FRONTLINE PONATINIB PLUS BLINATUMOMAB IN ADULT PATIENTS WITH PH+ ACUTE LYMPHOBLASTIC LEUKEMIA. PRELIMINARY ANALYSIS OF THE GIMEMA ALL2820 TRIAL	Laura Cannella	Received

PS-2282	PATIENT REPORTED OUTCOMES FROM BRUIN CLL-321: A RANDOMIZED PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKI PRETREATED CLL/SLL	Paolo Ghia	Received

PS-2283	PATIENT-PHYSICIAN COMMUNICATION REGARDING TKI-RELATED ADVERSE EVENTS AND THEIR IMPACT ON QUALITY OF LIFE IN CML – INSIGHTS FROM PATIENT AND PHYSICIAN SURVEYS IN THE US	David Wei	Received

PS-2284	EVALUATION OF SAFETY AND GUIDELINE COMPLIANCE IN HOME RED BLOOD CELL TRANSFUSIONS: A 10-YEAR RETROSPECTIVE STUDY IN SUBURBAN TOKYO	Takeshi Hagino	Received

PS-2286	QUALITY OF LIFE AND WORK IMPACTS AMONG CAREGIVERS OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) – A CAREGIVER SURVEY IN THE US	David Wei	Received

PS-2287	CHIP-RELATED MUTATIONS AS PREDICTORS OF CARDIOVASCULAR AND CEREBROVASCULAR EVENTS IN MYELOID NEOPLASMS: A RETROSPECTIVE COHORT ANALYSIS	Xiuli Sun	Received

PS-2288	A PATIENT-REPORTED OUTCOME MEASURE (PROM) TO CAPTURE PATIENTS´ EXPERIENCES WITH IMMUNO-ONCOLOGY THERAPY (IO)-INDUCED CYTOKINE RELEASE SYNDROME (CRS): THE IO-INDUCED CRS PATIENT DIARY	Sophie Van Tomme	Received

PS-2289	MYELOMA PATIENTS´ ATTITUDES AND PERCEIVED BURDEN TOWARDS TREATMENT ROUTES AND LOCATIONS: INSIGHTS FROM A EUROPEAN SURVEY	Eilidh Duncan	Received

PS-2290	INVESTIGATING THE KEY PREDICTORS OF QUALITY OF LIFE IN LEUKAEMIA PATIENTS: ANALYSIS OF GLOBAL STUDY DATA USING GRADIENT BOOSTED DECISION TREES.	Sam Salek	Received

PS-2291	HEALTH-RELATED QUALITY OF LIFE AND PREFERENCE FOR TREATMENT MODALITIES OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): RESULTS OF A REAL-WORLD STUDY	Alexander Röth	Received

PS-2292	PATIENT-REPORTED OUTCOMES FROM A PHASE 3, RANDOMIZED TRIAL EVALUATING THE COMBINATION OF POZELIMAB AND CEMDISIRAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Christopher Hartford	Received

PS-2293	SURVIVAL TRENDS AND HEALTHCARE UTILIZATION COSTS IN ACUTE MYELOID LEUKEMIA IN 2007-2022 AT THE HELSINKI UNIVERSITY HOSPITAL	Theerin Lanamtieng	Received

PS-2294	THE ECONOMIC IMPACT OF TREATMENT SEQUENCES FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN ITALY: A COST OF CARE SEQUENCING MODEL FOR PATIENTS WITH CLL	Andrea Visentin	Received

PS-2296	EFFECTS OF A SUPPORTIVE ONCOLOGY CARE AT HOME INTERVENTION ON HEALTH CARE UTILIZATION IN PATIENTS WITH NON-HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL	P. Connor Johnson	Received

PS-2297	HOSPITALIZATION TIME AND TREATMENT COSTS FOR ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN). A SPANISH PETHEMA STUDY	Irene Navarro-Vicente	Received

PS-2299	FROM SWINE TO SYNTHETIC: A CLIMATE ANALYSIS ON THE SHIFT FROM HEPARIN TO APIXABAN IN POST-OPERATIVE THROMBOEMBOLISM PREVENTION.	Holly Cherniwchan	Received

PS-2300	INTEGRATING THE CARBON FOOTPRINT INTO HEALTH TECHNOLOGY ASSESSMENT IN FRANCE: THE EXAMPLE OF THE HEALTHCARE PATHWAY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA	Caroline BESSON	Received

PS-2301	ACCESS TO SUTIMLIMAB FOR COLD AGGLUTININ DISEASE THROUGH THE ORPHAN DRUG ACCESS PROTOCOL IN THE NETHERLANDS: INSIGHTS FROM THE FIRST YEAR	Kathelijn Verdeyen	Received

PS-2302	UNDERSTANDING THE PREFERENCES OF PEOPLE WITH ACUTE LEUKEMIA FOR DIFFERENT HEALTH OUTCOMES	Samantha Nier	Received

PS-2303	INVESTIGATION AND MANAGEMENT OF NEUTROPENIA REFERRALS IN AREA WITH A HIGH PREVALENCE OF AFRO-CARIBBEAN PATIENTS	Priya Sriskandarajah	Received

PS-2304	AUTOMATED IMMUNOPHENOTYPIC PROFILING IN AML: A MACHINE LEARNING APPROACH TO EXPEDITE DIAGNOSIS AND DISEASE SUBCLASSIFICATION	Marco Roncador	Received

PS-2306	ARTIFICIAL INTELLIGENCE-DRIVEN GHOST CYTOMETRY ENABLES LABEL-FREE DETECTION OF LEUKEMIC CELLS AND TREATMENT RESISTANCE PREDICTION IN CHRONIC MYELOID LEUKEMIA	Kohjin Suzuki	Received

PS-2308	UNSUPERVISED DEEP LEARNING REVEALS HISTOLOGICAL MOTIFS IN CD34-STAINED BONE MARROW TREPHINES OF MYELOID NEOPLASMS	Carlo Pescia	Received

PS-2309	NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE DETECTION AND MONITORING IN MULTIPLE MYELOMA: ANALYSIS OF FEASIBILITY IN DAILY PRACTICE.	Silvia Armuzzi	Received

PS-2310	INTEGRATED GENOME AND EPIGENOME PROFILING OF PEDIATRIC LEUKEMIA USING NANOPORE-BASED TARGETED ADAPTIVE SAMPLING LONG-READ SEQUENCING	Shota Kato	Received

PS-2311	AMBIENT AI PLATFORM: AI-POWERED APPLICATION FOR CLINICAL REPORT TRANSCRIPTION ASSISTANCE AND CLINICAL TRIAL PATIENT MANAGEMENT IMPROVEMENT IN HEMATOLOGY	Saverio D´Amico	Received

PS-2313	PDT: A NOVEL DIAGNOSIS AND TREATMENT OPTION GENERATION ARCHITECTURE FOR RARE DISEASE	Xue Shi	Received

PS-2315	ACCURATE AND RELIABLE DETECTION OF CLONAL HEMATOPOIESIS IN PLASMA CELL-FREE DNA	Alyssa Parker	Received

PS-2316	ASSESSING THE UTILITY OF NGS-DETECTED CNVS AS AN ALTERNATIVE TO FISH FOR CYTOGENETIC ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA	Ana Gea Peña	Received

PS-2317	IMMUNOTHERAPY OF DRUG-RESISTANT HEMATOLOGIC MALIGNANCIES WITH CURE POTENTIAL BY SIMULTANEOUS TARGETING IL-2 PRE-ACTIVATED MISMATCHED T, NK & NKT CELLS AGAINST DETECTABLE CELL SURFACE CANCER ANTIGENS	Shimon Slavin	Received

PS-2318	AI-DRIVEN AUTOMATED LYMPHOCYTE PROFILING AND CAR-T CELL MONITORING FOR SCALABLE IMMUNOTHERAPY DIAGNOSTICS: THE SMARTCYTOFLOW PROJECT	Adrian Mosquera-Orgueira	Received

PS-2319	GENEXUS: AN ALL-IN-ONE APPROACH OF NEXT GENERATION SEQUENCING IN THE MOLECULAR DIAGNOSIS OF ACUTE MYELOID LEUKEMIA	Alessandra Potenza	Received

PS-2320	LYM-SYNGAN: ENHANCING CT-TO-PET MEDICAL IMAGE SYNTHESIS FOR LYMPHOMA USING A GENERATIVE ADVERSARIAL NETWORK WITH MULTI-LEVEL LINEAR ATTENTION AND EFFICIENT VISION TRANSFORMER	xiangyan Feng	Received

PS-2323	OPTICAL GENOME MAPPING IS A POWERFUL DIAGNOSTIC TOOL IN NON-HODGKIN LYMPHOMA	Amber Verhasselt	Received

PS-2325	DEVELOPMENT OF AN IN VITRO BIOMARKER PLATFORM FOR DETERMINING BISPECIFIC ANTIBODY EFFICACY IN HAEMATOLOGICAL MALIGNANCIES	Rachel Koldej	Received

PS-2326	EXPLORING THE BELGIAN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) POPULATION THROUGH AI AND DIGITAL TECHNOLOGIES: INSIGHTS FROM THE BE-CLLEAR STUDY	Ann Debecker	Received

EHA2025 Hybrid Congress

June, 12-15 Milan

Help Line

Homepage

Personal Area

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 11/06/2040 TO 11/06/2040

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions